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Abstract 
 
The “Amyloid Hypothesis” deliberates that Amyloid Beta (Aβ) peptides (Aβ40 & Aβ42) 
aggregation and accumulation in the brain primarily influences and progresses 
Alzheimer Disease (AD) pathogenesis. Several recent findings in AD have shown 
that Aβ and tau aggregates can transmit disease pathogenesis in a prion-like manner 
by transferring their conformational properties to normally folded units. In addition, 
there is a growing body of evidence accumulating that Aβ too can seed and act in a 
prion-like manner. Recently a link was reported between distinct brain-Aβ42 
conformations and rapid clinical decline, defining Aβ42 structural conformation to be 
a new variable in AD pathogenesis (Cohen et al. 2015). The critical question of how 
Aβ42 structural conformations (strains) correlate to AD specific pathology in the brain 
remains to be a poorly understood phenomenon. 
 
The development of thioflavin-T fluorescence based in-vitro seeding assays have 
enabled fibril amplification of Aβ conformations from brains, however these assays 
have been largely limited to utilizing soluble Aβ40 as the substrate. Additionally it is 
also established in seeding studies that Aβ42 fibrils cannot seed the monomeric 
Aβ40 substrate. Due to this, the bioactive Aβ42 AD specific toxic 3D conformation in 
brain remains elusive and continues to be a major bottleneck in AD research. 
 
Our research confronts this challenge by developing an in-vitro based Aβ 
Conformational Seeding Assay (Aβ-CSA) that utilizes recombinant Aβ(1-42)M35L 
peptide as the substrate. At the start, suitable assay conditions were established to 
detect de-novo aggregated Aβ seeding in the assay. Later, when brain material was 
seeded it resulted in prolongation of Aβ substrate aggregation in the assay. This 
delay was overcome by PK digestion, but still the brain aggregated- Aβ material in 
the brain homogenate did not seed in the assay. Mimicking the brain membranous 
milieu in the assay using a phospholipid DHPC model, lead to seeding of brain 
aggregated-Aβ material in the assay. The seeding of the brain aggregated-Aβ seed 
was possible as the 4mM DHPC micellar condition markedly suppressed the 
substrate Aβ spontaneous primary nucleation. This suppression enabled the brain 
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aggregated-Aβ seeding mechanism to dominate over the spontaneous nucleation of 
the substrate Aβ and enabled brain aggregated-Aβ amplification in the assay. 
 
Brain homogenates from 6-month transgenic mice [APP/PS1 (TG/WT)] and BL6 mice 
were used as brain-Aβ seeds in the assay. The TG mice contain brain aggregated-Aβ 
seeds; WT and BL6 were used as negative controls. The brain aggregated-Aβ 
seeded fibril growth kinetics was distinctly detected in the assay with a higher 
fluorescence and a shorter lagtime. Brain aggregated-Aβ seed amplification was later 
confirmed by two methods: (i) TEM investigation & (ii) A novel biophysical fibril 
fragmentation method Acoustic-SSA (Selective Shear Amplification) developed in our 
lab for prion amplification. This technique exploits the fibril mechanistic property to 
fragment and form seeds when sonication shear force is applied. The sonicated 
APP/PS1(TG) brain seeded aggregates did not seed in the developed assay 
compared to the robust seeding observed in sonicated APP/PS1(WT) and BL6 
seeded fibrils. This indicates difference in specific mechanical fragmentability 
between the APP/PS1(TG) seeded and APP/PS1(WT) or BL6 brain homogenate 
seeded fibrils hinting conformational difference. 
 
The developed Aβ-CSA with Aβ(1-42)M35L as the substrate is the first assay to 
amplify brain aggregated-Aβ and show distinct differences by seeding kinetics, TEM 
and Acoustic-SSA. The developed Aβ-CSA platform is an early step towards 
amplifying the brain aggregated-Aβ involved in Alzheimer’s disease. 
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1 Introduction 
 
1.1 Introduction to Alzheimer’s disease  
 
1.1.1 Alzheimer’s disease Highlights 
 
Alzheimer’s Disease (AD) is a devastating neurodegenerative disease characterized 
by dementia, cognitive impairment and behavioral disorders that affect normal living 
in humans. It is the most frequent form of dementia affecting an estimated 25-50% of 
people aged above 85 in the developed world (Hong-Qi et al. 2012). AD is one of the 
killer diseases, for which there are no cures, drugs and therapies to slowdown or halt 
the disease progression. The cost of caregiving imposes a huge economic burden on 
the nation and families. There are more than 1.2 Million AD patients living in 
Germany alone and approximately more than 28-36 million people are known to be 
affected worldwide (www.deutsche-alzheimer.de). AD is known to strike 1 in 20 
person between the ages 65-69 years and 1 in 3 persons between the ages 80-90. 
These are the statistics of the dementia cases, of which approximately 70% end-up 
being diagnosed with AD later is very alarming. AD running through families has 
been known to strike at age even less than 50 years. By the year 2050, the 
prevalence of AD has been forecasted to quadruple up to 1 in 85 persons worldwide 
unless effective measures of prevention and treatment are discovered (Brookmeyer 
et al. 2007). 
 
1.1.2 History of Alzheimer’s disease 
 
It has been more than a century since German neuropathologist   Dr. Alois Alzheimer 
(1864-1915) first described AD condition in the year 1906. Since then, there has 
been an explosive growth in the number of people affected by this disease. The first 
case of AD was documented in 51-year-old women from Frankfurt by the name 
Auguste Deter aged 51 years. She displayed a range of strange behavior, including 
personality changes and severe loss of short-term memory and finally succumbed to 
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the disease in Frankfurt in the year 1906.  Autopsy results showed uniformly atrophic 
brain with no intrinsic macroscopic abnormalities (Fig.- 1.1). On histopathological 
examination, there were plaques, neurofibrillary tangles and arteriosclerotic 
differences.  
 
Fig.- 1.1: Neuropathological and Anatomical features in Normal vs. AD brain. (A) Healthy brain 
displaying healthy neurons in the inset. (B) Brain affected by Mild AD showing differences compared 
to the healthy brain. (C) Severe affected AD brain showing overall atrophy followed by amyloid 
plaques and neurofibrillary tangles in the inset. 
Brain tissue preparations by Bielschowsky’s silver method showed distinct changes 
in neurofibrils when compared to the controls. With the progress in research, it was 
concluded that arteriosclerosis was no more essentially the hallmark of the disease. 
Rather, presence of neuritic plaques and neurofibrillary tangles were confirmed in all 
AD cases, representing as the hallmark of the disease (Fig.- 1.1). Emil Kraeplin, who 
was director of the Royal psychiatric clinic in Munich, separated this disease 
condition from senile dementia and termed it as Alzheimer in the textbook of 
psychiatry in year 1910. Molecular characterization of neuritic plaques and fibrillary 
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tangles was performed in 1960’s with development of EM (Electro Microscopy). 
Isolation of two fibrillar proteins (Amyloid Beta and Tau) in plaques and neurofibrillary 
tangles (Fig.- 1.1) was one of the major challenges solved in understanding the 
neurobiology of the disease (Selkoe et al. 2012). 
 
1.1.3 Discovery of Amyloid Beta (Aβ) and Tau  
 
Isolation of fibrillar proteins from the plaque was a major challenge, and was being 
pursued by researchers in the 1960's. George Glenner developed the isolation 
methods for protein purification from the plaque (Glenner & Bladen 1966). Later X-
Ray diffractions were performed from the purified protein fibrils for biophysical 
studies, which indicated to the presence of high beta sheet content in the protein 
isolate (Eanes & Glenner 1968). He was majorly interested in purifying the majorly 
occurring amyloid protein found in the cerebral blood vessels called it the cerebral 
vascular amyloid. His team developed a biochemical protocol in the 1980's, which 
exploited the non-solubilizing character of the amyloid protein. Using strong 
chaotrophic denaturants, the protein was purified and could be solubilized, 
characterized on the SDS-PAGE and HPLC and found to be in the range of 3KDa in 
size (George G. Glenner & Wong 1984). This evidently indicated that the protein 
present in the neurofibrillary tangles is different in amino acid composition as 
compared to the amyloid protein found in the brains (Masters et al. 1985; G G 
Glenner & Wong 1984; Wong et al. 1985). They chose to call this protein as Amyloid 
Beta (Aβ) protein.  
 
1.1.4 Amyloid Beta Biogenesis 
 
With the Partial amino acid sequence available from (George G. Glenner & Wong 
1984), the cDNA encoding part of amyloid beta precursor was cloned (Goldgaber et 
al. 1987) (Tanzi et al. 1987). They predicted from the full-length cDNA to be a 695 
amino acid type-I transmembrane protein, which contained 17-residue signal peptide, 
a single membrane-spanning region and a short cytoplasmic tail. This was called as 
Amyloid Precursor Protein (APP). The amyloid beta region was predicted to begin at 
28 residues amino terminal to the transmembrane domain extending 11-15 residues 
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further into the domain. Major isoforms of APP were later discovered resulting from 
alternative splicing in the APP gene. The widely abundant APP in humans was found 
to contain 751 amino acids encoding exon 7 (Ponte et al. 1988). Cultured Neurons 
and various transfected cell lines that over-expressed APP released a large soluble 
ectodomain called as soluble APP (sAPP) in the medium (Schubert et al. 1989; 
Sisodia et al. 1990). The cleavage left behind a 10kDa Carboxy Terminal Fragment 
(CTF) within the cell (Palmert et al. 1988). 
 
 
 
 
Fig.- 1.2: APP cleavage and formation of Amyloid Beta. Sequential cleavage of the amyloid 
precursor protein (APP) occurs by two pathways. (A). The Aβ-peptide starts within the ectodomain 
and continues into the transmembrane region (orange). (B) Non- amyloidogenic processing of APP 
involving α-secretase followed by γ-secretase is shown. (C) Amyloidogenic processing of APP 
involving BACE1 followed by γ-secretase is shown. The above figure adapted and modified from 
(O’Brien & Wong 2011). 
 
The cleavage site was later determined by protein sequencing of the CTF (Esch et al. 
1990). The sAPP form ended with Gln15 and the CTF amino terminus was Leu17, 
suggesting that Lys16 was cleaved by an ecto-peptidase in either of the fragments. 
The unknown endo-peptidase involved in APP secretion was henceforth called as α-
secretase and the soluble APP was called as sAPPα. Later, the APP processing by 
α-secretase was understood to occur both intracellularly (De Strooper et al. 1993) 
Introduction 
 
  
7 
and on the cell surface (Sisodia 1992). The action of APPs cleavage by α-secretase 
was proved to be amino acid sequence dependent (Zhong et al. 1994). As α-
secretase action involves cleavage within the Aβ region (non-amyloidogenic), it was 
concluded that pathogenic amyloid protein must be formed by a different pathological 
pathway (amyloidogenic). A smaller peptide was found containing a portion of Aβ, 
designated as p3, which started with position of 17 of Aβ, clearly suggesting that it 
would have been derived from 10kDa CTF present intracellularly after α-secretase 
cleavage of APP. 
 
Meanwhile, studies indicated the minor amounts of all APP peptides are turned over 
to produce secreted Aβ (Seubert et al. 1992). Aβ was also detected in plasma and 
cerebrospinal fluids of humans and mammals. This finding of Aβ peptide 
constitutively being produced and secreted sparked major interests in the number of 
investigations focused on Aβ generation. Moreover, it was also shown that a new 
soluble APP was found, cleaved precisely at the amino terminus of Aβ designated as 
sAPPβ. This finding indicated that β-secretase cleavage occurred in the secretory 
pathway as well. The picture got clearer in the analysis of a rare APP mutation called 
as the Swedish Mutation, where β-secretase role was dominant and provided the first 
direct evidence for a role in enhanced Aβ production (Mullan et al. 1992). 
 
As terminating soluble APP’s have been identified at the β-secretase site, it was clear 
that there was one more peptide involved in the cleavage that generated the C-
Terminus of Aβ and p3 fragment. It was designated as γ-Secretase. γ-Secretase 
activity was henceforth proven to occur after α-secretase and β-secretase activity on 
APP and the γ-Secretase acted on the CTF fragments later. The sequence specificity 
of γ-Secretase was described (Tischer & Cordell 1996) and was shown that 
substitution of negatively charged residues at 40-46 position, precluded the formation 
of Aβ and APP maturation with the membrane boundary at position 46/47. Sequential 
cleavage of the amyloid precursor protein (APP) occurs by two pathways as follows. 
(i) Non-amyloidogenic processing of APP involves α-secretase followed by γ-
secretase yielding p3 (Fig.- 1.2B). (ii) Amyloidogenic processing of APP involves 
BACE1 cleavage followed by γ-secretase yielding Aβ’s (Refer Fig.- 1.2C). Both the 
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processes generate soluble ectodomains (sAPPα and sAPPβ) and identical 
intracellular C-terminal fragments (AICD) (Fig.- 1.2B&C). 
 
1.2 Current Understanding of Alzheimer’s disease  
 
Currently, among few of the AD Pathology Hypotheses, Amyloid cascade hypothesis 
(ACH) has been widely accepted with certain modifications in the field. Recently, an 
experimental validation of the amyloid hypothesis has been provided where 
accumulation of Aβ has been shown to drive tauopathy (Choi et al. 2014). This has 
added further credence to this hypothesis. The original Amyloid cascade hypothesis 
posited that AD progression is due to deposition of protein Amyloid Beta (Aβ). Aβ, 
which form fibrils and later these fibrils accumulate and pack tightly to form amyloid 
plaques is known to be the commencing point in AD (Hardy 2006). In the progress 
and quest to understand how these fibrils form and lead to neurotoxicity, it was found 
that, there was lack of correlation between the deposited Aβ in the amyloid plaques in 
terms of the amount, location and cognitive impairment or neurodegeneration 
(Benilova et al. 2012).  
 
1.2.1 Amyloid Hypothesis 
 
Amyloid cascade hypothesis (ACH) postulates that, Aβ deposition is the primary 
event in the disease, which leads to astrocytosis, microglial reactivity and the 
development of NFT’s (Hardy & Higgins 1992; Hardy & Selkoe 2002) (Fig.- 1.3). 
Points supporting Amyloid Cascade Hypothesis are as follows: 
 
i. The APP gene is found on chromosome 21 & AD-like neuropathology is 
invariably seen in Down’s syndrome.  
ii. Inherited mutations in the APP gene that flank or occur within the Aβ region 
alter the amount or aggregation properties of Aβ and precipitate early-onset 
AD.  
iii. Inherited mutations within the Presenilin 1 and 2 genes increase the 
Aβ42/Aβ40 ratio throughout life and cause very early and aggressive forms of 
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AD.  
iv. ApoE e4 allele is a major risk factor for developing late-onset AD, whereas the 
e2 allele appears to be protective. Apo E regulates degradation of Aβ.  
v. Mice transgenic for human APP show a time-dependent deposition of Aβ and 
develop certain AD-like neuropathological and behavioral changes.  
vi. Injection of synthetic Aβ or co-expression of mutant APP with mutant tau 
accelerates tau hyperphosphorylation and leads to tangle AD-like formation.  
vii. Ex-vivo, Aβ exhibits disease-relevant toxic activity.  
viii. The levels of formic acid extracted Aβ peptides correlate with disease severity. 
ix. Synthetic Aβ peptides are toxic to hippocampal and cortical neurons, both in 
culture and in-vivo.  
 
Despite the evidence provided by AD causing mutations in Aβ, there are certain 
lacunas with the amyloid cascade hypothesis, as 99% of AD cases are known to be 
sporadic in nature for which there is no explanation in the hypothesis.  The 
hypothesis fails to explain amyloid beta in what conformation or form causes 
neuronal death? Due to this riddle, there were several extensions proposed to the 
existing hypothesis. Several researches suggest that there is a negative correlation 
between extracellular fibrillar amyloid burden and cognitive impairment or dementia 
(Price et al. 2009) . To accommodate these recent findings, the amyloid cascade 
hypothesis has been modified to propose that non-fibrillar, soluble Aβ-oligomers, 
rather than insoluble Aβ accumulates present in plaques, are responsible for initiating 
AD pathology (Glabe 2006; Shankar et al. 2007). In support of this Aβ-Oligomer 
model, levels of soluble Aβ correlated better with the degree of dementia in humans 
than amyloid deposits in the brain (Lesné et al. 2006). The Aβ-Oligomer hypothesis is 
currently dominating in the field, positing that Aβ-oligomers are more neurotoxic than 
the fibrils plaques themselves as drivers of neurodegeneration in the brain. However, 
the limitations of Aβ-Oligomer hypothesis has been that, the term “Oligomer” has 
been poorly defined and characterized in literature. And there are discrepancies in 
methods used in oligomer preparations from Aβ peptides and brain extraction 
techniques used to derive native Aβ-oligomers from the brain employed across the 
labs (Benilova et al. 2012), which adds to further complexity in defining the oligomer.  
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The basic definitive proof of Amyloid hypothesis and cascade has been lacking. 
However, by far, this hypothesis has been the most accommodating hypothesis 
accounting for AD progression. Until an infectious Aβ conformation can be generated 
with only the Aβ peptide, the amyloid protein based hypotheses of AD will continue to 
remain unproven and debated in the field. 
 
 
 
 
 
Fig.- 1.3: Modified amyloid cascade hypothesis. Question marks indicate less understood critical 
processes being investigated in AD. Adapted and modified from (Karran et al. 2011). 
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1.3 Amyloid Protein Chemistry and Biophysics 
 
German scientist Rudolph Virchow first introduced “Amyloid” term in the year 1854. It 
was used to denote a macroscopic tissue abnormality that exhibited positive iodine 
staining. Amyloid proteins demonstrate inherent birefringence when stained with 
Congo red dye. At that point of time, the amyloid substance was considered 
composed of starch by Virchow. Later in the year 1859, it was Friedreich and Kekule, 
who demonstrated the presence of mass of protein in the amyloid deposit based on 
its high nitrogen content. Initially investigation into amyloid started as protein and 
later on any protein that had the inherent propensity to change conformation and 
aggregate to form fibrils were included in the amyloid class of protein (Sipe & Cohen 
2000). The characteristics of amyloid protein when compared to other proteins, is 
their ability to form higher aggregates, oligomers and later into fibrillar structures. 
These fibril structures are highly resistant to protein turnover mechanisms and non 
degradable by the proteosomal machinery. This phenomena leads to accumulation of 
the amyloid protein, which later causes diseased condition due to amyloid protein 
accumulation and hence called as “Amyloidosis” (Hardy et al. 1986). 
 
1.3.1 Amyloid Beta Biophysics 
 
Amyloid formation process shares similarities to crystallization process, and may be 
therefore considered as an analogous phenomenon to understand. At the start a 
nucleus is formed, which then grows and gives rise to soluble intermediates, later 
with time, these finally aggregate to insoluble fibrils. X-ray diffraction studies have 
revealed cross-β model as a generic model for amyloid fibrils (Eanes & Glenner 
1968). X-ray diffraction of amyloids shows characteristic meridional and equatorial 
reflections. Diffraction studies on Aβ fibrils have revealed a cross–β pattern 
(Kirschner et al. 1986). Diffraction pattern identified that β-strands were perpendicular 
to the main fibril axis and β-sheet was parallel to the same axis. The characteristic 
two diffraction sets observed values were 4.7 Å - 4.8 Å (Meridional) and 10Å - 11Å 
(Equatorial) corresponded to inter-strand and stacking distances respectively 
(Marshall & Serpell 2009) (Fig.- 1.4). Parallel β-strand organization was the most 
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commonly found in most of the amyloid fibrils (Balbach et al. 2002) and the β-strands 
are coordinated either in in-register or in a β-solenoid arrangement.  
 
 
 
Fig.- 1.4:  X-Ray diffraction of Amyloid Fibril. A schematic of a Parallel β-sheet arranged in cross 
beta arrangement, diffracted by an X-Ray to obtain an diffraction pattern showing the 4.7 Å -4.8 Å 
(Meridional) and 10 Å-11 Å (Equatorial) reflections that define cross-beta structure (Marshall & Serpell 
2009). 
 
The first evidence that Aβ could contain parallel β-sheets and anti-parallel β-sheets in 
arrangement has been observed in few Aβ peptide fragments (Petkova et al. 2004). 
 
 
 
Fig.- 1.5: Schematic representations of cross β-sheet structures that amyloid proteins can 
adopt. (A) Parallel β-sheet (B) Anti-parallel β-sheet and (C) Top view of β-helix. Adapted and modified 
from (Tycko 2011). 
 
Shorter Aβ peptides contain only one β-strand, whereas the full length Aβ peptide 
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contains two or more β-strands segments. Anti-parallel β-strand arrangement was 
recently found in the full peptide Aβ(1-40) D23N  (Iowa mutation) (Tycko et al. 2009). 
The cartoon representations of various possible cross-β structures are shown in Fig.- 
1.5. Knowledge about the amyloid fibril structures are important for a number of 
reasons namely (i) To design compounds that can inhibit amyloid fibril formation or 
(ii) bind specifically to amyloid by rational drug design approaches (Sievers et al. 
2011; Sato, Kienlen-Campard, Ahmed, Liu, Li, Elliott, Aimoto, Constantinescu, J.-N. 
Octave, et al. 2006). 
 
1.3.2 Primary Structure of Aβ peptide 
 
 The amyloid plaques resulting from aggregation of Aβ fibrils peptides are the 
hallmarks of AD. Aβ peptides evolving from sequential cleavage have been explained 
in Aβ biogenesis section (Refer, Section- 1.1.4). Upon cleavage by gamma secretase 
of APP, the Aβ peptides are released mainly as unstructured monomers. From the 
hydrophobicity of the primary Aβ- structure, it can be divided into four regions: two 
hydrophobic and two hydrophilic parts (Fig.- 1.6).  
 
 
 
 
Fig.- 1.6: Random Coil Aβ peptide Sequence and swiss homology model of (A) Aβ40 and (B) 
Aβ42 rendered using chimera, showing C terminal and N terminal ends of the peptide(Arnold et al. 
2006). The two hydrophobic regions L17-A21 part and the C-terminus A30-V40/A42 exhibit secondary 
structure propensity for β-structure and are highlighted as green arrows in the primary structure 
(Abelein et al. 2014). 
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The first 16 N-terminal residues constitute a hydrophilic tail that is unstructured. The 
two hydrophobic regions are L17-A21 part and the C-terminus A30-V40 / A42 (Fig.- 
1.6), that are separated by the hydrophilic central region E22-G29. The predominant 
Aβ forms in AD are Aβ40 and Aβ42 shown below in random coil conformation (Fig.-
1.6). Amyloid fibrils are intrinsically insoluble and non-crystalline in nature making 
them non-amenable to high structure determination techniques such as X-ray 
crystallography or high-resolution solution state NMR. Based on solution state NMR, 
solid state NMR and electron microscopy studies it has been concluded that a 
hairpin-like conformation constitutes a common motif for the Aβ peptide in most of the 
described fibril structures. However there have been molecular heterogeneities 
observed, resulting from different hydrogen bonding partners in different hairpin 
conformations (Abelein et al. 2014). The interacting hairpins are known to be the 
building blocks of the fibrils and how these hairpin variations are organized in the 
cross-section of the fibrils, perpendicular to the fibril axis constitute the amyloid beta 
fibrillar heterogeneity (Paravastu et al. 2008a).  
 
The contacts between the β strands in the hairpin motifs have been summarized in 
the Fig.-1.7 taking into account different proposed models for Aβ. Fig.- 1.7 shows a 
schematic model of Aβ42 and Aβ40 sequence, summarizing current models for how 
the two β-strand regions may fold into β-turn-β (hairpin conformation) with variable 
intermolecular residue contacts. Investigation into multiple β-turn-β units at the fibril 
cross-section of Aβ42 also has been reported, where Met35 has been shown to form 
intermolecular contact with Gly37, indicating that the cross-section is composed of 
two β-turn-β units with a two fold symmetry (Sato, Kienlen-Campard, Ahmed, Liu, Li, 
Elliott, Aimoto, Constantinescu, J. Octave, et al. 2006). Several studies have 
concluded that the proposed models are over-simplifications. The N and the C 
terminal of the peptide show significant mobility making structure hard to assign by 
conventional low-resolution methods, thereby preventing the development of a 
detailed model. 
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Fig.- 1.7: Sequence and structure of Aβ40 and Aβ42 fibrils with intermolecular contacts. (A) 
Primary sequence of Aβ40 and Aβ42. (B) Structural constraints in Aβ40 and Aβ42 fibrils. NMR 
investigation in Aβ40 fibrils have shown that residues 1-10 are unstructured and residues 11-40 adopt 
a β-turn-β fold (Paravastu et al. 2008a; Tycko 2006). Side chain packing is observed between phe19-
Ile32, Leu34 and Val36 and between Gln15-Val36 as well as between His13-Val40 (green dashed 
lines). In both Aβ40 and Aβ42 fibrils, the hairpin conformation is stabilized by hydrophobic interactions 
(cyan residues) and by a salt bridge between the residues Asp23-Lys28 (black dashed line). In Aβ42 
fibrils, residues 1-17 may be unstructured (in gray), with residues 18-42 forming a β-turn-β fold. 
Molecular contacts have been reported within the monomer unit of Aβ42 fibrils between the residues 
Phe19-Gly38 (red dashed line) (Thorsten et al. 2005). DARR NMR measurements of Aβ42 specifically 
show the sidechain-packing registry within the β-turn-β structure involving the molecular contacts 
between Phe19-Leu34 (green dashed) and between Gln15-Gly37 (intermolecular) and His13-Gln15, 
this model suggests that the N-terminal β-strand starts at-least at residue 13, showing the first 10 
residues are unstructured (red dashed). In the Aβ42 fibrils, ssNMR measurements show contacts 
between Phe19-Leu34 and amide exchange measurements indicate solvent accessible turns at 
His13-Gln15, Gly25-Gly29 and Gly37-Gly38 (Black Segments) (Ahmed et al. 2010). Fig. Adapted 
modified from (Ahmed et al. 2010).  
 
1.3.3 Structural model of Aβ42 Fibrillation  
 
The starting point of fibrillation is formation of a protofilament structure, which acts as 
the interface for fibril formation. The protofilament structure consists of C-terminal 
hydrophobic sequence of Aβ folding into β-turn-β conformation; the fibrils are 
composed of multiple β-turn-β units that polymerize in a parallel and in-register 
orientation. The 3d structural Aβ4235Mox model of protofilament consist of two 
stacked, intermolecular, parallel, in register β-sheets that perpetuate along the fibril 
axis. The residues L17, F19 and A21 of the β1-sheet mediate the hydrophobic 
intermolecular contacts with the even number residues of β2-sheet (Fig.- 1.8). Fibril 
extension most likely occurs at the tip of the formed protofilaments. The interactions 
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between the Aβ42 molecules are hypothesized to occur by domain swapping-type 
interaction between the β-strands, implying the presence of distinct surface at the 
opposing ends. A hydrophobic cleft is formed by β1-strand and β2 strand of the 
template at the odd end of the protofilament. The incoming Aβ42 monomer could 
initially bind by means of the contiguous hydrophobic stretch of residues 17-21. This 
complex could be further stabilized by intermolecular salt-bridge (D23-K28) formation 
and backbone hydrogen bonds. Nevertheless, the newly added monomer could still 
disassociate as the β2-strand has substantially fewer interactions with the template 
than the β1-strand. Therefore, the last added monomer would be stabilized 
permanently only by the addition of next monomer. This suggests a sequence-
selective, cooperative mechanism of Aβ fibril extension that follows first order 
kinetics. From this, it was concluded that the Aβ1-42 fibrils are stabilized by 
intermolecular domain swapping interactions similar to those seen in other amyloids 
(Thorsten et al. 2005). 
 
 
 
Fig.- 1.8: Aβ4235Mox fibrillation model (PDB: 2BEG) (Thorsten et al. 2005). Ribbon diagram of the 
core structure of residues 17-42 of five Aβ molecules, each represented in a different colour, depicting 
the intermolecular nature of the inter-β-strand interactions. Individual molecules are labeled. Colored 
arrows indicate the β-strands of each Aβ molecule, the non-regular secondary structure is indicated by 
spline curves through the C-alpha atom coordinates of respective residues. Rendered using 
academically licensed PyMol. 
 
Intrinsic sample polymorphism of fibrillar Aβ structures has been a major obstacle for 
ssNMR studies, as it results in samples with low structural homogeneities. Aβ fibril 
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studies with ssNMR and electron microscopy have finally come to an acceptance that 
the structure of Aβ is not uniquely determined by the amino acid sequence. Rather, 
the fibril structure also depends on precise buffer preparation details and subtle 
variations in growth conditions. Obviously, these structural variations at molecular 
level lead to variations in ssNMR spectra (Petkova et al. 2005; Qiang et al. 2011). 
Nevertheless, an emerging consensus supports the polymorphism of fibril structure 
morphology, possibly with multiple structures co-existing, even though all tertiary 
structures are based on parallel in-register β- sheet secondary structures, generally 
showing hairpin variants among the contacts between the β-strands. The fibril cross-
sections display either twofold or three-fold symmetry for structural models 
determined from experimental constraints concerning the arrangement of the ordered 
hairpins (Paravastu et al. 2008b). In the next section, we will discuss more about 
structural models on Aβ polymorphisms. 
 
1.4 Amyloid Beta Polymorphism  
 
One of the central principles of biochemistry is that protein structures are entirely 
uniquely determined by primary amino acid sequences. This principle does not apply 
to the amyloid beta peptide. Amyloid Beta displays a plethora of aggregates and 
adopts heterogeneous fibrillar forms de-novo and in-vivo conditions also referred as 
amyloid beta polymorphisms (Walker et al. 2008; Levine et al. 2010; Arce et al. 2011; 
Toyama & Weissman 2011). 
 
1.4.1 De-novo Aβ Polymorphisms 
 
Aβ fibrils investigation by electron microscopy (EM) has revealed structurally 
polymorphic conformations of Aβ, which include protofibrils, low and high molecular 
mass oligomers. Later with long incubation times in-vitro they assembled in 
polymorphic fibrils (Goldsbury et al. 2005). Subtle variations in fibril growth conditions 
lead to significant, reproducible and self-propagating variations in molecular structure 
of Aβ40 fibrils. It was later shown by EM and Solid State NMR, that these different 
fibril morphologies have different underlying molecular structure and it was not mere 
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lateral protofilament association in the fibrils. These different morphologies were also 
demonstrated to have different neuronal toxicities. These findings in amyloid fibrils 
are analogues to prion strains in prion diseases (Petkova et al. 2005; Wang et al. 
2011). The conformational details of the non-β-strand segments in the peptide, the 
contact between β-sheets and the fraction of the peptide sequence that becomes 
structurally ordered in the fibrils have been reported to vary (Bertini et al. 2011). The 
N-terminal and the C-terminal of Aβ40 have been reported to be “staggered”, 
meaning that the two β-strands from the given peptide molecule do no make contact 
with one another. The direction of the stagger itself is difficult to determine from 
experimental measurements and has been postulated to be a source of 
polymorphism (Paravastu et al. 2008a; Petkova et al. 2006). Fibrils extracted from 
AD brain tissue when seeded to isotopically labeled monomeric Aβ40 and 
investigated by NMR concluded that AD brain derived Aβ seeded fibrils were 
homogenous as compared heterogeneity observed in concomitantly aggregated 
Aβ40 (Paravastu et al. 2009). 
 
Monoclonal antibodies were raised that could specifically recognize prefibrillar 
oligomers.  Immunological analysis of prefibrillar oligomers revealed the existence of 
Aβ polymorphisms in prefibrillar oligomers that can be distinguished based on their 
monoclonal antibody reactivity. These polymorphic prefibrillar oligomers were also 
able to seed the monomeric Aβ and are capable of seeding their own replication 
(Kayed et al. 2010). Five distinct fibrillar aggregates of Aβ40 were reported and each 
of these conformational structures were shown to exhibit unique physical properties 
and the extensive β-sheet content in the fibrils were correlated to their greater 
stability (Kodali et al. 2010). Molecular models have been proposed for Aβ 
polymorphism lately, where eight new microcrystal structures of segments of Aβ were 
determined. These structures formed self-complementing β-sheet pairs, called as 
steric zippers. These steric zippers reveal variety of modes of Aβ self-association 
(Colletier et al. 2011). A second type of amyloid polymorphism was suggested called 
as packing polymorphism. In packing polymorphism, the same peptide sequence can 
form distinct steric zipper structures by virtue of different packing in the fibril spine 
(Wiltzius et al. 2009).  
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1.4.2   In-vivo Aβ Polymorphisms  
 
Excessive accumulation of Aβ also occurs in the brain of cognitively normal aged 
people. The neuronal toxicity of Aβ was hence postulated to be dependent on its 
molecular composition and it was shown in the study that soluble beta-amyloid 
aggregates that accumulate in Alzheimer disease are different from those of normal 
aging with respect to the composition as well as the aggregation and toxicity 
properties (Piccini et al. 2005; Moore et al. 2012). Luminescent conjugated 
polyelectrolyte probes (LCPs) are able to distinguish Aβ42 fibril conformation formed 
under both quiescent and agitated conditions. LCPs are also shown to resolve 
conformational heterogeneity of amyloid deposits in frozen brain sections (Nilsson et 
al. 2007). An extensive review on diversity of Aβ in the aged brain and literature 
studies connecting to molecular heterogeneity is particularly useful to clarify the 
complex pathology of AD (Walker et al. 2008). Difference in structural rearrangement 
of side chains in one β-strand and presence of exposed hydrophobic surfaces   in 
asymmetric Brain Derived Aβ and symmetric agitated in-vitro Aβ are attributed to 
higher toxicity in brain-derived fibrils (Wu et al. 2010). 
 
 Quantitative binding studies using radio-ligand 11C-PiB (Pittsburgh compound B) 
have revealed difference in binding of the Ligand with AD brain homogenates, non-
demented humans and plaque bearing transgenic mice. Transgenic mice had the 
lower ligand binding per mole of Aβ peptide. The binding was lowest in synthetic 
peptide formed fibrils of Aβ40 and Aβ42. This difference in binding affinities indicates 
a structural difference in in-vivo formed fibrils in humans and transgenic mice (Levine 
et al. 2010). These distinct molecular polymorphic conformations or Aβ-strains could 
have different toxic effects related to phenotypic diversity in amyloid diseases too. 
The structural origin for such polymorphisms still remains elusive (Lim 2013). In a 
study by Jucker, it was shown that the polymorphic Aβ lesions present in the 
APP/PS1 mice brain when injected into APP-23 mice induced Aβ deposition with the 
morphological, conformational and Aβ40:Aβ42 ratio characteristics of Aβ as observed 
in aged APP/PS1 mice. The result from this study suggests that β-amyloidosis in the 
brain, C-terminal chain length of Aβ variants might contribute to the nature of the Aβ 
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conformers and the morphotypes can be sustained by seeded Aβ induction 
(Heilbronner et al. 2013). 
 
Recently, in a study by tycko and coworkers, the molecular structure of Aβ40 fibrils 
seeded from the brains of two AD patients were shown to have a single predominant 
fibril structure in each patient. Also these Aβ40 fibril structures were different as 
compared to in-vitro produced Aβ fibrils (Lu et al. 2013). In he next section, we shall 
discuss the molecular basis of Aβ polymorphism with the help of models proposed in 
literature. 
 
1.4.3 Steric Zipper model of Aβ Polymorphism  
 
The core structure of the Aβ fibril might not include the complete primary sequence, 
but rather diverse steric zipper interfaces. Each one of these interfaces can serve as 
the spine for structural fibril formation; this type of diversity in fibril spine formation is 
referred as Segmental Polymorphism (Refer, Fig.- 1.9B). In a second type of Amyloid 
polymorphism, the short Amyloid peptide segments can form distinct steric zippers by 
virtue of difference in packing of the fibril spine and β-sheet can arrange either 
parallel or anti-Parallel. (Refer, Fig.- 1.9A).  
 
β-Sheets formed from the same Amyloid segment are referred to as homotypic 
interaction and from different amyloid segments are referred to as heterotypic 
interactions. Aβ fiber diversity and polymorphism are compatible with this notion 
where fibers are formed from the same or mixed pair of Aβ segments displaying 
different morphologies owing to the above explained polymorphic associations.  
 
This overall suggest a combinatorial effects of all these different polymorphism 
mechanisms that constitute amyloid fiber diversity and polymorphs (Refer Fig. 1.9C). 
In, single-chain registration polymorphism, two segments of the same chain forms 
two steric zippers with different registrations of their side chains (Refer, Fig.- 1.9D). 
Combinatorial and single chain registration polymorphism are proposed models of 
amyloid polymorphism and yet have not been observed at an atomic level (Wiltzius et 
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al. 2009). Eleven short segments of 6-8 residues from the Aβ42 peptide representing 
thirteen diverse steric zipper interfaces have been determined at atomistic detail, 
each of which can serve as the spine for fiber formation. 
 
 
 
 
This merely constitutes the segmental polymorphism in Aβ, considering the packing 
and other mechanisms of polymorphism, there are many undetermined polymorphic 
structures (Colletier et al. 2011).  
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1.5 Prion-like Alzheimer disease proteinopathy 
 
In the 1980’s, the prion disease was proved to be the disease caused by protein 
misfolding process (Prusiner et al. 1984). “Prion disease” is a neurodegenerative 
disease caused by aggregation of an amyloid protein that extracellularly aggregates 
within the CNS (Central Nervous System) and forms plaques in the brain, which 
rupture the normal tissue. This disruption leads to spongy architecture in the brain, 
due to vacuoles formed in the neurons (Cohen 1995). This amyloid protein causing 
prion disease was later called as Prion Protein (PrP), the normal endogenously 
folded cellular form was called as (PrPC) and the misfolded pathogenic form was 
called as Scrapie Prion (PrPSc). Prion propagation is by transmission of the misfolded 
protein state. On gaining entry into healthy organism, the misfolded protein induces 
the existing normal protein to adopt itself into misfolded conformation. These freshly 
formed misfolded protein acts like an template which further can propagate the 
misfolded conformation by breaking down into seeds (Misfolded templates), and 
these seeds convert the other existing normal protein in the organism to misfolded 
protein state starting a prion cascade (Prusiner & Kingsbury 1985).  
 
It was during the same time, AD was also classified as an amyloid disease, caused 
by the aggregation of protein called Aβ (Amyloid Beta) (George G. Glenner & Wong 
1984). The aggregation and deposition of Aβ peptides are believed to be central 
events in the pathogenesis of AD. For more than 40 years, there exists certain 
similarities between prion diseases and Alzheimer’s disease and has evoked a 
speculation suggesting that AD might be infectious in a manner similar to prionoses 
(Prusiner 1984). Both the proteins (Prion and Aβ) caused neurodegeneration-shared 
similarity with respect to high beta sheet content in the purified brain plaques 
(Prusiner 1984). These shared featured between the two diseases lead to 
investigation of AD pathology akin to prion disease, and it was estimated that 
incubation studies on AD transmissibility would require few more years of incubation 
time than the CJD (Creutzfeldt-Jakob disease) prion disease (Goudsmit 1982; Brown 
et al. 1982). In order to test this hypothesis, nonhuman primates were intracerebrally 
inoculated with brain material from AD patients, but this experiment proved to be not 
conclusive (Goudsmit et al. 1980). Intracerebral inoculation of buffy coat from the 
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blood of AD patients into hamsters was also reported to induce prion-like spongiform 
encephalopathy (Manuelidis et al. 1988), but a subsequent follow up of the study 
failed to replicate the same finding (Godec et al. 1991). Surprisingly in later it was 
always shown that, inoculation of brain homogenates containing Aβ aggregates into 
susceptible transgenic mice and wild-type marmosets accelerated Aβ amyloidosis, 
suggesting that Aβ aggregates in the brain homogenate are capable of self-
propagation and could act like prions. In-vitro aggregation of Aβ and the prion is 
known to be a nucleation-dependent polymerization process (Refer, Introduction, 
section 1.7) (Fig.- 1.10). This process is potentially applicable to all amyloid proteins 
too (Eisenberg & Jucker 2012). In the disease state, the conformation of the protein 
is driven towards an aberrant 3D structure by the process of corruptive templating. 
 
 
 
 
Fig.- 1.10: Model of Nucleated Polymerization (NP) mechanism. The model proposes that the 
native and misfolded state of the Aβ peptide are reversible. Although the native conformation is 
strongly preferred but below a critical concentration of the peptide no aggregation occurs and in case if 
it exceeds the critical concentration level the peptide can form a corruptive seed that then amplifies the 
template misfolding to other Aβ monomers. Seed addition can rapidly induce aggregation and 
eliminated the lag period in fibril formation. Fragmentation of the larger aggregates can generate new 
seeds, which can accelerate fibril formation. Model adapted from (Harper & Lansbury 1997) 
 
1.5.1 Amyloid beta induction in non-human primates 
 
Owing to longer incubation period in monkeys, the first experimental result emerged 
in the year 1993. In this study Marmosets (Callithrix Jacchus), were inoculated 
intracerebrally with brain tissue from an early onset AD patient. After incubation of 6-
7 years, these inoculated animal brains were analyzed. Moderate number of amyloid 
plaques associated with argyrophilic dystrophic neuritis along with cerebral amyloid 
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angiopathy and no neurofibrillary tangles were found. The plaques also stained 
positive for the Aβ antibody. This study finally concluded that β-amyloidosis is a 
transmissible process (Baker et al. 1993; Baker et al. 1994). The same study was 
further continued to rule out the possibility of aging related Aβ plaque deposition in 
relation to inoculation, and it was found that animals injected in the elderly cohort 
showed amyloid pathology with 4 years of incubation, whereas there were only 4 out 
of 26 marmosets found to be amyloid positive in the elderly marmoset control group. 
These data, therefore proves that, β-amyloid found in middle aged marmosets 
injected with Alzheimer brain tissue was, therefore, not a consequence of their 
ageing (Maclean et al. 2000). 
 
A very long-term comprehensive study on seeding of β-amyloidosis in primates was 
investigated and results were published in the year 2006. In this study, it was found 
that intracerebrally injected Aβ containing brain homogenates from either human AD 
subject or marmoset, induced β-amyloidosis in both aged and young monkeys. In the 
study synthetic Aβ was also inoculated in both aged and young monkeys and 
surprisingly, inoculation with synthetic Aβ did not induce cerebral amyloidosis. It was 
concluded from this study that Aβ or its associated factors could initiate or accelerate 
the process of cerebral amyloidosis in primates (Ridley et al. 2006). In a recently 
published study, AD-like pathology was shown to be induced by synthetic Aβ-
Oligomers in non-human primates. In particular, the authors saw evidence of 
neurofibrillary tangles, a cardinal feature of AD that rodent models fail to recapitulate 
unless they express mutant tau (Forny-Germano et al. 2014). 
 
1.5.2 Amyloid beta induction in transgenic mice  
 
With the development of AD mouse models, the Aβ induction experiments were 
carried out in transgenic mice, offered flexibility to study in large numbers with 
significantly lower incubation period as compared to that in primates. The first mice 
model was β-APP mice model; AD brain homogenates from human were infused 
unilaterally into hippocampus and neocortex of 3-month-old β-APP transgenic 
mouse. Later were euthanized and examined after 4 weeks to find no amyloid 
deposition, however at the end of 5 months, profuse Aβ senile plaques and vascular 
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deposition was found, some of which were birefringent with Congo Red. There was 
considerably, less limited deposition in the age matched β-APP and non-AD brain 
inoculated mice controls. There was no beta-amyloidosis in mice receiving extract 
from a young control case too (Kane et al. 2000). The same study was continued to 
clarify anatomical distribution of seeded Aβ -immunoreactivity. It was noted that, 
transgene-derived Aβ deposits were present bilaterally in the forebrain, but plaque 
load was still clearly greater in the extract-injected hemisphere, providing an 
evidence for seeding activity (Walker et al. 2002). 
 
Intracerebral injection of dilute Aβ containing brain extracts from AD patients or aged 
β-APP transgenic mice were performed in young APP/PS1 and APP23 mice and it 
induced cerebral β-amyloidosis in the mice in a time and concentration dependent 
manner. Synthetic Aβ mixtures of fresh and aged Aβ42 and Aβ40 did not induce 
seeding activity in the transgenic mice brain. Hence, it was concluded that, 
phenotype of the exogenously induced amyloidosis depended both on the source of 
the seeding agent and also on the host, giving rise to notion of Aβ polymorphic 
strains in-vivo similar to that in prions (Meyer-luehmann 2006).  
 
With the APP23 mice, it was shown that amyloidosis could be achieved in many 
different brain areas of the mice through injection of dilute Aβ containing brain 
extracts. Stainless steel wires coated with minute amounts of Aβ containing extracts 
also induced amyloidosis despite boiling in water and only by plasma-sterilization did 
not induce amyloidosis. The exogenously induced amyloidogenic process 
determined the Aβ deposition in the brain region of the host akin to strain specific 
seeding in prions (Eisele et al. 2009). Later studies by the same group demonstrated 
that intraperitoneal inoculations with Aβ rich extracts was also induced β-amyloidosis 
in the β-APP transgenic mice after prolonged incubation times (Eisele et al. 2010).  
 
The β-amyloid inducing factor in the brain extract was investigated and was found 
that the Aβ in the brain were more PK-resistant than the synthetic fibrillar Aβ 
generated in-vitro and this in-vivo PK resistance retained the amyloid inducing 
capacity in APP23 transgenic mice. Fragmentation of Aβ seeds by extended 
sonication increased the seeding capacity of the extract (Refer, Fig. 1.10 for 
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understanding). In this study, PK sensitive Aβ (fractionated) was shown to induce 
amyloidosis 30% less as compared to the normal seeding extract (unfractionated). 
These findings demonstrate that small and soluble Aβ seed can induce amyloidosis 
also raises the possibility that these seeds may mediate β-amyloidosis in the brain 
(Langer et al. 2011). 
 
1.5.3 Summary of inoculation studies 
 
From all the above studies, there is a commonality, the transgenic mice produced 
higher amount of Aβ and when confronted with the introduced seed, the overall 
process of amyloidosis accelerated and in absence of seed, the mice still had age 
dependent amyloidosis. In a new transgenic model designed, HuAPPwt (Human APP 
wild-type), these mice never acquired amyloidosis with age. With these mice, it was 
shown that Aβ deposition could only be induced by injection of AD brain extract into 
these mice. In addition, without exposure to this material the mice shall never 
develop alterations. This finding clearly indicated the role of injected seed as the 
amyloidogenic agent. (Morales et al. 2011). On the similar lines human APP21 rat 
model was also developed, which does not manifest endogenous deposits of Aβ 
within the course of its median lifespan of 30 months. These animals were injected 
with the AD brain extract at the age of 3 months and incubated for 9 more months. 
After a 9-month incubation period, these rats too developed senile plaques and 
cerebral amyloid angiopathy in the injected hippocampus, whereas control rats 
remained free of such lesions (Rosen et al. 2011). Bioluminescence imaging 
technique was used to monitor Aβ deposition in-vivo in live bigenic mice (APP23 : 
Gfap-luc). In this study, the bigenic mice were inoculated by purified brain-Aβ 
aggregates and with synthetic Aβ aggregates in separate cohorts. The synthetic 
inoculated cohorts exhibited lower specific biological activity compared to the brain 
derived Aβ aggregate inoculated cohorts (Stohr et al. 2012). Overall, there is a 
burgeoning evidence to indicate that aggregated Aβ in the brain extract is essential 
for its β-amyloid-inducing activity and that the Aβ conformation in-vitro can be 
different from the one found in the brains. This has also been discussed in Aβ 
polymorphism section of this thesis. In the next section we will discuss, how amyloid 
aggregation has been studied in-vitro. 
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1.6 Amyloid Binding Dyes 
 
Small molecules like Congo Red and Thioflavin-T have been essential tools for 
characterizing Aβ aggregates, both in-vivo and in-vitro. These small molecules can 
also be used to monitor Aβ self-assembly in-vitro and confirm Aβ deposits in-vivo.  
 
1.6.1 Thioflavin-T 
 
Thioflavin-T is a benzothiazole containing fluorescent dye first observed to bind to 
amyloids in-vitro (VASSAR & CULLING 1959) and later in-vivo (Naiki et al. 1989) 
(Refer, Fig. 1.11B). Binding was also observed with synthetic Aβ fibrils (LeVine 
1993). This technique of using Thioflavin-T was adopted for quantifying relative 
amounts of aggregated Aβ in solution and also to monitor kinetics of fibril formation 
(LeVine 1999). Since then, Thioflavin-t has been widely adopted for monitoring Aβ 
aggregation.  
 
 
 
Fig.- 1.11: Thioflavin-T fluorescence (A) Structure of Thioflavin T (B) AD transgenic Mice brain 
cortex stained with Thioflavin-T (200x) (Shi et al. 2011)  
 
It was observed that, abolishment of β-sheet structure completely diminished 
thioflavin-T binding, providing indications that thioflavin-t binds to the cross- β 
secondary structure. Thioflavin-T fluorescence is known to increase when it binds to 
Aβ fibrils, because of the rotational freedom of the carbon-carbon bond between the 
benzothiazole and aniline rings is restricted (red) (Fig.- 11A).  
 
In the unbound state, the ultra fast twisting dynamics around the carbon-carbon bond 
are thought to effect rapid self quenching of the excited state due to rotational 
freedom and thereby resulting in low emission (Singh et al. 2010; Srivastava et al. 
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2010).  So, the mechanism of action of thioflavin-T binding to the fibrils can be 
summarized as the increase in the population of excited state when bound, due to 
the carbon-carbon bond restriction and rotational freedom in the carbon-carbon bond 
leading to self quenching in the unbound state. Binding of thioflavin-t to fibrils has 
been extensively used to monitor aggregation kinetics of fibril formation in many 
studies. The next section shall detail amyloid aggregation models that have been 
proposed using thioflavin-t fluorescence. 
 
1.7 Amyloid aggregation pathway models  
 
Techniques using thioflavin-t fluorescence have been developed to study and 
characterize the kinetics behind self-assembly of Aβ proteins into fibrils. Using the 
data from kinetic experiments involving amyloid formation in-vitro hypotheses have 
been formulated. Aggregation kinetic experiments have often reported different 
results, especially during the early times in the aggregation process before the fibrils 
have formed. As a consequence two competing hypotheses have been proposed to 
explain the results: Nucleated polymerization (NP) mechanism (Jarrett & Lansbury 
1993; Lomakintt et al. 1996) and nucleated conformational conversion (NCC) 
mechanism (Serio 2000). A simple schematic illustration of the nucleated 
polymerization model has been explained in the Fig.-1.10. Some of the salient 
features of the NP model are: (i) the lagtime exists for the seed to form, and the 
concentrations of oligomers smaller than the seed (critical nucleus) are assumed to 
be negligible and it represents the aggregate with the highest energy along the 
pathway. (ii) The concentration of soluble amyloid protein must exceed the critical 
fibril concentration for fibrils to form. (iii) The aggregation lagtime depends strongly on 
the initial concentration of the protein present (Powers & Powers 2006). On the 
contrary, several lines of evidence have shown presence of non-vanishing oligomer 
concentrations when monomer concentration is below the critical fibril concentration. 
These results led researchers to propose the NCC mechanism. In NCC mechanism, 
quickly formed oligomers undergo a slow conformational transition from a largely 
unstructured aggregate to a more organized nucleus (seed) that can grow into β-
sheet dominated fibril (Lee et al. 2011). Since, there could be major structural 
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differences between unstructured oligomers and highly ordered fibrils, some 
researches have suggested that the early oligomers may resemble micelles, when 
the free monomers are above critical micellar concentration (Schmit et al. 2011). 
 
There is much debate as to whether amyloid fibrils nucleate directly from protein 
solution or whether oligomers form first and then convert into fibrils (May be both the 
processes could be occurring concurrently). Since both NP and NCC mechanisms 
could be two extremes of underlying nucleation, a recently proposed NCC model, 
where it operates like a NP model (Schreck & Yuan 2013) takes a more balanced 
approach. i.e.- it contains the feature that the concentration of the seed (nuclei) is 
proportional to the monomer concentration raised to the nc power, as hypothesized in 
the NP model (Fig.-1.12a). There are more complex processes that add up to the 
large number of possible aggregation scenarios where elongation, dissociation and 
fragmentation processes determine whether fibrils grow longer or whether they break 
into smaller aggregates and drive the overall aggregation kinetics (Fig.- 1.12 b, c & d) 
(Cohen, Vendruscolo, Welland, et al. 2011).  
 
In an elaborate study on Aβ42 aggregation, researchers reported that Aβ fibrils act as 
nucleation centers, speeding the assembly of monomers into toxic oligomers through 
a fibril-catalyzed secondary nucleation reaction, rather than classical mechanism of 
homogenous primary nucleation. The result from this study reveals a positive 
feedback loop that originates from the interactions between the monomeric and 
fibrillar forms of Aβ42 peptide (Cohen et al. 2013) (Fig. – 1.12 e & f). This study is 
one of the rigorous works on Aβ42 kinetics in which Cohen and his coworkers 
considered three possible models for Aβ42 aggregation and tested them against 
experimentally measured aggregation. In the first model, the rate of Aβ42 
aggregation was only dependent on monomer concentration. However, fibril 
stabilities are also known to influence aggregation and fibril fragmentation would be a 
major aggregation driver (Fig.- 1.12d), as breaking fibril produces more fibrillar ends 
and Aβ assemblies can primarily start growing from those ends. The second model 
reflects the above-mentioned scenario, with the formation of Aβ aggregates 
depending strictly on the fibril concentration.  
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In the third model, the possibility considered was –secondary nucleation- in which the 
surfaces of the fibrils catalyze the formation of entirely new aggregates at a rate that 
depends on the concentration of both monomers and fibrils (Fig.- 1.12f). All of these 
three models were tested with 10 initial monomer concentrations. The third model 
gave the best fit for the experimental data suggesting that once fibrils form, they 
catalyze formation of new oligomers (Fig.- 1.12f). At present, very little is known 
about the structure of the oligomers  (cyan color) formed by secondary nucleation 
(Fig.- 1.12f). In an parallel kinetic study on nucleated polymerization and secondary 
nucleation indicated that secondary nucleation can occur on the surface of only 
specific types of Aβ fibrils indicating polymorphism specific growth kinetic processes 
(Jeong et al. 2013). Polymorphic fibril structure specific kinetic processes have also 
been reported to differ between agitated and quiescent Aβ40 fibrils in a study 
indicating different rate constants for aggregation (Qiang et al. 2013). Conclusively, 
this section summarizes, the commonly followed pathways by amyloid peptide to 
convert from its native state to amyloid fibrils (Fig.- 1.12) and describes the 
mechanisms of nucleation and the other allied processes like elongation, 
dissociation, fragmentation that overall contribute to fibril amyloid state. 
 
1.7.1 Monitoring amyloid aggregation kinetics 
 
The simplest way to represent the aggregation pathway that leads to formation of 
amyloid fibrils is by plotting the amyloid aggregate content in the sample versus time. 
This approach arises from the technique to monitor in real time the amount of 
amyloid material present after the induction of aggregation. The most widely used 
technique involves employing thioflavin-t dye, whose fluorescence increases upon 
binding to the amyloid material. The plot obtained from thioflavin-t fluorescence 
based aggregation kinetics usually resembles a sigmoidal trace. The aggregation 
trace can be divided into three phases as shown in the Fig.- 1.13. 
 
At the starting of the process, the amount of amyloid material does not increase as 
indicated by the black curve (Fig.-1.13). This phase is usually referred to as the 
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lag-phase. Several molecular events that occur in this phase have been simplified 
and illustrated in the inset below for simpler understanding. The protein undergoes 
an assembly followed by increase in size as the time passes leading to formation of a 
multimer / oligomer that nucleate to form the seed.  It is important to understand that, 
formation of non-amyloidogenic oligomers during the lag-phase cannot be detected 
by the thioflavin-t spectroscopy. The rate-limiting step aggregation is the formation of 
the seed to promote fibrillation.  The high-energy barrier for nucleation causes an 
elongated lag phase in spontaneous fibril formation. The length of lag-phase is 
generally referred to as the lagtime. The kinetic analysis of lagtime is employed to get 
information about the size of the seed and the rate of fragmentation of fibrils 
(Knowles et al. 2009). It has been shown that fibril fragmentation rates strongly 
affects aggregation kinetics as fibril fragments acts as a seed to augment 
aggregation. In the case of adding a seed (red-curve) (Fig.- 1.13), the lag-phase can 
be suppressed and increasing the seed concentration can all together eliminate the 
lag-phase in the seeded reactions.  
 
 
 
Fig.- 1.13: Spontaneous and Seeded amyloid aggregation versus time. Aggregate mass on the Y-
axis and time on the X-axis. The three phases of amyloid formation and the processes involved as 
simplified and explained in the legend below.  
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At the end of lag-phase, the aggregation nuclei or the seed is formed, following the 
conversion of non-amyloid like oligomers into amyloid-like ones. Consequently, the 
fluorescence of thioflavin-t positive aggregates formed increase over time evidenced 
by increased fluorescence intensity recorded. This phase is called as the exponential 
phase or the elongation phase. In this phase, template dependent and template 
independent conversion of non-amyloid-like into amyloid-like oligomers, 
fragmentation of formed aggregates along with formation of new aggregates by 
monomer or oligomer binding to the aggregate ends takes place resulting in fibril 
elongation. At the end of exponential phase the fluorescent intensity curve reaches 
the plateau phase. The thioflavin-t fluorescence signal does not increase further and 
amyloid fibrils are found in the sample when analyzed by electron microscopy. 
 
In conclusion, the plot of amyloid content (aggregation) versus the time (Fig.-1.13) 
gives fundamental kinetic information about the mechanism of protein aggregation 
and its processes as described in the section (Refer, Section. 1.7 & Fig.-1.12). The 
kinetics of the aggregation can be depend on several factors like the primary protein 
sequence, hydrophobic protein stability, monomeric substrate concentration, 
secondary structural preference, charges, agitation, physicochemical environment 
(Chiti et al. 2003; DuBay et al. 2004; Agopian & Guo 2012).  
 
1.7.2 Seeded Fibril Growth 
 
In the seeded fibril formation process, the lag phase is considerably abolished, 
accompanied by faster aggregate formation on addition of a preformed seed (cyan 
curve) (Refer Fig.- 1.14A). The added seeds are shown in cyan color as they belong 
to a different molecular conformation when compared to the red seeds that are 
formed in the de novo in the aggregation pathway.  By addition of cyan seeds, the 
conformational template is available to the substrate. The added seed actively 
recruits soluble or oligomeric Aβ to form fibrils resembling its conformational template 
(Fig.1.14A). The spontaneous (black curve) aggregation (Fig.- 1.14B) occurs in the 
similar fashion as shown in the Fig.- 1.13. Addition of seed to the substrate results in 
amplification of the seed template by seeding mechanism. 
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Exploiting this seeding property of the Aβ fibril growth, quantification techniques have 
been developed to detect minute quantities of Aβ42 seeds using an in-vitro assays 
(Arosio et al. 2014). Extending the seeding property, molecular templating seed 
mechanism has been shown in the case of Aβ40 fibrils, where seeding propagated 
different fibril morphologies bearing respective underlying molecular structures. 
These structures were found to be self-propagating when fibril were grown from 
preformed seeds in the assay and they resembled the parent fibril structure (Petkova 
et al. 2005). In the next section, we will look at some seeding assays that have been 
used for both detection and characterization of Aβ material from the brains and other 
biological specimens. 
 
 
 
Fig.- 1.14: Schematic model of seeded fibril growth. (A) Preformed Seed added to the assay called 
as seeded aggregation (cyan curve). (B) Spontaneous aggregation (black curve). 
 
 
1.8 Amyloid Beta seeding assays  
 
The working principle behind seeding assays have been explained in detail in the 
“Seeded Fibril Growth” section (Introduction, Section 1.7.2). Seeding assays can 
detect oligomers and fibrils, which are produced years or decades before the onset 
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of clinical symptoms and substantial brain damage in AD (Buchhave et al. 2012). The 
major advantage of using seeding assay is that, in-vitro seeding experiments have 
shown that seeded fibril growth preserves the molecular structure of the seed 
(Petkova et al. 2005; Paravastu et al. 2009; Lu et al. 2013). This molecular structural 
information might help in defining targets to inhibit amyloid formation and 
accumulation in the brain. All Aβ seeding assays utilize thioflavin-t fluorescence to 
monitor Aβ aggregation. The assays are performed mostly in a 96 well plate format 
with multiple replicates, as amyloid aggregation kinetics is heterogeneous. Table-1.1 
summarizes current developments in seeding assay literature and gives information 
on the nature of Aβ seed source, Aβ substrate used, assay condition parameters and 
characterization techniques used in the assay.  
 
 
Table- 1.1: Aβ  seed amplification and characterization assays. (* Indicates Aβ detection / 
quantification and # indicates Aβ detection and characterization) 
 
 
Assay 
Name 
Aβ Seed 
(derived) 
Aβ 
Substrate 
Fragmentation 
Of Seed Methods Ref. 
Fibril 
Amplificatio
n Assay-I# 
Human Brain 
Purified Aβ40 
Fibril 
Sonication 
Th-T, 
TEM, 
NMR 
(Paravas
tu et al. 
2009) 
Kinetic 
Aggregatio
n Assay* 
Mammalian 
cell culture 
media & mice 
brain 
homogenate 
Aβ40 
Fibril 
Sonication & 
Assay 
Agitation 
Th-T (Du et al. 2011) 
Fibril 
Amplificatio
n Assay- II# 
Human Brain 
purified Aβ40 
Fibril 
Sonication 
Th-T, 
TEM, 
NMR 
(Lu et al. 
2013) 
Aβ-PMCA* 
Human CSF / 
Oligomers Aβ42 
Assay 
Agitation Th-T 
(Salvado
r et.al, 
2014) 
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1.8.1 Fibril amplification assay- I 
 
In this assay (Paravastu et al. 2009), Aβ fibrils seeds are extracted from the frontal 
lobe brain tissue obtained from autopsy using a Aβ purification protocol described 
earlier (Roher & Kuo 1999). This assay was designed on the basis of a previous 
study, where it was shown that preformed Aβ40 fibrils can propagate their molecular 
conformations when seeded to the soluble Aβ40 (Petkova et al. 2005; Paravastu et 
al. 2008b). Using the fibril amplification assay, it was demonstrated that fibrils 
extracted from the brain tissue of the diseased AD patients can be used to seed the 
isotope-labeled soluble Aβ40 substrate to generate isotope-labeled fibrils in sufficient 
quantities for NMR characterization studies. Greater fibrillar homogeneities were 
observed in the samples seeded from patients as compared to the unseeded de-
novo aggregated control sample (Paravastu et al. 2009).  
 
However, this assay has several limitations like only synthetic Aβ40 substrate peptide 
could be used to capture the in-vivo brain-Aβ conformation. Moreover, NMR studies 
performed by the same group have also shown that in-vitro Aβ42 fibrils did not seed 
the soluble Aβ40 peptide and hence concluded that brain-seeded Aβ40 fibrils mostly 
likely arose from Aβ40 seeds and not Aβ42 seeds in the brain (Lu et al. 2013). The 
other disadvantage of this assay is that the brain aggregated-Aβ extraction protocol 
involves many steps where denaturants and detergents are used. This multiple 
protocol can alter, modify or select out a particular Aβ conformation from the brains 
and detergents traces can potentially alter and interfere with Aβ oligomerization 
kinetics in-vitro in the assay (Rangachari et al. 2006). 
 
1.8.2 Kinetic aggregation assay 
 
This assay (Du et al. 2011) is a selective and sensitive method for quantifying Aβ 
load from complex biological samples. The kinetic aggregation assay uses synthetic 
Aβ40 as the substrate peptide. The assay is able to quantitatively detect seeding 
competent Aβ aggregates in mammalian cell culture media, from C. elegans lysate 
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and in mouse brain homogenate. The added seed samples are sonicated and PK-
digested before added for seeding. Sonication is performed to increase the seed 
concentration and PK digestions to inactivate other proteins, which can potentially 
interfere with the aggregation in the assay.  
 
The aggregation was monitored by thioflavin-T and analyzed in terms of lagtime. It 
was found that the assays can quantify Aβ seeds in a concentration and time 
dependent manner even in the presence of complex biological samples (Du et al. 
2011). This is the first established seeding assay analogous to Colby’s seeding 
assay for prions (Colby et al. 2007). The limitations of the assay are: It uses only 
synthetic Aβ40 as the substrate peptide, which is not known to capture the Aβ42 
aggregate conformation (Lu et al. 2013; Pauwels et al. 2012). The assay does not 
employ any characterization technique to show any differences between the de-novo 
aggregated and the bio-seeded Aβ aggregates.  
 
1.8.3 Fibril amplification assay- II  
 
This assay (Lu et al. 2013) is more sophisticated version of the fibril amplification 
assay described earlier (Paravastu et al. 2009). The purification of Aβ seed from the 
brain involved fewer extraction steps, preserved more components of the brain tissue 
and permitted pure NMR samples to be generated in a single seeding step from 
smaller quantities of brain tissue. Aβ seeds were purified from the brains of two AD 
patients with distinct clinical histories. When the seeds were added to the assay with 
synthetic Aβ40 as the substrate and allowed to seed the fibril growth, the resultant 
fibril structures showed a single predominant Aβ40 fibril structure in each patient; 
however, the Aβ40 fibril structures were different from one another (Lu et al. 2013). 
The critical limitations of this assay are that it only uses synthetic Aβ40 as the 
substrate. In the same study, the authors declared that in-vitro Aβ42 fibrils did not 
seed the monomeric Aβ40 substrate in their assay; thereby declaring that the 
seeding of the substrate could have only occurred by Aβ40 fibrillar seeds.  
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1.8.4 Aβ-PMCA (Protein Misfolding Cyclic Amplification) 
 
This is the first study, where Aβ42 peptide has been used as the substrate to detect 
Oligomeric-Aβ from CSF (Salvadores et al. 2014). This assay exploits the nucleation 
polymerization of Aβ oligomers along with fragmentation property (intermittent 
agitation) to form new seeds, that can seed in the assay. The original PMCA protocol 
was originally developed to replicate the misfolding and aggregation of the prion 
protein (PrPSc) implicated prion disease (Morales et al. 2012), the same methodology 
was adapted to the Aβ in Aβ-PMCA. PMCA traditionally uses sonication as a 
mechanical force for fragmentation to break fibrils, however as shown by Caughey 
and colleagues, sonication can also be replaced by a strong agitation to achieve 
similar results using a procedure called QuIC (Quake-induced conversion) (Atarashi 
et al. 2011). In Aβ-PMCA, strong intermittent agitation has been used to fragment the 
fibrils, which increase the number of seeds, available for seeding in the assay.  This 
assay can detect up to 3 fmol of Aβ oligomers clearly and easily distinguishable from 
that observed in absence of Aβ seeds in-vitro (Salvadores et al. 2014). Using CSF, 
this assay is able to distinguish AD patients from control individuals affected by a 
variety of other neurodegenerative disorders or non-degenerative neurological 
diseases with an overall sensitivity of 90% and specificity of 92%. The limitations of 
this method, however has been that; it can only be used as a detection technique 
and not for amplification of in-vivo brain-Aβ42 conformational structure. As this assay 
is not compatible to utilize brain homogenate as seeds like the kinetic aggregation 
assay, thereby cannot be used to amplify the brain-Aβ conformation. This is because, 
Aβ42 aggregation kinetics is difficult to control under the influence of brain 
homogenate cellular debris and accessory components and that is one of the 
reasons, why CSF material was only used to seed the substrate Aβ42 in the Aβ-
PMCA.  
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1.9 The Research Question 
 
In summation to what has been published so far in literature, it can be speculated 
that proteopathic diseases such as Alzheimer's disease, Parkinson's disease, 
Huntington's disease, amyotrophic lateral sclerosis and prion diseases are 
increasingly being realized to have common disease pathological propagation by 
seeding mechanism like prions (Cushman et al. 2010; Jucker & Walker 2013; Stohr 
et al. 2012).  
 
In AD, Aβ40 levels in humans are roughly 5-fold larger than Aβ42 levels. However, 
Aβ42 is often considered important in AD, because of its strong propensity to 
aggregate in-vitro (Bitan et al. 2003; Yan & Wang 2006). In in-vivo studies, Aβ42 
peptides were also suggested to be more neurotoxic and may generate more free 
radical damage than Aβ40 (Klein et al. 1999). Due to the strong amyloidogenicity of 
the Aβ42 peptide and irreproducibility of aggregation kinetic data, many labs around 
the world have described this peptide as “Peptide from Hell” (Finder & Glockshuber 
2007). Currently, in the literature there are only methods to amplify and characterize 
the in-vivo brain-Aβ aggregate using synthetic Aβ40 as the substrate peptide using 
seeding assays. However the limitations of these assays are that, Aβ40 substrate 
cannot capture the Aβ42 conformation in the brain (Pauwels et al. 2012; Lu et al. 
2013; Kuperstein et al. 2010). 
 
The exact nature of the Aβ42 AD seed, in the brain still remains a conundrum and a 
bottleneck to be solved in the AD field. To this time, there have been no high-
resolution atomic measurements of fibrillar structures of Aβ in-vivo fibrils, which leads 
us to the question of whether the structural conformations observed in in-vitro 
preparations are faithful representations of those found in-vivo? This presses the 
need to develop a seeding assay that can conformationally template the brain 
aggregated-Aβ 42 structures for characterization studies. This assay must use 
recombinant Aβ42 as its substrate as synthetic forms lends itself to a variety of 
substitutions and modifications along with intrinsic adducts that severely affect the 
oligomerization kinetics (Finder et al. 2010). These intrinsic impurities can interfere 
Introduction 
 
  
40 
with the conformational templating mechanism, making the assay fibril samples 
incompatible for seeding studies. Establishing such an assay, will improve overall 
understanding of brain aggregated-Aβ conformations and how these conformations 
seed and lead to AD condition. So, far no studies have clearly indicated or 
characterized a particular Aβ42 species or conformation that can act as a seed and 
progress AD condition in the brain. Thus, our study is a first attempt to distinguish 
and characterize the brain-Aβ from the in-vitro spontaneously aggregated de-novo Aβ 
fibrils by developing an Aβ42- conformational seeding assay.  
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2 Aims and Objectives 
 
The mechanism of conformational conversion of soluble Aβ to fibrillar Aβ by seeding 
is still a poorly understood phenomenon. Several studies have attempted to 
understand the seeding mechanism by developing seeding assays. These assays 
mostly utilize synthetic Aβ40 peptide as the substrate (Paravastu et al. 2009; Du et 
al. 2011; Lu et al. 2013; Spirig et al. 2014) except for this assay (Salvadores et al. 
2014), where synthetic Aβ42 is used as the substrate. However, there are no studies 
in literature that utilize recombinant Aβ42 used as the substrate to amplify the in-vivo 
brain aggregated-Aβ conformation. This is crucial as Aβ42 peptide is known to be the 
main culprit and the toxic conformation in Alzheimer’s disease (Irie et al. 2005; Bitan 
et al. 2003). Our research has addressed this critical bottleneck by developing the Aβ 
conformational seeding assay (Aβ-CSA) using recombinant Aβ(1-42)M35L as the 
substrate and in-vivo transgenic mice brain aggregated Aβ as seeds.    
 
The first objective of this work was to develop a standardized approach by 
establishing a thioflavin-t fluorescence based in-vitro Amyloid Beta (Aβ) seeding 
assay using recombinant Aβ(1-42)M35L as the substrate and in-vitro aggregated Aβ 
as seeds. This assay must be able to detect Aβ seeding in a seed concentration and 
time dependent manner. The key parameters that can influence the Aβ aggregation 
kinetics in this assay will be investigated. In particular, these include (i) Substrate Aβ 
concentration  (ii) Concentration of Aβ seed detectable in the assay (iii) Aggregation 
buffer composition (iv) Assay plate-reader parameters like Agitation, Read Interval. 
To optimize these parameters in a systematic manner in the assay, an analytical 
method will be developed to determine the lagtime of aggregation from the raw 
kinetic data. 
 
The second objective of this work is to transfer the knowledge from the established 
Aβ seeding assay and then add transgenic mice brain-Aβ extracts as seeds in the 
form of brain homogenate.  This step requires standardizing and abrogating factors 
that are detrimental to Aβ aggregation and conformational seeding. In addition, this 
step should also ensure that, there is no interference of brain homogenate debris on 
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the seeding mechanism in the assay.  
 
Finally, the third objective is to characterize differences between the brain seeded 
and de-novo spontaneously aggregated Aβ fibrillar end products from the assay by (i) 
Aβ seeding kinetics (ii) TEM Investigation and (iii) Acoustic SSA (Selective Shear 
Amplification) technique of fragmenting the fibrils to assess fibril fragmentability by its 
seeding capacity in the assay. 
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3 Material and Methods 
 
Materials  
 
3.1 Instrumentation and Consumables 
 
A list of all instruments lab apparatus and consumables used during this thesis can 
be found in table- 3.1 below. 
 
Instrument / Consumables Manufacturer 
Autoclave (Top7000PST, Sauter) 
De-ionized water generation Millipore Systems 
Electron Microscope Zeiss Libra 120 plus 
Fluorescence Spectrometer TECAN M-1000 
Incubator Thermo Scientific Heraeus 
Mass Spectrometer Bruker Daltonics 
Micro-centrifuge Eppendorf Desktop 
Mid-bench Centrifuge Sigma (4K15C) 
pH Meter Thermo Electron 
Shaker  Eppendorf Thermo Mixer 
Spectrophotometer Thermo (Helios-Omega) 
Thermoshaker Infors HT 
UV Spectrometer Helios-Omega UV-Vis 
Ultra-centrifuge Rotor Beckmann 
Ultrasonifier (Cell-Lysis) Bandelin Sonopuls 
Ultrasonifier (MODIFIED) Misonix S-4000 
Ultrasonifier Horn Misonix 
Ultra-centrifuge Device (Discovery, Sorvall) 
96 Well Lids (Transparent, low profile lid) Greiner Bio 
96 Well PP plate (Flat bottom, Non-sterile) Greiner Bio 
Centrifuge tubes Beckman (Polycarbonate) 
Materials & Methods 
 
  
44 
Column packing Frits Isolute 
Falcon tubes (PP) Corning 
Filter membrane Millipore (0.2µm) 
Glass bottles Schott 
Micro-Cuvettes Bio-lab 
Micro-Tubes (PP) Eppendorf (1 & 1.5ml) 
Needles (18G & 23G) 
Pipette Tips Safe Seal Biozyme / Tip One 
Pipettes Eppendorf Professional + 
Sealing Para film Parafilm, USA 
Single use columns Isolute Accessories 
Tubings Tygon Saint Gobain 
Ultra-centrifuge (Discovery, Sorvall) 
 
Table -3.1:  List of Instrumentation and Consumables used in the Study 
 
3.1.1 Enzymes 
 
Proteinase-K (Merck), Protease Inhibitor (Roche) 
 
3.1.2 Bacterial Strain 
 
BL21 (DE3) from Strategene 
 
3.1.3 Chromatography Material 
 
Chelating Sepharose Fast flow (GE Lifesciences) (Lot - 10179318) and Toyopearl 
SP-650M (Tosoh Bioscience) 
 
3.1.4 Recombinant Peptides 
 
Aβ(1-42)M35L and Aβ(1-40)M35L 
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3.1.5 Phospholipid and Dyes  
 
Phospholipid 1,2-dihexanoyl-sn-glycero-3-phosphocholine (DHPC) was purchased 
from Avanti Polar Lipids, USA. Thioflavin-T dye (Merck), Commassie dye (Bio-Rad). 
 
3.1.6 Transgenic Mice Brain Homogenates  
 
Mice Cage id Euthanization Age Lab/ Company 
APP/PS1 (TG) 42#1268 6 months Matthias Jucker Lab 
APP/PS1 (WT) 42#1260 6 months Matthias Jucker Lab 
APP-23 (TG) 23#1057 N.A Matthias Jucker Lab 
APP-23 (WT) 23#1049 N.A Matthias Jucker Lab 
BL6 - 8 weeks Harlan 
 
Table- 3.2: Transgenic AD Mice and other models used to make brain-homogenate 
 
3.1.7 Buffers to Setup the Assay 
 
Composition of the aggregation buffer used in the study are as the following shown in 
the table- 3.3. Thioflavin-T* dye is added freshly 10-15 minutes before starting the 
aggregation reaction. The protein elution buffer is used to elute the protein from the 
cation-exchange column. The standard PBS is used for homogenizing the brains 
used in this study (Table- 3.2). 
 
Buffer Name Constituents Concentration / pH 
2X Aggregation 
Buffer (AB) 
Tris. HCl 
NH4OH 
Thioflavin-T* 
pH 
400mM 
50mM 
100µM 
7.7 
Protein Elution 
Buffer 
NH4OH 
pH 
50mM 
11 
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Standard PBS 
NaCl 
KCl 
Na2HPO4 • 2 H2O 
KH2PO4 
pH 
137mM 
2.7mM 
10mM 
2.0mM 
7.4 
 
Table- 3.3: Commonly used buffer in the Study (* in the text above) 
 
All the buffers are prepared fresh and filtered through 0.2µm Millipore filters and 
consumed within two weeks. 
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Methods 
 
3.2 Recombinant Protein Expression and Purification 
 
3.2.1 Plasmids 
 
The Plasmids given below (Table- 3.4) are used in this study. Dr.Thorsten Lührs and 
Frau. Stefanie Loss engineered these plasmids in the year 2007 at HZI. 
 
Sr.No Vector Fusion Construct Features 
1 
pETRO 
2.31 
6x His- (NANP)19 -
RSM-Aβ (1-42) 
M35L by 
Dr.Thorsten Lührs 
N-Terminal Hexa His-TAG and 
engineered cyanogen bromide 
methionine cleavage site at the N-
terminus of the Protein of interest 
2 
pETRO 
2.31 
6x His- (NANP)19 -
RSM-Aβ (1-40) 
M35L by 
Dr.Thorsten Lührs 
N-Terminal Hexa His-TAG and 
engineered cyanogen bromide 
methionine cleavage site at the N-
terminus of the Protein of interest 
 
Table – 3.4: Vector Aβ constructs used in the study 
 
There are several elements contained in this protein sequence construct detailed in 
the figure- 3.1. The Amino terminus contains a hexa-histidine tag for Immobilized 
metal ion affinity chromatography (IMAC) purification on the nickel chelate column. 
The -NANP- sequence tag is repeated 19 times. This tag is bulky and a highly 
hydrophilic segment, which occurs, in the surface protein of parasite plasmodium 
falciparum.  It has been integrated due to its high expression with E.coli, and it 
renders the amyloid protein soluble in aqueous solutions. The Methionine has been 
strategically introduced at the start of the Aβ (M35L) sequence, to facilitate cleavage 
of the protein construct by Cyanogen Bromide (Döbeli et al. 1995; Thorsten et al. 
2005). The Vector plasmid map of Aβ(1-40)M35L is given in the figure -3.1. The 
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Vector plasmid is the same for Aβ(1-42)M35L is the same as the Aβ(1-40)M35L 
except that it codes for 2 more amino acids in the C-terminus. 
 
 
 
Fig.- 3.1: Vector construct of Aβ(1-40)M35L 
 
3.2.2 Protein Expression Bacteria 
 
BL21 (DE3) competent E.coli strain cells are used in this study for high-level protein 
expression and easy induction. These cultures are initially sub-cultured and later 
maintained as stock of 100 µl cell suspension aliquoted in small eppendorf tubes  
(1.5mL), which are flash frozen and stored at -80 °C until further use. The genotypic 
description of the construct is given below: 
 
E.coli Strain Genotypic Construct Source 
BL21 (DE3) 
F– ompT gal dcm lon hsdSB(rB- mB-) λ(DE3 [lacI 
lacUV5-T7gene 1 ind1 sam7 nin5]) 
Stratagene 
 
3.2.3 Bacterial Transformation and Culturing 
 
Transformation of BL21 (DE3) was done by quick heat shock method and was plated 
onto (LB) Agar plate containing the antibiotic ampicillin. The constituents of the LB 
Materials & Methods 
 
  
49 
agar are given in the table- 3.5. 
  
Medium Composition 
Lysogeny Broth (LB) 
1% (w/v) Tryptone, 0.7% (w/v) NaCl, 
0.5% (w/v) yeast extract, adjusted to 
pH 7.5 
LB-Agar Amp 
Lysogeny Broth + Ampicillin 
(100µg/mL), 1.5% (w/v) agar-agar 
 
Table- 3.5: Composition of Lysogeny Broth and Lysogeny Agar 
 
Bacterial cells suspension aliquot were transferred to ice bath from -80 °C storage. 
The 100µl of BL21 (DE3) cell suspension in the aliquot was allowed to thaw on ice for 
10 minutes. 40-50ng of the vector plasmid from table- 3.4 was transferred into the 
BL21 (DE3) thawed suspension on ice under the clean bench. After pipetting the 
vector plasmid, the suspension is incubated on ice for 15 minutes. After incubation, 
the suspension is transferred onto LB Amp –Agar petri plate under the clean bench 
hood and the suspension is spread over the agar surface with the help of sterile 
glass beads shaking. The glass beads are later discarded and the LB Amp –Agar petri 
plate is transferred into 37°C incubator overnight (14-15 hours) until colonies are 
detected in the plate. The culture medias and buffers used in this work are explained 
in the table- 3.6, 3.7 and 3.8. Both the culture media and the buffers used have been 
heat sterilized by autoclaving (121°C, 2 bar, 20 min). Heat sensitive media 
ingredients were sterile filtered (0.2µM pore size, Millipore). Antibiotics and MEM 
Vitamins (Sigma-Aldrich 100x) in the media are added after the media cooled down 
to less than 50°C. 
 
 
Media Medium Main Function 
Pre-culturing Media ZYP-7050 Colony multiplication 
Auto-Inducing Media ZYP-5052(Studier 2005) Protein Expression 
 
Table- 3.6: Media used to culture recombinant bacterial cells 
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Both the ZYP-7050 and ZYP-5052 medias only differ by a presence of lactose in the 
later and absence in the former. 
 
Media Ingredients Concentration 
Tryptone 1% 
Yeast Extract 0.5% 
Na2HPO4 25mM 
KH2PO4 25mM 
NH4Cl 50mM 
Na2SO4 5mM 
MgSO4 2mM 
Trace Elements (1000x) O.2x 
MEM Vitamins (100x) 2x 
Antibiotics (Ampicillin) (1:1000) 1µg/mL 
Table- 3.7: Composition of Culture Medias 
 
The carbon source in media ZYP-7050 is Sugar 5050 Mix and for ZYP-5052 is 
Sugar 5052 Mix. The composition of the sugar mixes is shown in the table 3.8. 
 Ingredients Concentration 
Sugar 5050 Mix 
Glycerol 0.5% 
Glucose 0.05% 
Sugar 5052 Mix 
Glycerol 0.5% 
Glucose 0.05% 
Lactose 0.2% 
Table- 3.8: Carbon source used in the culture medium 
 
Methods to express the recombinant protein were adopted from the auto inducing 
media protocol established by (Studier 2005). The methods were standardized for Aβ 
protein expression in this work (Data not shown).  
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Pre-Culturing  
 
Transformed bacterial colony is cultivated for gene expression and plasmid 
amplification. A transformed single colony of bacteria from the agar plate is 
inoculated into ZYP-7050 pre-warmed (37°C) pre-culture media described in the 
table 3.7 and 3.8. This media is handled in culture flasks (500ml) with baffles and is 
placed in a shaker (Infors HT) at 37°C, shaking at the speed of 180RPM. The Media 
is cultured; until the bacterial cell growth reaches the exponential phase to the OD600 
between 4 to 5. It took around 7-8 hours to reach this OD. 
 
Main Culturing 
 
Inoculation of pre-cultured bacterial material into auto-inducing media is called as 
main culturing. The composition of the main culture or auto-inducing medium is 
discussed in the table 3.7 and 3.8. The Auto-inducing main culture is pre-warmed to 
37°C and cells from pre-culture media are inoculated to a starting OD600 of 0.1. The 
main culture flasks are large volume culture flasks (1000ml) with baffles and placed 
inside shaker at 37°C with vigorous shaking at 200 RPM. In the main culture 
medium, the bacterial cells are induced by the lactose sugar activating the Lac 
Operon containing the DNA of the protein of interest and thereby resulting in desired 
protein expression. 
 
Bacterial Harvesting  
 
Bacterial cells from the main culture are harvested when they reach the OD600 of 6-7. 
The main culture media is centrifuged (6000g, 10 minutes, 4°C) in 1000ml centrifuge 
flasks and the pellets recovered are stored at -80°C not more than 3 months before 
used for pellet protein purification. 
 
3.2.4 Recombinant Protein Purification  
 
An Inclusion body purification of the Aβ protein is performed from the harvested 
pellet. The pellet is resuspended by constant magnetic stirring in “Buffer G” at room 
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temperature for 1 hour. The composition of “buffer G” is given below. The volume of 
“buffer G” added to re-suspend the pellet is ten times the mass of the pellet. After one 
hour, the suspension is then sonicated for 16 minutes (ON:OFF= 0.5s: 0.5s, 150 
Watts) (Bandelin Sonopuls TT13/F2). The ultrasonication shear force ruptures the 
bacterial cells, and the sonicated suspension is centrifuged at 18,000g for 30 
minutes. Centrifugation, pellets down the cell debris and now the protein remains in 
the supernatant in a denatured state.  
 
Solution/ Buffer Composition Company 
Buffer G 
6M Guanidine-HCl, 10mM Tris-
HCl, 100mM NaPi, pH = 8.0 
Sigma-
Aldrich 
 
IMAC Denatured Protein Purification 
 
IMAC stands for Immobilized Metal ion Affinity Chromatography. The protein rich 
supernatant is incubated of Ni-Sepharose equivalent to the mass of the weighed 
harvested pellet. The Ni-Sepharose is stored in 20% ethanol solution. It is 
equilibrated with “Buffer G” before adding to the supernatant from the earlier step. 
The supernatant suspension with the Ni-Sepharose is slowly stirred in a beaker using 
a magnetic stirrer at room temperature for 1 hour. 
 
Material Composition Company 
Chelating 
Sepharose  
Fast flow (Lot 
No.- 10179318) 
Nickel (NiSO4) is Immobilized to 
chelating Sepharose by protocol 
provided by the company 
GE-
Amersham 
 
In the incubation step, the Nickel is able to capture the His-tagged expressed protein 
from the supernatant. The suspension is briefly spinned at 1000g for a minute to 
recover the Ni-Sepharose laden with the expressed protein and the supernatant is 
discarded. The expressed protein laden Ni-Sepharose sediment is re-suspended in 
10 times volume of Ni-sepharose in “Buffer G” and is washed by centrifugation-
sedimentation method (1000g /1 Minute) for 4 times discarding the supernatant and 
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resuspending the pellet at each step. The Sediment is then re-suspended in 8M Urea 
and washed for 4 times by the same method. This is followed by one time wash with 
de-ionized Milli-Q water. Later, the sediment is washed 4 times with 40% Acetonitrile. 
After discarding the supernatant, 3.4% Formic Acid volume is added to the volume of 
Ni-Sepharose sediment. A solution containing 40% Acetonitrile and 3.4% Formic acid 
is then added in equal volume to the Ni-Sepharose sediment, mixed, and allowed to 
incubate for 5 minutes at room temperature. The Solutions and buffers required in 
this step are summarized in the table- 3.9. 
 
Chemical / Buffers Composition Company 
Urea 8M Urea Solution Merck 
Acetonitrile 40% Acetonitrile J.T.Baker 
Formic Acid <98% Pure Roth 
Table- 3.9: Chemical materials used IMAC protein purification 
 
Expressed Protein Elution and Quantification 
 
Added formic acid results in the pH change and the pH change induces the liberation 
of His-Tags from the immobilized Nickel. For Aβ(1-42)M35L, the suspension is 
centrifuged and the supernatant containing the protein is filtered by filter paper (Pall 
Life-science).  3-4 fractions of the protein are eluted by further adding 40% 
Acetonitrile + 3.4% formic acid solution. In the case of Aβ(1-40) M35L elution, the 
protein laden Ni-Sepharose is loaded onto a column, packed by frits on both ends, 
and the protein is eluted drop by drop. The concentration of the expressed protein is 
determined by UV absorbance. The fractions of high yield and purity are combined 
together and the protein concentration is adjusted between 20-25mg/ml using 40% 
Acetonitrile and 3.4% formic acid solvent. To this fraction, equal volumes of <98% 
Formic Acid (Roth) analytical grade is added to denature the expressed protein 
completely, bringing the final protein concentration down to ~10-12.5 mg/ml. 
 
Cyanogen Bromide Cleavage  
 
As explained in plasmids section (Refer, Section- 3.2.1), the expressed protein can 
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be cleaved at the starting Methionine position, which precedes the Aβ sequence (M-
DAEFRHD….). Cyanogen bromide is added to the protein fraction at the 
concentration of 50 mg/mL and incubated for 3-4 hours at room temperature to 
achieve efficient peptide cleavage to separate the desired Aβ peptide from the -
NANP- expression tag. The cleaved protein mixture is aliquoted, flash freezed and 
stored at -80°C and used within 6-8 months.  
 
Chemical Concentration Company 
Cyanogen Bromide (BrCN) 5M BrCN Stock Sigma-Aldrich 
 
Cation Exchange Chromatography 
 
Ion exchange chromatography is a technique that allows the separation of ions and 
polar molecules based on their charge. The cleaved raw protein solution consists 
mixture of the Aβ peptide (Hydrophobic) and the –NANP19 (Hydrophilic) tag repeat. 
The stationary cation exchange material displays a negatively charged functional 
group, which are able to retain the positively charged cations. To separate the Aβ 
peptide from the raw peptide mixture, cation exchange chromatography method is 
used. The materials and buffers required for cation exchange chromatography are 
summarized in the table- 3.10.  
 
Buffer Composition Company 
Buffer A 1% Acetic Acid Roth 
Buffer B 
1% Acetic Acid, 20% 
Acetonitrile, 1M NaCl 
Roth, JT Baker, 
Merck 
Buffer C 
1% Acetic Acid, 20% 
Acetonitrile 
Roth, JT baker 
Buffer D 
50mM Ammonium 
Hydroxide (pH 10-11) 
Fluka 
Table- 3.10: Materials and Buffers used in the Ion-exchange chromatography 
 
10-12 mg of the cleaved raw peptide containing approximately 50% Formic Acid is 
diluted to 0.7% Formic Acid with de-ionized Milli-Q water. This solution is loaded 
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drop-by-drop onto the cation exchanger column (2mL – Toyopearl SP-650M) and 
equilibrated with Buffer A.  After loading the column with the peptide, the column is 
washed with 5 CV of buffer-A, buffer-B and buffer-C. Before elution, the column is 
washed with 2CV wash with Buffer A and finally eluted with Buffer D. The fractions 
are collected in micro-uv cuvettes and protein concentration is determined in the 
cuvette fractions. The fractions with higher protein purity are combined together and 
maintained on ice until further purification by ultra-centrifugation.  
 
Ultracentrifugation Purification 
 
The combined fractions of the peptide are then purified by ultra-centrifugation. The 
protein is pipetted in 5ml Beckmann rotor polycarbonate tubes and ultra-centrifuged 
(Order Ref- 349622, Lot- P202MPI) at 1,68,000g for 1 hour at 4°C. After 
centrifugation, the concentration of the protein is determined by UV- absorbance. 
After concentration determination, the protein is stored on ice until further use. 
 
3.2.5 Peptide Quantification by UV Absorbance 
 
The physico-chemical parameters of the expressed Aβ peptides and Aβ peptides 
used in this study are summarized in the table- 3.11. The parameters were calculated 
using program called as PROTPARAM (Walker 2005) found in the web 
(www.expasy.org). 
 
Protein Amino-Acids MW (kDa) pI ε280 (M-1 cm-1) 
Aβ(1-42)M35L 42 4496.0 5.31 1490 
Aβ(1-40)M35L 40 4311.8 5.31 1490 
Table- 3.11: Physico-chemical parameters of the protein purified 
 
From the information in the table- 3.11, we can calculate the protein concentration 
using Lambert Beer law. The concentration of the protein was determined by 
absorption of the protein at 280nm against the protein constituent buffer. ε280 refer to 
the molar extinction coefficient expressed in units of M-1 cm-1, at 280nm measured in 
water. By dividing molar extinction coefficient by molecular weight, the result gives 1 
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unit of absorbance gram per liter of the protein.  With molecular coefficient, molecular 
weight and absorbance at 280nm we can determine the concentration of the protein.  
 
3.2.6 Characterization of Peptide by Mass Spectrometry 
 
ESI-MS / MALDI-TOF-MS was performed to verify the mass, intactness and salt 
contamination in the recombinantly produced protein. Fresh soluble protein of high 
concentration and high pH (10-11) was always used for analysis for accurate results. 
For MALDI-TOF-MS, the molecular masses were determined in the positive-ion 
mode on a Bruker Ultraflex time-of-flight mass spectrometer (Bruker Daltonics 
GmbH).  
 
 
Fig.- 3.2: Mass Spectroscopic (MS-ESI) Analysis of Aβ(1-42)M35L (Top) showing a molecular 
mass of 4495 Daltons and Aβ(1-40)M35L (bottom) showing a mass of 4311 Daltons. 
 
Manfred Nimtz, Anja Meier and Undine Felgenträger performed Mass spectrometry 
measurements at the institute (HZI, Braunschweig). Freshly prepared soluble Aβ 
from ultracentrifugation was analyzed by MS-ESI to verify the molecular mass, 
protein intactness and salt contamination from cation-exchange purification. Mass 
spectrometric analysis of purified Aβ(1-42) M35L and purified Aβ(1-40) M35L 
peptides (Fig.- 3.2) are well inside agreeable molecular weight limit with peaks at 
4495 Da and 4311 Da respectively. Presence of a single peak indicates intactness of 
the purified protein. The consequent step was to select the right substrate 
concentration of Aβ’s to use in the amyloid seeding assay. 
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3.3 Other Methods 
 
3.3.1 Preparation of Phospholipid DHPC 
 
DHPC encompasses two hexanoic acid chains and a choline headgroup (Fig.- 3.3). 
Stock solutions of DHPC (1,2-dihexanoyl-sn-glycero-3-phosphocholine), were 
prepared by solubilizing the phospholipid powder in 2X Aggregation Buffer (400mM 
TRIS-HCl; 50mM NH4OH; pH 7.7). DHPC stock solutions were prepared using lipid 
specific density; volume, mass and concentration calculations to achieve desired 
stock concentration. DHPC is highly hygroscopic and hence prepared under nitrogen 
cabinet and later the stock solution (200mM) is mixed at room temperature placing on 
a rotation wheel on slow rotation for 4-5 hours for dissolving lipid solids completely. 
Care must be taken to avoid frothing the DHPC stock solution while dissolving. 
 
 
Fig.- 3.3: Structure of Lipid Micelles (DHPC) 
 
3.3.2 Preparation of Amyloid Beta Seeds  
 
Aβ Seeds are preformed fibrillar / oligomeric form of Aβ peptide. They are classified 
into two from where they have been generated or derived. Two types of Seeds used 
in this study are: (i) De- novo Seeds and (ii) Brain aggregated-Aβ seeds.  
 
De-novo Fibrillar Seeds 
 
Freshly Soluble Aβ at high concentration (100µM) is allowed to aggregate 
spontaneously at 100µM in 1X Aggregation buffer at room temperature and allowed 
to equilibrate for ca. 2-3 weeks. The concentration of the peptide is kept high 
(100µM) to facilitate accelerated fibril formation. There are two types of de-novo 
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aggregated fibrils used as seeds in our study, they are: (i) Aβ(1-42)M35L fibrillar 
seeds and (ii) Aβ(1-40)M35L fibrillar seeds. The de-novo fibrillar seeds are formed 
under quiescent condition at room temperature. 
 
Brain Aggregated-Aβ Seeds 
 
 Brain Aβ seeds are Aβ accumulates deposited in the brain of transgenic mice used 
in this study (Refer, Table- 3.2). Brain Seeds are prepared by homogenizing the brain 
of transgenic mice. 10% Brain Homogenate is prepared by homogenizing the brain 
by needle-syringe homogenization method in 1X PBS buffer.  Syringe 
homogenization procedure is initially performed with few strokes with 18G needle and 
later few strokes with 23G needle on ice. After homogenizing, the brain homogenate 
is spinned down at 3000g for 5 minutes at 4°C. The supernatant is carefully pipetted 
and collected in aliquots, flash freezed and stored at -80°C until further use. The 10% 
Brain Homogenate are used as brain- Aβ seeds later in the assay.  
 
3.3.3 Proteinase-K Digestion of Brain Homogenate  
 
Brain homogenates are Proteinase-K (PK) digested to inactivate the native cellular 
proteases present in the brain homogenate. This is done to prevent the cellular 
proteases from digesting the soluble Aβ added as substrate in the assay. The total 
protein content in the brain homogenate is determined using Bradford assay (~5-6 
mg/ml). 1:500 of PK is added w/w to the determined total protein content in the brain 
homogenate. The in-vivo brain aggregated Aβ aggregates are PK digestion resistant 
(Stohr et al. 2012) and hence PK does not affect the in-vivo aggregated Aβ in the 
brain. The PK digestion reaction is carried on at room temperature for 2 hours on a 
thermo-shaker (25°C, 100 RPM). The PK is inactivated by boiling the sample at 95°C 
on a heating block for 10 minutes and subsequently cooling it on ice. Later, this PK 
digested brain homogenate is added to the assay as a source of brain derived Aβ 
seeds.   
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3.4 Thioflavin-T Fluorescence Spectroscopy 
 
3.4.1 Experimental Setup 
 
Fluorescence spectroscopic measurements were carried out in TECAN M1000 
Fluorescence plate reader controlled by Tecan i-control software. A 96 well plate 
(Black Polypropylene, Greiner Bio, Flat bottom, Non-sterile) was used for the assays. 
The reaction is pipetted into the micro-wells, leaving aside the borders of the 96 well-
plate to avoid plate-edge effects. The plate is closed with a 96 well plate transparent 
lid (Greiner Bio, Transparent, low profile lid) and sealed with paraffin wax tape for 
insulation to avoid evaporation and transpiration. The temperature of device during 
the measurement is maintained at constant temperature of 25°C and the readings 
are recorded in the range between 24.5°C – 25.5°C. 
 
Thioflavin-t fluorescence intensity is measured in the 96 well-plate at 488 nm after 
excitation at 442 nm using a Tecan (M1000) spectrofluorometer plate reader. For 
both, excitation and emission, a bandwidth of 5 nm was used and multiple readings 
were obtained per well (4 x 4, border 1000 µm) in a circular pattern. A single flash 
was used with a flash frequency of 400Hz. Some experiments are recorded under 
quiescent mode and some under agitation mode to ensure homogeneity in sample 
representation during measurements. The 96 well plate was linearly agitated for 10 
second with 5 mm linear amplitude. This agitation enables fragmentation of Aβ 
aggregates to form seeds in the assay, which accelerates the seeding in the assay.  
The gain was set manually in the range 90-105 and the Z-position (~ 21500 µm) is 
adjusted manually before starting of the measurements. The kinetic cycle for 
measurements was programmed from 10-40 minutes as mentioned for each 
experiment. 
 
3.4.2 Starting Amyloid Beta Aggregation Reaction in the Assay 
 
Soluble Aβ obtained after ultracentrifugation purification is solubilized in high pH 
buffer- D (50mM NH4OH, pH 11). The Aβ peptide remains soluble and usable for 
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assay within 2-3 hours on ice after purification. For aggregation and seeding studies 
in the assay, the pH of Aβ peptide is brought down to 8.1. This is done using the 2X 
Aggregation buffer (400mM Tris-HCl in 50mM NH4OH, pH 7.7). The 2x aggregation 
buffer stock is added to the desired concentration of soluble substrate Aβ in equal 
volumes leading to final 1X aggregation reaction condition (200mM TRIS, 50mM 
NH4OH, pH 8.1) in the assay. Adjusting the pH of the 2X Aggregation buffer can vary 
the final pH of the aggregation reaction condition. Thioflavin-T compound is added 
approximately 3 times the concentration of protein to the reaction mix (~90µM).  The 
phospholipids and thioflavin-t dye to be added in the assay are first solubilized in the 
2X aggregation buffer to the desired concentration and then added to the substrate 
Aβ peptide in equal volume to start the aggregation reaction. This strategy has been 
used in order to reduce the experimental time delay between the start of aggregation 
and recording the fluorescence measurement in-vitro.  
 
3.4.3 Data Parsing and Smoothing for Lagtime Analysis 
 
The data is measured using the TECAN M1000 device. The data is digitally recorded 
in a Microsoft excel sheet file (Fig.- 3.4). The excel sheet contains quantitative 
fluorescence intensity measurements recorded in time intervals from the user 
selected wells of the 96 well plate. The data is acquired in kinetic cycles as 
programmed by the user in the TECAN proprietary i-control software.  
 
The generated raw data is parsed by a macro excel file. The “Parse” macro extracts 
the time interval mean values generated from the multiple reads (Fig.- 3.4A) and 
prints them onto a summary tab in the excel file (Fig.- 3.4B). The macro processed 
data is saved as a summary tab in the excel sheet file. Later, the kinetic data 
recorded from each well corresponding to the reactions is plotted against the time 
domain in a scatter plot and analyzed for the quality of the aggregation data. It was 
generally found that reactions with added seed produced systemic fluctuations in the 
aggregation data (Fig- 3.5A). We were able to get rid of the fluctuations used a 
filtering algorithm discussed in the next section.   
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Fig.- 3.4: Parsing and creating summary from original raw data from TECAN device. 
 
Savitzky-Golay Signal Smoothing 
 
Signal smoothing is widely used to increase the signal to noise ratio of a signal 
without distorting the signal a lot. The goal of smoothing is to remove rough fast 
changing components of the signal and highlight slow changes in value for that it is 
easier to see trends in the data. There are different filters available to perform signal 
smoothing (i) Moving Average filter (ii) Savitzky-Golay (SG) filter. The moving 
average filter is good at rejecting noise but introduces transient effects in the process 
and the processed data from the filter lags behind the original data. This lag is due to 
the delay introduced by the smoothing filter. This delay needs to be taken care of 
explicitly in this case as we are evaluating the aggregation lagtime of reactions.  
 
To track data more closely and to account for transient effects we chose Savitzky-
Golay filter also known as digital smoothing polynomial filter or least squares 
smoothing filter to smooth our data. SG filter performs polynomial fitting to segments 
of data known as frames. They are particularly effective for data smoothing and are 
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typically used to smooth out noisy data that even without noise span a large range of 
frequencies. SG filters tend to preserve the high frequency components of the data 
while smoothing it. The Savitzky-Golay filter method essentially performs a local 
polynomial regression to determine the smoothed value for each data point. This 
method is superior to adjacent averaging because it tends to preserve features of the 
data such as peak height and width, which are usually attenuated by adjacent 
averaging.  
 
One approach for smoothing the time series data is to replace each value of the 
series with a new value, which is obtained from a polynomial fit to 2n+1 neighboring 
points (including the point to be smoothed), with n being equal to, or greater than the 
order of the polynomial. A second order polynomial fit with 17 data points was 
designed for the moving frames SG filter. The data consists of a set of n {xj, yj} points 
(j = 1, ...., n), where x is an independent variable (time) and yj is an observed value 
(fluorescence units). They are treated with a set of m convolution coefficients, Ci 
according to the expression given below equation [1]. 
 
 
 
For an 17-point smoothing quadratic polynomial, m = 17, i = (-8, -7, -6, -5, -4,   -3, -2, 
-1, 0, 1, 2, 3, 4, 5, 6, 7, 8) and the jth smoothed data point Yj, is given by this equation 
[2] in the excel spreadsheet as below: 
 
 
 
Where C-8 = -21 / 483, C-7 = -3.5 / 483, C-6 = 14 / 483… etc. The convolution 
coefficients values used for smoothing are -21, -3.5, 14, 26.6, 39, 46.5, 54, 56.5, 59, 
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56.5, 54, 46.5, 39, 26.5, 14, -3.5 and -21. The formula filter of window size 17 is 
moved over the data points and smoothed data points are obtained for the same 
data. However, the (m-1)/2 points at the start and end of the series cannot be 
calculated using this process, hence the raw data is artificially extended by adding, in 
reverse order, copies of the first (m − 1)/2 points at the beginning and copies of the 
last (m − 1)/2 points at the end. 
 
For all the data points on the Fluorescence-time F(t) aggregation curves (black and 
red) with set of n {xj, yj} points (Fig- 3.5A), the Savitzky-Golay  equation [2] is moved 
in 17 - frames to derive the filter smoothened values (Yj) and later plotted against 
time (Fig- 3.5B). Data smoothing was only done, when there was an increase in 
noise levels compared to signal, required for determining the aggregation lagtime 
(e.g.- as in figure 3.5A).  
 
 
Fig- 3.5: 17- point Savitzky-golay smoothing. (A) Indicates raw data from spontaneous aggregation. 
(B) Indicates the same data after Savitzky-Golay filter smoothing. 
 
3.4.4 Determination of Lagtime  
 
The starting time point of aggregation of the peptide or the length of the lag phase is 
referred to as the lagtime (t lag). There are several methods used to determine the 
lagtime of amyloid aggregation. A frequently used way to measure the lagtime is to 
extrapolate the slope of maximal growth rate of the aggregation curve (Ft) back to the 
time axis and use the intersection with the fluorescence baseline as the value for the 
starting point of aggregation (Fig.- 3.6). Maximal aggregation rate (Ka) is taken to be 
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the slope of the linear portion of the aggregation kinetic curve (Ft), visualized by the 
red dotted line in fig- 3.6. The intercept of this maximal slope line with the time-axis is 
determined as the lag-time (t lag) of aggregation for that particular aggregation 
reaction (Auer & Kashchiev 2010). 
 
 
Fig.– 3.6: Determination of Lagtime (t lag). The green curve trace represents the aggregation kinetic 
data time-point curve F(t). The dotted redline shows the maximal growth rate (Ka). The maximal 
aggregation rate (Ka) is determined with the aid of the F(t) inflection point co-ordinates t0 and F0. Partly 
adapted from (Auer & Kashchiev 2010). 
 
The maximum rate of aggregation (Ka) is calculated by finding the maximum slope of 
the F(t) curve by using a moving slope formula in excel with a window size of 5 
aggregation data points. The moving slope formula calculates the best fit for the 5 
points and it is extended over the entire data points in the series. Later to determine 
the intersection of the maximal slope with the time axis to calculate the lagtime (t lag), 
the y- intercepts of the F(t) curve data points corresponding to the maximal slope line 
are calculated using the intercept formula in the excel. Now, determining the x-
intercept of the maximal slope (Ka) becomes easier using the slope-intercept straight-
line equation [3] as given below: 
y = mx + b 
 
Where, y is equation of the straight line, m is the slope, “x” is the x-intercept and “b” is 
the y-intercept. The baseline of the F(t) curve averaging the first five data points is 
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subtracted with the y-intercept to get the real value of the y- intercept “b”. To 
determine the x-intercept (t lag), the value of y is substituted to 0 and then values for 
the maximal slope “m” and the corresponding value of the y-intercept “b” are 
substituted in the formula.  
 
3.5 Characterization of Amyloid beta aggregates  
 
3.5.1 Transmission Electron Microscopy  (TEM) 
 
The electron microscopic analysis was done with the energy-filtered transmission 
electron microscope (EF-TEM) Zeiss Libra 120 plus Zeiss Oberkochen, Germany), 
running at 120 kV and with 1 µA emission current. Images were recorded within a 
magnification range of x12500 to x50000 with a 2048 x 2048 cooled CCD-camera 
(SharpEye, Tröndle, Moorenwies, Germany) under the regime of the iTEM software 
package (OSIS, Münster, Germany) in the 'elastic bright field mode', using an energy 
slit width of 10 eV. Protein fibril sampling copper grids were layered with butvar foil, 
air-dried and C-coated from carbon thread by resistance evaporation, using a BalTec 
MED020 (BalTec, Liechtenstein), and were glow-discharged from air for roughly 10 
seconds.  
 
TEM of Aβ aggregates 
 
Aβ fibrils were adsorbed to freshly glow-dischared C-butvar foils for usually 60 
seconds at ambient room temperature. The fibril concentrate was maintained at 
134mg/ml deduced from the initial monomeric peptide concentration. They were 
shortly blotted with filter paper (Schleicher & Schüll, Dassel, Germany). The 
preparate was then immediately touched to a drop of 1 % (w/v) uranyl acetate; pH 
4.0 and was blotted within 3 to 5 seconds and air-dried before TEM analysis. Electron 
microscopy experiments were performed in close collaboration with Dr. Heinrich 
Lünsdorf (HZI, Braunschweig). 
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3.5.2 Acoustic SSA Setup 
 
Fragmentation of Aβ aggregates by Acoustic SSA (Selective Shear Amplification) 
was performed using instrument (Misonix S-4000, Qsonica LLC, USA) with 
Microplate Probe (Horn). Dr.Thorsten Lührs along with Felix Deluweit, HZI, 
assembled the acoustic SSA setup; the construction and the working principles have 
been described in detail in Felix’s PhD thesis. Ultrasound is propagated via a series 
of compression and rarefaction waves induced in the molecules of the medium 
through which it propagates. In application of sufficiently high power, the rarefaction 
cycle may exceed the attractive forces of the molecules of the liquid and in this way 
the cavitation- bubbles are formed in the medium.  
 
 
Fig.- 3.7: Working Principle and experimental setup of Acoustic SSA (Selective Shear Amplification) 
 
When these cavities collapse in successive compression cycles, it generates energy 
in the medium. Such violent collapses of bubbles can generate large shear forces in 
the bulk medium that could be used for homogenous mixing, particle dispersion and 
polymer fragmentation. High energies are generated when these bubbles collapse 
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and these occur more in number closer to the sonotrode surface. The cavitation 
bubbles decreases, as we move away from the surface of the sonotrode. This 
phenomenon is used to control the shear forces acting on the sample to be 
fragmented by adjusting the heights (using screws) away and near from the 
sonotrode surface (Fig. 3.7). The nearest region to the sonotrode surface 
experiences more force and it successively decreases as we increase the height 
(Level 4à Level 1) with the help of the screw-nut arrangement (Refer Figure- 3.7). 
 
Fragmentation of Aβ fibrils using Acoustic SSA 
 
The amyloid fibril sample is pipetted into a PCR tube (100µL), this tube is inserted 
into a screw-cap microtube with a cut bottom, which acts as a holder for the PCR 
tube. The holder tube exposes the conical surface of PCR tube to the temperature 
controlled sonicator water bath (Fig.- 3.7). A Screw is attached to the cap of the 
microtube, which acts a height adjuster when screwed clock or anticlockwise. Each 
360° turn in the screw corresponds to 1mm increase or decrease in height from the 
sonicator probe surface. Different ON:OFF sonication shear timings along with 
periodic number of cycles are used to fragment the Aβ aggregate material. After 
sonication, the samples are stored on ice bath. The fibril samples under study were 
always sonicated at the same position to prevent variance in applied sonication force 
due to positional effects on the sonotrode surface. To understand more about 
positional effects in detail, one can refer Felix Deluweit PhD thesis, where the 
working of the Acoustic SSA has been standardized. The fragmented amyloid 
material is later seeded to the Aβ conformational seeding assay (Aβ-CSA) to assess 
the extent of fragmentation. Optimally fragmented fibrils would generate more seeds 
that can efficiently seed the substrate peptide in the assay as compared to non-
optimally fragmented fibrils, which would inefficiently seed for the same seed 
concentration. These differences can be observed analyzing the aggregation kinetics 
of the reactions. 
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4 Results 
 
4 Experimental Strategy  
 
A three-step strategy was used to achieve the Aims (Refer Chapter –II Aims and 
Objectives). The experimental strategy has been explained in detailed in the 
schematic (Fig.- 4.1). 
 
1. To Develop an In-vitro based Aβ seeding assay to distinguish Spontaneous 
and Seed driven Aβ aggregation exploiting the amyloid nucleated 
polymerization and seeding mechanism. 
 
2. Transfer the technical knowledge from the developed seeding assay to seed 
and conformationally amplify the brain aggregated -Aβ from the brain 
homogenate added reactions. The assay must also be flexible for screening 
different biological conditions that can modulate Aβ aggregation so as to abet 
seeding and amplification of brain aggregated-Aβ conformation. 
 
3. To biophysically characterize spontaneous aggregated Aβ and in-vivo mice 
brain seeded Aβ aggregates by investigating morphological differences using 
TEM and fibril fragmentability differences using Acoustic- Selective Shear 
Amplification (Acoustic-SSA) technique.  
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4.1 Development of Aβ  Seeding Assay  
 
Development of the Aβ seeding assay requires standardization and optimization of 
parameters like (i) Reproducible recombinant production of soluble Aβ peptide [Aβ(1-
40)M35L and Aβ(1-42)M35L]. (ii) Optimization of substrate Aβ peptide concentration 
and Aβ-seeding in the assay. (iii) Optimization of buffer conditions for reproducible Aβ 
peptide aggregation (iv) Standardization of assays parameters like plate read 
interval, aggregate fragmentation by adjusting agitation and (v) A consistent way to 
analyze lag times. 
 
4.1.1 Aβ Fibrillation is Substrate Concentration Dependent 
 
Spontaneous fibrillation kinetics of Aβ peptides was investigated at varying micro 
molar substrate concentrations in the assay. Soluble Aβ(1-42) M35L & Aβ(1-40)M35L 
were freshly prepared by cation exchange and ultracentrifugation as described in 
detail (Ref. Methods, Section 3.2.4). Soluble Aβ peptides are diluted to 50µM, 40µM, 
30µM and 20µM in the standard aggregation buffer (200mM TRIS-HCl; 50mM 
NH4OH; pH 8.1) and pipetted in a 96 well plate to start the Aβ aggregation reaction 
(Refer, Methods, Sec. 3.4.2). Each reaction cohort contains ten replicates.  Each 
single sigmoidal aggregation trace represents fluorescence intensity versus time of 
one aggregation reaction from a single well (Fig.- 4.2). The raw aggregation kinetic 
data of Aβ(1-42)M35L and Aβ(1-40)M35L reactions are presented in the Fig.- 4.2(A) 
and 4.2(B) respectively. The data recording parameters of the plate reader device for 
this experiment was set to reading interval frequency of 40 minutes, Gain-105 
(manual) and data was recorded under quiescent conditions. The lagtime of 
aggregation were determined as explained here (Refer 3.4.4). Henceforth, all the 
aggregation data will be analyzed and presented in this scatter plot format with 
determined lag times on the Y-axis and the investigation parameter on the X-axis 
(Fig.- 4.2C).  
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Fig.- 4.2: Concentration dependent spontaneous aggregation of Aβ  in the assay. (A) Aβ(1-
42)M35L and (B) Aβ(1-40)M35L in varying substrate concentrations of 50,40,30 and 20µM showing 
time and protein concentration dependent fibrillation. (C) The red trace corresponds to determined 
aggregation lagtimes of Aβ(1-42)M35L and the blue trace corresponds to aggregation lagtimes of 
Aβ(1-40)M35L peptide. The error bars indicate standard deviation from the median of lagtimes. N=10, 
replicates per reaction cohort.  
 
The spontaneous aggregation lagtimes of Aβ(1-42)M35L at varying substrate 
concentrations shows concentration and time dependent aggregation. Increase in 
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substrate concentration resulted in decreased lagtime and vice-versa. Aβ(1-40)M35L 
aggregation has flat lagtime response to increase in substrate concentrations from 
50-30µM, and the lagtime marginally increases at 20µM concentration. Although both 
the substrate peptide differ by only two amino acids by show a clear variability in 
substrate concentration dependent aggregation. This result also shows that Aβ(1-
42)M35L is more aggregation prone and amyloidogenic compared to Aβ(1-40)M35L. 
30µM of Aβ peptide substrate concentration is chosen as the ideal concentration for 
the assay as higher substrate concentrations increases the propensity for 
spontaneous Aβ peptide aggregation leading to reduction in lagtime and low 
substrate concentrations can lead to arbitrary nucleation among the replicates of Aβ 
spontaneous aggregation. The substrate concentration changes in the assay system 
can significantly alter the resoluting capacity to map lagtime differences between the 
spontaneous and the seeded reactions. Increase in substrate can enhance 
spontaneous primary nucleation to dominate over the added seed nucleation. The 
next step was to select the appropriate pH for the substrate aggregation in the assay 
system.  
 
4.1.2 Aβ aggregation kinetics is highly pH sensitive 
 
Change in pH is known to affect amyloid aggregation kinetics and morphology in 
literature (Fraser et al. 1991). To discern and select an optimal pH condition for the 
aggregation assay, aggregation kinetics of Aβ(1-42)M35L & Aβ(1-40)M35L was 
monitored under varying pH conditions adjusted in the aggregation buffer. Soluble 
substrate Aβ’s were diluted to 30µM in aggregation buffer corresponding to final pH 
values in the range 8.1 to 9.1. The pH values of the range were precisely measured 
using a pH meter and corresponded to 8.1, 8.27, 8.42, 8.56, 8.74, 8.93, 9.16 and 
9.48.  
 
The Aβ’s aggregation reactions were set to the above-mentioned pH conditions with 
5 replicates per pH value. Reading interval frequency was maintained at 40 minutes, 
Gain was adjusted to 90 (manual) and data was recorded under quiescent 
conditions. Fig.- 4.3(A) shows spontaneous aggregation of Aβ’s under varying 
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aggregation buffer pH’s on the “X-axis” and final plateau fluorescence intensity on the 
“Y-axis”. Fig. 4.3(B) displays aggregation of Aβ’s under varying pH conditions on the 
“X-axis and determined aggregation lagtimes on the “Y-axis”.  
 
 
 
Fig.– 4.3: Effect of pH on Aβ  fibrillation at 30µM substrate concentration. For A and B, Red curve 
indicates Aβ(-42)M35L peptide and blue indicates Aβ(-40)M35L peptide. (A) Aggregation of Aβ’s 
under varying pH conditions correlated to Final plateau fluorescence intensity and (B) Aggregation 
lagtimes. The raw kinetic data is presented for Aβ(1-40)M35L (C) and for Aβ(1-42)M35L (D). (N=5) for 
each reaction, error bars indicate standard deviation from the median recorded values.  
 
The observed trend is consistent with literature, where Aβ aggregation are known to 
be affected by change in pH condition. Increasing pH is known to retard aggregation 
propensity and aggregation is stronger closer to the pI (Isoelectric Point) of the 
peptide. This result, offers a glimpse into linear increase in thioflavin-T fluorescence 
intensity with an increase in pH values (Fig.- 4.3 C&D). The pH dependent 
aggregation kinetics of both Aβ(1-42)M35L and Aβ(1-42)M35L substrates are distinct 
in the assay. This is due to the presence of two extra hydrophobic amino acids at the 
C-terminal of Aβ(1-42)M35L peptide.  
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TEM micrographs were further analyzed to correlate to the kinetic changes observed 
for the Aβ’s samples at pH 8.1 and 9.1 (Refer, Results, Section- 4.4.1, Fig.- 4.12 and 
4.13). From this experiment, it was decided to maintain the pH of the aggregation 
buffer at pH 8.1, as aggregation propensity at this pH was reproducible and optimal 
and did not influence the formation of oligomeric aggregates that could induce 
formation of a particular Aβ fibril type in the assay.  
 
4.1.3  Soluble Aβ’s Reciprocally Delay Each Other’s Spontaneous Aggregation 
and Aβ42 fibril Does Not Seed Substrate Aβ40  
 
In AD condition, Aβ peptides and its truncations are found aggregated in the brains. 
An increase in Aβ42:Aβ40 ratios seems to coincide with more threatening forms of 
the disease. Co-incubation kinetics of Aβ peptides in varying stoichiometric ratios 
along with cross-seeding was performed to understand the transition and seeding 
dynamics involved between the substrate Aβ peptides and seeding in the assay. 
 
Soluble Aβ substrates were diluted to 30µM and mixed in stoichiometric ratios [Aβ(1-
42)M35L : Aβ(1-40)M35L] as (10:0/ 7:3/ 5:5/ 3:7 and 0:10) in the aggregation buffer. 
These mixtures were allowed to aggregate spontaneously and with and without de-
novo aggregated Aβ seeds (Ref. Sec 3.3.2) added to them by logarithmic dilution 
from 5 - 0.00005µM. There were two replicates for the seeded reactions and four 
replicates for the spontaneous reactions. Plot- 4.4(A) and 4.4(B) contain Aβ(1-
42)M35L and Aβ(1-40)M35L de-novo seeded respectively at varying stoichiometric 
mixtures of Aβ substrate peptides. The reading interval for this experiment was 
reduced to 25 minutes from the earlier 40 minutes and reads were acquired under 
quiescent condition. 
 
With the increase in frequency of reading interval in the assay to 25 minutes from the 
earlier 40 minutes, there is decrease in the lagtime of the spontaneous aggregation 
for substrate Aβ(1-42)M35L by a factor of half (Fig.- 4.4) compared to earlier 
experiments (Refer, Fig.- 4.2 & 4.3). This decrease in lagtime is due increase in the 
frequency of plate movement while taking the measurements. This movement results 
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in mild agitation, which accelerated the soluble Aβ substrate aggregation. 
Aβ(1-42)M35L and Aβ(1-40)M35L spontaneously aggregate approximately at similar 
lagtimes between 6 to 8 hours under the mentioned assay conditions (Refer- Fig.- 
4.4). Inhibition of Aβ(1-42)M35L spontaneous aggregation is observed in the 
presence of soluble Aβ(1-40)M35L substrate and vice versa. Increasing the 
stoichiometric concentration of soluble Aβ(1-42)M35L with soluble Aβ(1-420)M35L 
substrate or vice versa leads to increase in aggregation lagtime indicating inhibition 
of aggregation. It is clear from the above observations, that soluble Aβ’s reciprocally 
delay spontaneous aggregation of each other in concentration dependent manner 
(Fig.- 4.4A & B). 
 
Aβ(1-42)M35L de-novo aggregated fibrils are able to seed Aβ(1-42)M35L substrate 
protein in a concentration and time dependent manner. The Aβ(1-42)M35L fibrils 
seeding was found to be more Aβ(-142)M35L substrate dependent in the 
stoichiometric ratio mixtures where Aβ(1-42)M35L dominated  in this assay (Fig.- 
4.4B).  However, there is a weak seeding effect observed for Aβ(1-40)M35L fibrils 
seeding the soluble Aβ(1-40)M35L and Aβ(1-42)M35L substrate (Comparing, Fig- 
4.4A with Fig.- 4.4B, also refer SD, Fig.- 7.1 and 7.2). This could be very well due to 
floccular morphology of the Aβ(1-40)M35L fibrils, that could be visually confirmed.  
 
The established Thioflavin-T based Aβ seeding assay works as proof of principle to 
detect minutest amount of Aβ42(M35L) fibrils, even in the nanomolar ranges. The 
next step was to add in-vivo brain homogenate from AD transgenic mice as seeds in 
the assay. This would enable seeding and amplification of the in-vivo brain 
aggregated-Aβ seed specific conformational template to the soluble Aβ(1-42)M35L 
substrate peptide in the assay. The raw kinetic data for this experiment has been 
presented in the supplementary section (Refer, SD, Fig.- 7.1 & 7.2). 
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4.2 Brain homogenate retards Aβ  aggregation in the assay 
 
After establishing the assay to detect the de-novo generated seeds. The next step 
was to add the in-vivo brain aggregated -Aβ containing APP/PS1(TG) brain 
homogenate (BH) as seed to the assay. The in-vivo brain aggregated-Aβ is 
anticipated to seed the soluble substrate Aβ(1-42)M35L in the assay as analogous to 
the de-novo aggregated fibrillar seeds.  
 
 Preparation of BH seed suspension to be added as seed in the assay is described in 
detail (Refer, material Methods, section 3.3.2). The wild-type (WT) mice and BL6 BH 
are added to the assay as a material for negative control. The BH material as a seed 
is added to the assay in two ways. Adding 10% brain homogenate seed directly to 
the assay in the presence of (i) Protease Inhibitor (PI) or (ii) by Proteinase-K (PK) 
digestion of the added brain homogenate. 
 
4.2.1 Brain homogenate seeding with 2X Protease Inhibitor  
 
Protease Inhibitor (PI) is a cocktail of protease inhibitors that are excellent inhibitors 
of serine and cysteine proteases present in the cells. They can protect soluble 
substrate Aβ peptide from cleavage by cellular protease present in the brain 
homogenate added as a seed to the assay. PI was used two times more than the 
manufacturer (Roche) recommended concentration in the brain aggregated- Aβ 
seeding experiment in the assay. 
 
Soluble Aβ(1-42)M35L substrate was diluted to 30µM in the aggregation buffer 
containing 2X Protease Inhibitors and added with the brain homogenates [BL6, 
APP/PS1(TG/WT)]. APP/PS1(TG) brain is known to contain higher fraction of brain 
aggregated Aβ42 seeds, which can seed the soluble Aβ(1-42)M35L substrate in the 
assay. Six replicates representing each reaction cohort was used in this experiment. 
PBS is added as an additional control in the assay, as the 10% brain homogenate is 
prepared in the standard PBS buffer. Brain homogenate is added at 0.075% and 
0.1% concentrations to total reaction volume. In this experiment, the kinetic read 
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interval was set to 10 minutes with 10 seconds agitation between each read. The 
agitation parameter along with increase in frequency of read interval (10 minutes, 
from the earlier 25 minutes) was introduced in the assay, as without agitation the 
aggregation did not occur, when the brain homogenates were added (Data not 
shown). Agitation resulted in better mixing of Aβ reactions inside the well, leading to 
homogenous fluorescence intensity measurements in the well. Agitation additionally 
introduces fragmentation of formed aggregates and even the added fibrils / seeds in 
the system accelerating the aggregation kinetics in the system. This results in the 
increase in the population of seeds that can act as growing ends to accelerate 
aggregation (Refer, Introduction, Section- 1.7).  
 
Introducing agitation for 10 seconds in combination with 10 minutes read interval, 
dramatically reduces the spontaneous aggregation lagtime of Aβ(1-42)M35L to a 
factor of half (Lagtime of ca. 4 hours) (Refer Fig.- 4.5C) as compared to 25 minutes 
read interval with no shake program (Lagtime ca. 8 hours) (Refer, Fig.- 4.4A&B). No 
seeding activity was detected between (TG) vs. BL6 or WT at both 0.075% and 0.1% 
brain homogenate concentrations (Refer, Fig.- 4.5A&B). Overall, there was increase 
in the lagtimes of the aggregation in all reactions was observed, wherever brain 
homogenate was added when compared to non-brain homogenate added reactions. 
Increase in brain homogenate concentration (from 0.075% to 0.1%) increased the 
aggregation lagtime in a concentration and time dependent manner (Compare, Fig.- 
4.5A&B). There is a large standard deviation recorded in the lagtime values recorded 
among the of APP/PS1(TG) seeded reactions indicating that the aggregation was 
spontaneous and not influenced by the brain aggregated-Aβ seed from the brain 
homogenate. From this experiment, it is clear that amyloid nucleation and 
aggregation processes are very sensitive and vulnerable to addition of brain 
homogenate, which retards the substrate Aβ aggregation in the assay. There was no 
detectable effect on Aβ(1-42)M35L spontaneous aggregation in the presence of 
protease inhibitor or PBS on in the assay. The kinetic raw aggregation data for this 
assay has been shown and explained in the supplementary section (Refer, 
Supplementary Data, Fig.- 7.4). 
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Fig.- 4.5: Brain homogenate seeding with 2X Protease Inhibitor. (A) Brain homogenate APP/PS1 
(TG/WT) and BL6 added at 0.075% (v/v) as seed and a same volume of PBS is added as negative 
control. (B) Brain homogenate APP/PS1 (TG/WT) and BL6 added at 0.01% (v/v) as seed and a same 
volume of PBS is added as negative control. (C) Spontaneous Aggregation of the substrate without 
protease inhibitor. The error bars indicate standard deviation from the median of lagtimes analyzed. 
(N=5, for all the reactions). 
 
In summary, addition of brain homogenate as seed in the assay retarded aggregation 
of Aβ substrate in the assay. In the absence of added protease inhibitors, the 
aggregation reaction is completely inhibited in the assay (Data not shown), as the 
cellular proteases from the brain homogenate cleaved the soluble Aβ substrate in the 
assay. Retardation of aggregation in the presence of brain homogenate added 
reaction was considerably observed despite adding high amount of protease 
inhibitors in the assay. This pressed the need for using an alternative Proteinase-K 
(PK) digestion, which is a stronger proteinase digestion enzyme. 
 
4.2.2 PK digestion abrogates the retardation effect of brain homogenate 
 
Proteinase-K (PK) is a broad-spectrum serine protease enzyme. PK was added 
(1:500) w/w adjusted to total protein content in the brain homogenate. The protein 
content in the 10% brain homogenate was estimated using a Bradford assay. The 
protein concentration in the brain homogenate was estimated to be ca. 6 microgram 
per microliter. Brain homogenate is incubated with PK (1:500) at room temperature 
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for 2 hours and later heat inactivated by boiling the mixture at 95°C for 10 minutes 
and later placing it on ice bath (Ref. Section, 3.3.5). Freshly prepared soluble Aβ(1-
42)M35L substrate is added to this mixture and diluted to 30µM final concentration in 
the aggregation buffer. 10% APP/PS1 (TG/WT) brain homogenate fraction is added 
at 1% and 2% in the assay after PK digestion. Standard PBS is added as the 
negative control, as the brain homogenate is homogenized in the PBS buffer. De-
novo Aβ(1-42)M35L fibrillar seed (1µM) is spiked in standard PBS, to ascertain the 
effect of PK digestion on de-novo fibrillar seeds. Each reaction cohort in this 
experiment was performed with 6 replicates (Fig.- 4.6).  The error bars indicate 
standard deviation from the median of the determined lagtimes. The kinetic reading 
parameters included: 10 minutes read frequency interval with 10-seconds shake 
(agitation) before each read. 
 
The overall observed lagtime analyzed for brain homogenate added reactions in the 
assay are approximately in the same regimes of spontaneous aggregation without 
the brain homogenate (Lagtimes of ca. ±2 hours). This result indicates that PK 
digestion can annul the effect of brain material induced aggregation retardation 
induced in the assay to a considerable extent. Comparing PK digestion to Protease 
inhibitor addition (Fig.- 4.5), it is evident that PK digestion of the BH in the assay is a 
more promising approach to deal with the BH induced retardation effect in the assay. 
However, no seeding activity was still detected between the APP/PS1(TG) and 
APP/PS1(WT) brain seeded samples (Fig.- 4.6A&B), despite increasing the brain 
homogenate seeding concentration to 0.2% (Fig.- 4.6 B) in the assay. Increasing the 
brain homogenate concentration from 0.1% to 0.2% in the assay system marginally 
increased the detected lagtimes owing to higher brain material load in the assay. The 
de-novo spiked Aβ(1-42)M35L fibrillar seed (1µM) in the PBS buffer (0.1% & 0.2%) 
was found to be PK resistant (Fig.- 4.6A&B), as it could still actively seed the soluble 
Aβ(1-42)M35L substrate in the assay as observed in the standard  seeding reactions 
without PK digestion (Fig.- 4.9C). The raw kinetic data for this experiment is available 
in the supplementary section (Refer, Supporting Data, Fig.- 7.4). 
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Fig.- 4.6: Addition of Proteinase-K (PK) digested brain homogenate seed in the assay. (A) 
Represents analyzed lagtimes of reactions seeded with 0.1% PK digested Brain homogenate 
APP/PS1 (TG/WT) added as seeds, along with PBS and spiked de-novo seed in PBS buffer. (B) 
Represents analyzed lagtimes of reactions seeded with 0.2% PK digested brain homogenate 
APP/PS1 (TG/WT) added as seeds, along with PBS and spiked de-novo Seed in PBS buffer. (C) 
Standard spontaneous and seeded aggregation of Aβ(1-42)M35L in aggregation buffer without PK 
digestion. Error bars indicate standard deviation of analyzed lagtimes from the median value. (N=5, for 
all the reactions)  
 
The seeding difference between the APP/PS1(TG)  and the APP/PS1(WT) brain 
homogenate seeds could not be detected suggesting that the brain homogenate 
components like native proteins and membranes, might be suppressing the seeding 
capabilities of the Aβ fibrils present in the TG mouse brains. Later, it was decided to 
screen for phospholipid conditions in the seeding assay that can mimic the 
membrane-like in-vivo brain environment. Another possibility, why the brain seed did 
not seed in the assay, could also be due to the low concentration of added brain-Aβ 
seed, which could not dominate and compete with the concomitant (spontaneous) Aβ 
nucleation and aggregation. Therefore, it was hypothesized that, membrane-like 
conditions would mimic the brain biological environment, where the kinetics of 
aggregation and seeding could be different compared to in-vitro aggregation in the 
assay. It was hypothesized that the lipid condition could aid in conformational brain 
aggregated-Aβ seeding in the assay. 
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4.3 Mimicking Phospholipid Condition in the Assay 
 
Brain aggregated-Aβ seeding activity did not occur by introduction of brain 
homogenate in the assay under standard buffer conditions with both protease 
inhibitors addition and by proteinase-k digestion. This gave rise to an idea of 
mimicking in-vivo biological conditions in-vitro by adding lipid membranes-like 
condition in the assay. The membrane-like condition was hypothesized to interact 
akin to cellular membranes in the brain, where synthesis of Aβ and seeding activity 
could be much more efficient as compared to standard in-vitro conditions in the 
assay. This phospholipidic milieu will enable to understand and investigate kinetics of 
Aβ spontaneous and seeded aggregation in membrane-like conditions in the assay.  
 
Another, plausible reason why brain-Aβ could not seed in the assay could also have 
been due to, low availability of brain aggregated-Aβ seeds in the brain homogenate 
added to the assay. Low concentration of brain-Aβ seeds could have not been 
sufficient to robustly compete and dominate over the spontaneous aggregation of 
substrate Aβ(1-42)M35L in the assay. To overcome this bottleneck, we would need 
an experimental assay condition, where the primary nucleation of the substrate Aβ is 
specifically suppressed. This would enable brain aggregated -Aβ seed added to the 
assay to compete and seed robustly over the primary concomitant nucleation of the 
substrate Aβ. To investigate these membrane-like conditions in-vitro, screening of 
phospholipid was carried on in the assay system so far established. 
 
4.3.1 Phospholipid DHPC suppresses substrate Aβ primary nucleation and 
enables Aβ seeding in the assay 
 
DHPC (1,2-dihexanoyl-sn-glycero-3-phosphocholine) is a short-chained phospholipid 
molecule and an excellent phospholipid model system to study effects of lipid 
interactions on Aβ aggregation (Dahse et al. 2010). DHPC is added in the assay to 
monitor the Aβ oligomerization kinetics. To 30µM Aβ(1-42)M35L soluble substrate 
concentration in the Assay, DHPC was added in incremental steps of 1mM from 0-
6mM in both spontaneous and de-novo  added seed condition. De-novo Aβ(1-
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42)M35L fibrillar seeds were spiked at a concentration of 0.25µM in this experiment 
(Fig.- 4.7). There are five replicates for each reaction in the experiment. The kinetic 
recording parameters for the experiments are 10 minutes reading interval with 10s 
agitation before each read. The gain was set manually to value 95. 
 
 
 
Fig.- 4.7: Addition of DHPC in the assay under spontaneous and de-novo seeded condition 
(N=5). (A) Aggregation of Aβ(1-42)M35L under varying concentrations of DHPC (0-6mM). (B) 
Standard aggregation and (C) in the presence of 4mM DHPC. Black curve indicates the spontaneous 
and the red curve indicates seeded aggregation. Error bars indicate standard deviation from the 
median lagtime values analyzed.   
 
Varying concentrations of DHPC is mixed with 30µM Aβ(1-42)M35L with both 
spontaneous / de-novo Aβ(1-42)M35L fibrils, the data is presented in Fig.- 4.7A. 
DHPC screening in the assay demonstrates that the Aβ aggregation and seeding 
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kinetics is strongly affected by the phospholipid DHPC at different concentrations 
(Fig.- 4.7A). However, the nature of these effects precisely depends on the 
concentration of DHPC used in the assay. At 1mM DHPC, there is a strong influence 
of the DHPC on soluble Aβ(1-42)M35L substrate and its subsequent seeded reaction 
evidenced by accelerated aggregation. There are no seeding differences detected 
between the seeded and the spontaneous aggregation at 1mM DHPC condition in 
the assay. In the ranges from 2 to 6mM DHPC, the Aβ spontaneous aggregation is 
impeded indicated by increasing lagtime up to 4mM and then gradually starts 
declining at 5mM and 6mM DHPC concentration in the assay  (Fig.- 4.7A). There is 
significant increase in the lagtime values of spontaneous Aβ aggregation at 4mM 
DHPC concentration ~20 hours as compared to the spontaneous at ~6 hours (Fig.- 
4.7B&C).  Differences in seeding activity in the presence and absence of 4mM DHPC 
is shown as fluorescence intensity kinetic data (Refer, Fig.- 4.7B&C). The kinetic raw 
data has been smoothed using 17-point Savitzky-Golay filter. The raw kinetic data for 
this experiment has been provided in the supplementary data section of this thesis 
(Refer, Supplementary Data, Fig.- 7.5). 
 
DHPC also considerably affects the seeded aggregation in the assay system. The 
seeded aggregation kinetics is indistinguishable from spontaneous aggregation at 
1mM and 2mM DHPC having no seeding resolution. Seeding resolutivity denotes the 
quantitative difference in determined lagtime between the spontaneous aggregation 
and the seeded aggregation reaction. The seeding resolutivity gradually starts to 
increase at 3mM and 4mM DHPC and later decreases at 5mM and 6mM DHPC. The 
seeding resolutivity of the assay is maximum at 4mM DHPC condition, approximately 
4 times the seeding resolutivity compared to the standard spontaneous and seeded 
aggregation.  
 
It was a serendipitous finding that; DHPC at 4mM suppressed spontaneous and 
seeded aggregation by more than 3 fold compared to standard spontaneous and 
seeded aggregation reaction and enabled higher seeding resolutivity in the assay 
(Refer, Fig.- 4.7B&C). From these observations, it was decided to add 4mM DHPC in 
the assay to increase the seeding resolutivity in the system. Higher seeding 
resolutivity is crucial in the seeding system as it grants a broad lagtime window to 
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detect lower dilution of added seed in the assay. The next step was to test the effect 
of 4mM DHPC in the presence / absence of brain homogenate in the assay and 
determine the seed detection limit in the assay by logarithmically diluting out the 
seeds. This would help in understanding the dynamics of seeding mechanism in the 
presence and absence of brain homogenate in the assay. 
 
4.3.2 Assay can detect low concentration of Aβ-fibrils spiked to the brain 
homogenate 
 
This experiment was designed to investigate the comparative seeding sensitivities 
between brain homogenate added and standard seeding reactions in the assay. The 
aim was to understand the aggregation kinetics and seed detection in the presence 
and absence of 0.1% BL6 brain homogenate added in the assay system under 4mM 
DHPC condition. De-novo Aβ(1-42)M35L fibrillar seeds are logarithmically diluted 
from 250nM to 2.5pM and mixed with / without 0.1% BL-6 brain homogenate in the 
aggregation buffer (Fig.- 4.8B). Later they are PK digested and added as seed in the 
assay to 30µM soluble substrate Aβ(1-42)M35L with (Fig.- 4.8B&C) and without (Fig.- 
4.8A) 4mM DHPC. Spontaneous Aβ aggregation with 4mM DHPC in the presence 
and absence of 0.1% brain homogenate is performed as controls in this assay (Fig.- 
4.8C). The aggregation data for the substrate Aβ(1-42)M35L in the presence of only 
4mM DHPC* (Fig.- 4.8C ii) is appropriated from the last experiment (Refer, Results, 
Section- 4.3.1). There are 5 replicates to each reaction cohort in this assay. All the 
reactions in this assay are PK digested except for spontaneous aggregation of 
substrate Aβ(1-42)M35L in 4mM DHPC (Fig.- 4.8C ii). Error bars indicate standard 
deviation from the median of determined lagtimes. The assay parameters of this 
experiment are: 10 minutes reading interval with 10 seconds agitation before each 
read. The raw kinetic data for this experiment has been provided in the 
supplementary section (Refer, Supplementary Data, Fig.- 7.6). 
 
The assay could detect spiked de-novo Aβ seed reliably up to 25pM in the presence 
of 0.1% brain homogenate under the 4mM DHPC condition. There are profound 
seeding differences in lagtimes between reactions with / without 0.1% brain 
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homogenate. Seeding lagtime times are longer for reactions with 0.1% brain 
homogenate (Fig.- 4.8B i) compared to reactions without brain homogenates (Fig.- 
4.8B ii). This significant difference in lagtimes can be attributed to presence of added 
brain homogenate material that interferes with the amyloid spontaneous and seeded 
nucleation. In the next step we used the brain material from the AD transgenic mice 
APP/PS1 (TG /WT) and APP-23 (TG/WT), PK digested and add them as seed in the 
assay with 4mM DHPC condition.  
 
 
 
4.3.3 APP/PS1(TG) Brain Aggregated-Aβ seeds in the assay  
 
With the combined knowledge of PK digestion and phospholipid DHPC condition in 
the assay; APP/PS1(TG/WT), APP23(TG/WT) and BL6- brain homogenates were 
added as seeds in the assay. 0.2% brain homogenate material was first PK digested 
(1:500), PK inactivated, and stored on ice. This mixture is later added as seeds to the 
Fig.- 4.8: Detection of de-novo spiked Aβ  seed in the assay. (A) Standard controls in 
Aggregation buffer (i) Spontaneous aggregation. (ii) 2.5nM de-novo seeded reaction and (iii) 
0.1% BH PK-Digested. (B) Logarithmically diluted seed (250nM- 2.5pM) with 4mM DHPC 
seeded in the (i) presence and (ii) absence of 0.1% brain homogenate. (C) Substrate Aβ 
spontaneous aggregation in the (i) presence and (ii) absence of 0.1% brain homogenate 
under 4mM of DHPC. Error bars indicate standard deviation from the median lagtime values 
determined. (N=5). (* Indicates data from the previous experiment)  
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soluble Aβ(1-42)M35L substrate in the assay. APP/PS1 (TG) brain contains Aβ 
material (Aβ42:Aβ40) in (70:30) ratio and APP23(TG) contains (30:70) ratio (Meyer-
luehmann 2006). APP/PS1(TG) brain homogenate material contains more Aβ42 seed 
material, so in principle it was hypothesized to seed the Aβ(1-42)M35L substrate in 
the assay. The APP/PS1(WT) and APP23(WT) brain material forms the negative 
control for the transgenic mice brain that does not contain any Aβ aggregates. The 
BL6 brain homogenate is additionally added as a negative control. 
 
The assay is setup by mixing the 30µM soluble Aβ(1-42)M35L with the PK digested 
brain homogenate and 4mM DHPC is added before starting the reaction (Fig.- 
4.9C,D & E). DHPC is not added to the cohort A (Fig.- 4.9A) and they contains 
standard aggregation controls like (i) Standard spontaneous Aβ aggregation (ii) 
Spontaneous Aβ aggregation in PK digested aggregation buffer and (iii) 0.2% BL6 
brain material PK digested and added to Aβ substrate. Cohort B presents 
aggregation controls in the presence of 4mM DHPC (i) Spontaneous Aβ aggregation 
(ii) Spontaneous Aβ aggregation in PK digested standard aggregation buffer (iii) 0.2% 
PBS added to spontaneous aggregation buffer. Cohort C contains 0.2% PK digested 
brain homogenate seeded reactions with 4mM DHPC (i) APP/PS1(TG) and (ii) 
APP/PS1(WT). Cohort D contains 0.2% PK digested brain homogenate seeded 
reactions with 4mM DHPC (i) APP23(TG) and (ii) APP23(WT). The last reaction 
cohort E contains 0.2% PK digested BL6 brain homogenates and added with 4mM 
DHPC. The kinetic aggregation data is recorded with 10 minutes reading interval with 
a 10 seconds agitation before each read. The gain for this experiment was set to 90 
(manual). There are 6 replicates for all the reactions in this experiment. Error bars 
indicate standard deviation from the median of detected lagtimes. The raw kinetic 
data for this experiment has been included in the supplementary data section of this 
thesis (Refer, Supplementary Data, Fig.- 7.7). 
 
The aggregation kinetics of the APP/PS1(TG/WT) and BL6 seeded reactions were 
monitored (Fig.- 4.10A). From the kinetics it can be clearly observed that 
APP/PS1(TG) brain homogenate seeded the soluble substrate Aβ(1-42)M35L in the 
assay. The APP/PS1(TG) seeded reaction (Fig.- 4.10A, red trace) also displayed 
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higher fluorescence intensity as compared to APP/PS1(WT) or BL6 brain 
homogenate seeded reactions.  
 
 
 
The higher fluorescence in APP/PS1(TG) seeded reactions along with the reduction 
in aggregation lagtime compared to the APP/PS1(WT) added reactions indicates that 
the brain aggregated Aβ from the APP/PS1(TG) mice brain homogenate seeded in 
the assay. The brain-Aβ seeding with higher fluorescence is also observed in the fibril 
amplification assays utilizing Aβ40 substrate (Paravastu et al. 2009; Lu et al. 2013). 
The seeding can be further confirmed by observing the seeded aggregation kinetics 
of replicates moving together as a bundle with lesser standard deviation between 
them (Fig.- 4.10A).  
 
The data from the negative control brain homogenate [APP/PS1(WT) and BL6] 
Fig.- 4.9: Seeding of Brain homogenates in the Assay. (A) Standard aggregation controls (i) 
Substrate spontaneous (ii) Substrate Spontaneous PK digested PBS and (iii) 0.2% BL6 brain 
material PK digested spontaneous aggregation. (B) DHPC (4mM) aggregation controls (i) 
Substrate spontaneous aggregation (ii) Substrate spontaneous PK digested buffer and (iii) 
Substrate spontaneous with PK digested PBS. (C) 0.2% APP/PS1 (TG/WT) brain PK digested 
and seeded in the assay with 4mM DHPC. (D) 0.2% APP23 (TG/WT) brain homogenates PK 
digested and seeded in the assay with 4mM DHPC. (E) 0.2% BL6 brain homogenate PK 
digested and seeded in the assay with 4mM DHPC. (N=6). Error bars indicate standard 
deviation from the median lagtimes.  
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added reactions with 4mM DHPC bear close resemblance to spontaneous 
aggregation with a larger spread and higher standard deviation among the  
replicates. APP23 (TG) brain homogenate did not seed in the assay (Fig.- 4.10B), 
this might be due to the difference in molecular composition of Aβ seeds present in 
the APP23(TG) brain. The in-vivo brain aggregated-Aβ experiment has been 
repeated multiple times and in all the experiments, it was found that only 
APP/PS1(TG) brain material seeded in the assay and APP23(TG) did not seed the 
soluble Aβ(-42)M35L substrate.  Seeding activity was not observed, when 0.1% brain 
material was used to seed the Aβ(1-42)M35L substrate in the assay (Data not 
shown). 
 
 
Fig.- 4.10: APP/PS1(TG/WT), APP23(TG/WT) and BL6 Brain Homogenate Seeding. PK digested 
0.2% brain homogenate were seeded in the assay with 4mM DHPC. (A) Raw aggregation kinetics of 
APP/PS1(TG) (Red), APP/PS1(WT) (green) and BL6 (black) reactions and (B) APP23(TG) (orange), 
APP23(WT) (violet) and BL6 (black). 
 
The seeding in the assay was considerably improved by introducing a number of 
measures that reduced the time delay between the digestion of the brain seed 
material and production of the recombinant soluble Aβ(1-42)M35L substrate from 
cation-exchange purification. A mild agitation using the thermo-shaker during the PK 
digestion of the brain homogenate greatly improved the brain aggregated-Aβ seeding 
in the assay (Fig.- 4.11). PK digestion of brain homogenates and introduction of 
phospholipid DHPC (4mM) in the assay enabled APP/PS1(TG) brain aggregated -Aβ 
to seed and conformationally amplify in the assay with soluble Aβ(1-42)M35L as the 
substrate. The amplification was further confirmed by TEM of the aggregates (Refer, 
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Section- 4.4.2). The seeding was possible, as DHPC micelles at 4mM significantly 
suppressed the substrate Aβ spontaneous nucleation thereby giving an edge to 
conformational seeding to occur from the brain aggregated-Aβ seed even at low 
concentration in the assay.  
 
 
 
Fig.- 4.11: Improved APP/PS1(TG) brain aggregated-Aβ  seeding. The data has been smoothed 
using a 17-point Savitzky-Golay filter. Gain = 90 (Manual)  
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4.4 Characterization of Aggregates by Negative Staining 
Transmission Electron Microscopy (TEM) 
 
Negative stain TEM is a relatively rapid method to investigate, morphological fibrillar 
characteristics of amyloid proteins at a molecular level. To study the morphological 
differences between the aggregates that are generated in our assay, the final 
aggregated reaction samples were examined by TEM. 
 
4.4.1 Aggregation Buffer pH Affects Aβ-fibril Morphology  
 
To analyze the effect of pH on Aβ fibril morphology, the final in-vitro aggregated 
samples from the assay were used to investigate morphological differences using 
TEM. For TEM analysis, grids were prepared by the methods as described here 
(Methods, section 3.5.1). The age of the aggregate samples were approximately 200 
hours post aggregation when analyzed in this study. The mechanism of formation of 
fibrils and its intermediates has been explained in detail (Introduction, Section 1.7). 
Overall, from the micrographs (Fig.- 4.12 & 4.13), we can see that Aβ(1-42)M35L and 
Aβ (1-40)M35L form fibrils, oligomers and other intermediate aggregate structures. 
 
Aβ(1-42)M35L de-novo spontaneously formed fibrils (red arrows) and oligomers 
(green arrows) at pH 8.1 are detected at moderate (200nm) and higher (100nm) 
magnification (Fig.- 4.12A&B). The Aβ(1-42)M35L fibril sample at pH 8.1 overall 
displays fibrils with thin, fragile, rod-like, linear with lateral branching morphologies 
with oligomers loosely associated with them (Fig.- 4.12A and insets A1 & A2). 
Oligomers are found loosely associated to the fibrils observed with higher 
magnification in (Fig.- 4.12B, inset B1 and B2).  
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Fig.- 4.12: Effect of pH on Aβ(1-42)M35L fibril formation. TEM study at medium (200nm)  (A&C) 
and higher (100nm) (B&D) magnifications. TEM micrographs correspond to Aβ(1-42) M35L at pH’s 8.1 
(A & B) and 9.1 (C & D). Red arrows indicate the fibrils and the green arrows indicate oligomers in the 
micrographs. The inset stamps display detailed view of marked morphological structures. The white 
bar in the right bottom indicates the scale of magnification. 
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Fibrils and oligomers of Aβ (1-42)M35L are similarly detected at pH 9.1 (Fig.- 4.12C 
& D). The oligomeric population predominates in the sample as compared to the 
fibrils at pH 9.1 (Fig.- 4.12C; inset C1 and C2). At higher magnification, large 
amounts of oligomers are densely clustered to fibrils like beads on a string (Fig.- 
4.12D; inset D1 and D2). The size of Aβ(1-42)M35L oligomers ranges from ca. 30 - 
40nm in diameter observed at both pH’s 8.1 and 9.1 samples. 
 
The Aβ(1-40)M35L spontaneous de-novo aggregates at pH 8.1 forms dense fibers 
(cyan arrows) running like cables in contact with, each other (Fig.- 4.13A&B). Fibers 
are predominantly seen, which look organized, smooth with periodic twist and 
occasionally overlapping each other (Fig. - 4.13A&B, inset A1 and B2). At closer 
inspection, fibrils are observed twisted and twined with one another at regular 
internodal spacing of ca. 7 - 10nm. The pairs of such fibrillar motifs combine and run 
over each other (Fig.- 4.13B and inset B2). Oligomers (green arrows) are detected in 
the sample and in general are scattered and sometimes bounded to fibrils with sizes 
ranging from ca. 15 - 25nm in diameter. The Aβ(1-40)M35L peptide at pH 9.1 forms 
thick and linear cluster of fibers which appear tightly twisted and intertwined with 
each other densely embedded by oligomers (Fig.- 4.13C& D; insets C1 and D1). 
Oligomers (green arrows) were observed densely packed to into the fibrillar 
structures protruding on the surface (Fig.- 4.13 D1) and sometimes sparsely 
distributed independently in the sample probe (Fig.- 4.13C and inset C2). 
 
This result gives a clear indication that change in pH results in morphological 
differences in the aggregated Aβ protein. The differences have been succinctly 
summarized here (Table- 4.1). Increase in pH clearly leads to increase in population 
of oligomers detected in the sample. From these observations, it can be safely 
indicated that increase in oligomeric populations leads to increase in fluorescence 
emission spectra values observed in the assay (Refer, Fig.- 4.3). In order to reduce 
the effect of pH in forming oligomers in the assay, it was decided to limit the pH of the 
aggregation buffer in the assay to pH 8.1.  
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Fig.- 4.13: Effect of pH on Aβ(1-40)M35L fibril formation. TEM study at medium (200nm) (A&C) 
and higher (100nm)(B&D) magnifications. TEM micrographs correspond to Aβ(1-40)M35L at pH’s 8.1 
(A&B) and 9.1 (C&D). Cyan arrows indicate the fibrils and the green arrows indicate oligomers in the 
micrographs. The inset stamps display a detail view of marked morphological structures. The white bar 
in the right bottom indicates respective scales. 
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By adjusting the aggregation buffer to pH 8.1 in the assay system, the duration of 
each experiment and its data acquisition time could be overall reduced within a day 
by reduction in lag-phase of aggregation. 
 
 
 Amyloid Beta de-novo aggregates at pH’s 8.1 and 9.1 
Type Aβ(1-42)M35L (pH 8.1) Aβ(1-40)M35L (pH 8.1) 
Fibrils 
Higher fibrillar population, 
appear thin, fragile, rod-like 
and linear with multiple 
lateral branching 
morphologies. 
Smooth and dense fibers, 
individual fibrils running 
parallel like flat cables and 
striated in appearance. 
Oligomers 
Sparsely scattered in the 
sample, Oligomer size 
(~30-40nm) 
In general scattered, but 
sometimes found tightly bound 
to fibrils. Sizes range from 
(~15-25nm). 
Special 
features 
Oligomers loosely 
associated with fibrils and 
fibrillar heterogeneity 
observed. 
At closer magnification, 
periodic twisting of fibrils are 
observed with an inter-nodal 
spacing of ~7-10nm. 
 Aβ(1-42)M35L (pH 9.1) Aβ(1-40)M35L (pH 9.1) 
Fibrils 
Thick Fibers, barely visible 
as beaded by oligomers 
Thick and linear cluster of 
fibers, appearing tightly twisted 
and intertwined 
Oligomers 
Higher Oligomeric 
population, Oligomer size 
(~30-40nm) 
Oligomers are interspersed in 
the sample with sizes ranging 
from ~15-25nm 
Special 
features 
Oligomers densely 
clustered alongside the fibril 
length like beads on a 
string. 
Fibers are densely embedded 
by oligomers and sometimes 
also found naked 
Table - 4.1: Morphological comparison of de-novo spontaneously aggregated Aβ sample 
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4.4.2 Distinct Morphological Differences are Observed in APP/PS1(TG) Seeded 
and Control Brain Homogenate Added Reactions 
 
TEM grids were prepared from APP/PS1(TG/WT) and BL6 brain homogenate seeded 
aggregates from the assay. The sample age was approximately 84 hours when the 
TEM analysis was carried out. The final aggregation reactions products from the 
assay are referred to as 1st Generation (1G) as they are seeded from the mice brain 
homogenate seed added to the substrate Aβ in the assay. Once the aggregation 
process is deemed to be complete by reaching the plateau phase the Aβ aggregates 
are adsorbed to freshly prepared carbon butvar foils (Refer, section 3.5.1) and the 
TEM preparates are analyzed at 2µM, 500nm and 200nm resolution. A slim white line 
seen on the right bottom side of each micrograph represents the reference scale 
(Fig.- 4.14 & 4.15). 
 
In the BL6-1G aggregate sample at 2µm resolution (Fig.- 4.14 A&B), we can observe 
small cluster of fibers that appear thread-like and knotty in appearance indicated by 
red arrows. Oligomeric Aβ species are observed uniformly distributed and 
consistently negatively stained (green arrows). Oligomers are also found occasionally 
bound to the fibrils. Some pre-fibrillar amyloid material is also observed in the sample 
indicated by cyan arrows (Fig.- 4.14 A, B and inset B1). Clusters of massively 
clumped fibrils adsorb more dye and appear intensely stained (Fig.- 4.14 A1). On 
closer examination of BL6 homogenate seeded reactions (Fig.- 4.15A) at medium 
magnification (500nm), the fibers appear flexible, moderately thick and intertwined 
with each other. At higher (200nm) resolution Fig. 4.15 (B), the intertwined fibrils look 
twisted with each other with internodal spacing observed at regular intervals (Fig.- 
4.15B & inset B1). There are also short and thick fibers observed displaying different 
and distinct morphologies occasionally found in the sample showing higher sample 
heterogeneity. In our observation, there were no major morphological differences 
detected between BLG-1G and APP/PS1(WT)-1G seeded sample probes (Fig.- 4.14 
C&D and Fig.- 4.15 C&D). The APP/PS1(WT)-1G aggregate macromolecular and 
morphological features look rather similar to those of the BL6-1G probes at all the 
analyzed magnifications (2µM, 500nm and 200nm). 
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Fig.– 4.14: TEM micrographs of brain seeded reactions (A-F) at lower magnification 2µm. Red 
arrows indicate fibrillar material and green arrows indicate oligomeric species. The black arrows 
indicate APP/PS1(TG) fibrils and purple ones indicate prefibrillar oligomers. The insets include 
detailed molecular features analyzed in the micrographs. The white slim line below the micrographs 
indicates the scale (2µm). (A &B) represents BL6 brain homogenate-seeded reaction; A1 &B1 are 
insets showing detailed features of micrographs. C and D micrographs are 0.2% APP/PS1(WT) brain 
material seeded reactions, C1 and D1 show insets of detailed features of micrographs C and D. E and 
F are micrographs of 0.2%  APP/PS1(TG) brain seeded reactions, showing detailed insets of features 
in E1 and F1. 
 
In APP/PS1(TG) seeded samples (Fig.- 4.14 & Fig.- 4.15E&F),  large prefibrillar 
oligomeric structures are found coalesced together ranging from ca. 150-300nm in 
diameter (Fig.- 4.14E&F). These structures are found to adsorb more negative-stain 
indicated by purple arrows in (Fig.- 4.14 E&F). These pre-fibrillar oligomeric structure 
look like ball of yarn coalesced together with oligomers. These larger pre-fibrillar 
oligomers were absent in the BL6-1G or APP/PS1(WT)-1G aggregate samples. A 
close view of these large prefibrillar oligomers is provided in the insets (Fig.- 4.14E1).  
Small oligomeric structures were rarely detected in the APP/PS1(TG)-1G samples as 
compared to its strong background presence in BL6-1G and APP/PS1(WT)-1G  
Results 
 
  
98 
samples indicated by green arrows in (Fig.- 4.14 A,B,C&D, and also detailed view in 
insets B1&D1). The small oligomers that are observed in abundance in APP/PS1 
(WT) and BL6 brain homogenate seeded samples (Refer Fig. 4.14A,B,E &F) are 
rarely to be observed in APP-PS1(TG) seeded samples.  
 
 
Fig.– 4.15: TEM micrographs of brain material seeded reaction in the Assay (A-F) at higher 
magnifications (scale 500nm and 200nm). Red arrows indicate fibrillar material and green arrows 
indicate oligomeric species. A and B micrographs represent BL6 BH seeded reactions at different 
magnifications. C and D micrographs represent APP/PS1(WT) BH seeded reactions at different 
magnifications. E and F micrographs represent APP/PS1(TG) BH seeded reactions at different 
magnifications. The blue arrows indicate APP/PS1(TG) fibrils and purple ones indicate prefibrillar 
oligomers. The insets include detailed molecular features analyzed in the micrographs.  
 
The fibrillar content was hardly observed in APP/PS1(TG)-1G sample in comparison 
to APP/PS1(WT) and BL-6 seeded samples. At medium magnification (500nm), very 
few thin but short and slender fibrils were observed (Fig.- 4.14F and inset F1). At 
higher magnification (200nm), these fibrils appeared like fiber-optic filaments, rigid, 
needle-like appearance and straightened up with no periodic twisting features or 
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flaccid features (Refer, Fig.- 4.15 E, F and detailed features insets E1&F1). Fibrillar 
heterogeneity was not clearly observed in the APP/PS1(TG)-1G aggregates. They 
are found to be laterally associated with each other which is distinctly in contrast to 
BL6-1G and APP/PS(WT)-1G aggregate sample probes. TEM analysis for same 
cohort of aggregates but from a an another in-vivo brain homogenate seeding 
experiment revealed the similar morphological features as explained here. The 
differences between the fibrillar morphologies among the brain-seeded samples have 
been succinctly summarized using a table- 4.2 below. 
 
 Brain Seeded Aggregate Sample Probes 
Type APP/PS1(WT)-1G & BL6-1G APP/PS1(TG)-1G 
Fibrils 
(i) Thick, flexible, thread-like, knotty 
appearance, fibrillar crossovers at 
regular intervals, pre-fibrillar 
aggregates also detected.   
(ii) Fibrillar heterogeneity clearly 
observed 
(i) Sporadically detected, thin, 
needle-like, slender, laterally 
arranged and fragile. 
(ii) Fibrillar heterogeneity not 
observed. 
Oligomers 
Large population of small oligomers 
producing a strong spongy-like 
background 
Large pre-fibrillar Oligomeric 
structures appearing like ball of 
yarn appearance (150-300nm). 
Smaller oligomers rarely found. 
Special 
Features 
Oligomers are found independently 
as well as sparsely bound to the 
flexible fibrils 
Small oligomers were rarely 
found and oligomeric binding to 
fibril was absent. 
 
Table. - 4.2: Morphological comparison brain homogenate seeded Aβ . 
 
4.5 Acoustic SSA Distinguishes Fragmentability of Aβ  Aggregates 
 
Formation of matured fibers and aggregates with time results in the reduction of 
seeding capacity of Aβ aggregates. Fragmentation of aggregates by ultrasonication 
has been known in literature to increase the seeding capacity (Petkova et al. 2005; 
Fritschi et al. 2014). When fragmented, these fibrillar aggregates generate seeds 
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because of the fragmentation of fibril structure. Although, this method has been used 
to fragment the amyloid aggregates to increase the seeding capacity. Specific 
mechanical fragmentation of Aβ fibrils by controlled sonication as a characterization 
technique to distinguish structural conformations has yet not been reported. This 
study is one of the first initial attempts to understand the specific fibrillar mechanical 
stability of Aβ conformations using a novel Acoustic-SSA technique. This technique 
has been explained in detail in Acoustic SSA section (Refer, Material-Methods, 
Section 3.5.2). Controlled fragment is achieved by adjusting the height of the sample 
away from the sonicating sonotrode surface. The fragmented Aβ sample is then 
seeded to the seeding assay and monitored for seeding kinetics. 
 
4.5.1 De-novo aggregated Aβ fibrils optimally fragment at 1.5mm height in the 
Acoustic-SSA setup 
 
A proof-of-the-concept experiment of fragmentation by ultrasonication using Acoustic 
SSA was carried out, using de-novo aggregated Aβ(1-42)M35L spontaneous 
quiescent fibrils. The method of operation of sample preparation and Acoustic-SSA 
has been explained in detail (Refer, Section 3.5.2). The de-novo aggregated Aβ(-
42)M35L fibrillar seeds were non-sonicated / sonicated at different heights (0.5, 1.5, 
4.5 and 9.5) mm above from the flat horn of the sonicator probe surface. 
 
The height was varied using the screw and the wing-nut arrangement. The position of 
the sample holder is always kept constant relative to sonotrode surface, owing to 
positional effects observed by Dr. Felix Deluweit (SBIB, HZI) in prions amplification 
experiments using the Acoustic-SSA method. The sonication settings are: 30 
seconds total ON time with 10 pulses (3 second per pulse) and 7 seconds 
quiescence gap between each pulse. The fragmented de-novo Aβ seed material is 
logarithmically diluted to (3, 0.3, 0.03 and 0.003)µM and added to PK digested 0.2% 
BL6 brain homogenate in aggregation buffer and then seeded to soluble Aβ(1-42) 
M35L substrate with 4mM DHPC in the assay (Fig.- 4.16). 
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Fig.- 4.16: Controlled fragmentation of de-novo Aβ(1-42)M35L fibrils by Acoustic-SSA. 
Fragmented / Non-fragmented fibrils at different heights and seeded in assay by logarithmically 
diluting out the Seed. The spontaneous aggregation of the substrate Aβ(1-42)M35L on the top 
extreme left. The error bars indicate standard deviation from the median values of the detected 
lagtimes. (N=4)  
 
There are four replicates for each reaction in this experiment. The seeds are then 
mixed with soluble Aβ in the assay and are analyzed for aggregation lagtimes (Fig.- 
4.16). The error bars indicate standard deviation from the median values of the 
analyzed lagtimes. The assay parameters used in recording kinetics are 10 minutes 
read interval with 10 seconds agitation before the start of each read. The gain used 
in recording the data is 95 (manual). Fig.– 4.17 displays the fluorescence intensity 
raw kinetic data of the assay. The Y-axis represents the fluorescence in arbitrary 
units and the X-axis represents time in hours. The kinetic aggregation data has been 
smoothed using a 17-point Savitzky-Golay filter. 
 
The non-sonicated de-novo seeded reactions in the assay only seed at high 
concentration (3µM). With the lowering of seed concentration, the seeding resolution 
(concentration and time dependent seeding activity) is abruptly abolished and 
aggregation becomes random in the assay. Sonication shear force applied to the 
sample is height dependent, higher shear force is experienced closer to the 
sonotrode horn probe and lesser force away from the probe. Fibrils exposed to 
sonication shear force fragment and generate seeds. These seeds are added in the 
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assay to assess the fibril mechanical fragmentability under specific sonication forces. 
 
 
Fig.- 4.17: De-novo Aβ(1-42)M35L fibrils fragmented using Acoustic-SSA. Aggregation data of 
fragmented T-fibrils using Acoustic-SSA at different heights and seeding at different concentrations in 
the assay. (A) Non-sonicated and seeded. (B) Ultrasonicated at 0.5mm and seeded. (C) 
Ultrasonicated at 1.5mm and seeded. (D) Ultrasonicated at 4.5mm and seeded. (E) Ultrasonicated at 
9mm and seeded. (N=4). The curves are smoothed using an 17-point Savitzky-Golay filter. The Y-axis 
represents the fluorescence intensity in arbitrary units and the X-axis represents time in hours.  
 
Scanning the height range, it was observed that 1.5mm was the optimal height for 
sonication of de-novo Aβ(1-42)M35L fibrils. The optimal fragmentation of the de-novo 
Aβ(1-42)M35L fibrils can be inferred by the determined lagtimes that gives 
information on the seeding resolutivity of the logarithmically diluted seeds in the 
assay. The 1.5mm sonicated samples seed until the last logarithmic dilution 
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(0.003µM) with concentration to time dependence. This is only possible, when fibrils 
are optimally fragmented to seeds that can seed even in lowest dilution titer. From 
the knowledge derived from fragmentation by sonication of de-novo Aβ(1-42)M35L 
spontaneous quiescent fibrils, it was possible to apply the same methodology to 
APP-PS1(TG/WT) and BL6 seeded reactions to asses their mechanical fibril 
fragmentability.  
 
4.5.2 APP/PS1(TG)-1G Fragmented Aggregates Seed Poorly in Assay 
 
The APP/PS1(TG/WT) and BL6 brain homogenate seeded reaction aggregates are 
referred to as APP/PS1(TG/WT)-1G and BL6-1G, 1G refers to its first generation. 
The BL6-1G and APP-PS1 (TG /WT)-1G age-matched Aβ fibril material at 1µM were 
fragmented by sonication at 0.5mm height for 30 / 60 seconds in the acoustic-SSA 
setup. After fragmentation, they were seeded to soluble Aβ(1-42)M35L substrate with 
4mM DHPC in the assay. There are 5 replicates for each reaction cohort in the 
assay. The parameters used for monitoring are 10 minutes read interval with 10 
seconds agitation before the start of each read. The raw kinetic and fluorescence 
intensity data for the assay is presented with time domain on the X-axis and 
fluorescence intensity values on the Y-axis (Fig.- 4.18).  
 
Seeding activity is observed distinctly in BL6-1G and APP/PS1(WT)-1G fragmented 
aggregates in the assay. They display similar seeding kinetics in the aggregation 
assay both processed at 30 and 60 seconds sonication time and at 0.5mm height in 
the Acoustic-SSA (Fig.- 4.18A,B,D&E). APP/PS1(TG)-1G fragmented and seeded 
reactions under the same conditions (0.5mm height , 30/60 sonication time) have a 
late lag phase, indicating poor availability of seed concentration required for seeding 
in the assay (Fig.- 4.18C&F).  
 
The poor availability of seed in the APP/PS1(TG) could have been due to mild or 
excessive fragmentation of the aggregate in the Acoustic-SSA conditions that could 
have resulted in either poor generation of seeds or depolymerization of the TG-1G 
seed structure itself. Fragmentation of the aggregate is both depend on the 
processing time and the applied intensity of sonication force. The processing 
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fragmentation time was increased from 30 seconds to 60 seconds; but still there was 
no improvement in seeding effect of APP/PS1(TG)-1G material (Fig.- 4.18C&F).  
Rather increasing the processing time only worsened the seeding activity indicated 
by the randomness in lagtime of aggregation (Fig.- 4.18F).  
 
 
 
Fig.– 4.18: Difference in Seeding Kinetics after Fragmentation in Acoustic-SSA. Kinetic data of 
APP-PS1(TG/WT)-1G and BL6-1G fibril (1µM) fragmentation at 0.5mm height for 30/60 seconds using 
Acoustic-SSA. BL6-1G fragmented for 30 and 60 seconds at height 0.5mm and seeded in the assay 
(A&D). APP/PS1(WT)-1G fragmented for 30 & 60 seconds at height 0.5mm and seeded in the assay 
(B&E). APP/PS1 (TG)-1G material fragmented for 30 and 60 seconds at height 0.5mm and seeded in 
the assay (C&F). (N=5) The data has been smoothed with 17-point Savitzky-Golay data smoothing 
filter.  
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While, BL6-1G and WT-1G fragmented seeds showing similar seeding kinetics in the 
assay at both 30 and 60 seconds fragmentation processing time (Fig.- 4.18 A, B, 
D&E). Increasing the processing time to fragment the APP/PS1(TG)-1G was also 
tested, but still it did not seed in the assay (Refer, Supplementary Data, Fig.- 7.8).  
The height set in this experiment (0.5mm) was the lowest point where maximal shear 
forces can be applied to the sample in the acoustic SSA. Increasing the height to 
reduce the applied shear force on the sample was also performed on APP/PS1(TG)-
1G samples and it still did not generate seeds to seed in the assay (Refer, 
Supplementary data, Fig.- 7.9). The seeding kinetics differences between brain 
aggregated-Aβ seeded APP/PS1-TG-1G and the de-novo aggregated 
[APP/PS1(WT)-1G and BL6-1G] arises due to the fibril mechanistic fragmentational 
differences encoded in its molecular structure. This indicates to presence of a 
specific brain aggregated -Aβ molecular conformation from the APP/PS1(TG) brain 
that has conformationally seeded in the Aβ-CSA (Conformational Seeding Assay). 
Polymorphic Aβ having different rates of fragmentation in the presence of shear 
forces has already been shown in the case of Aβ40 fibrils (Qiang et al. 2013). And, 
this study is the first one to show initial indications of difference in fibril fragmentability 
between brain aggregated-Aβ seeded fibrils and de-novo aggregated Aβ42 fibrils.  
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5  Discussions 
 
Investigation into the pathogenic agent in Alzheimer’s disease has lead researchers 
to arrive to a common speculation that Aβ peptide aggregation and accumulation is a 
dominant disease biomarker. Since a decade many studies have strongly indicated 
that Aβ can also act like prions propagating by conformational seeding and 
maintaining a distinct Aβ strain (Watts et al. 2014; Stöhr et al. 2014; Lu et al. 2013; 
Hatami et al. 2014; Aguzzi 2014; Spirig et al. 2014) (Also, Refer, Introduction, Section 
1.5). Currently, there is enough credible evidence to suggest that AD could be 
transmissible in the same sense as in prion diseases (Meyer-luehmann 2006; Eisele 
et al. 2010; Langer et al. 2011; Stohr et al. 2012; Hamaguchi et al. 2012; Rosen et al. 
2012; Morales et al. 2015). Similar to prions strains, Aβ peptide is also known to 
adopt polymorphic conformations in-vivo depending on the aggregation 
environmental conditions and several other factors (Cohen et al. 2015; Nilsson et al. 
2007). To this date, the in-vivo specific Aβ structure in the brain still continues to be 
an major bottle neck in the field. 
 
In order to amplify and characterize the in-vivo specific Aβ conformation in the brain, 
our project primarily focuses on developing an Aβ Conformation Seeding Assay (Aβ-
CSA) using Aβ42 as a substrate. The first goal of the project was to enable 
conformational seeding of the brain aggregated-Aβ to the soluble Aβ42 substrate in 
the assay. The aggregation in the assay was monitored by thioflavin-t fluorescence 
kinetics. Later, the aggregates derived from the assay were characterized by 
negative staining TEM and Acoustic-SSA (Selective Shear Amplification) technique. 
Acoustic-SSA is a novel fragmentation technique that exploits the fibril mechanistic 
property to fragment and form seeds when selective sonication energy is applied. 
 
5.1 Developments of Aβ-fibril amplification and seeding assays 
 
Several in-vitro based seeding and fibril amplification assays have been reported in 
literature (Refer, Introduction, Section- 1.8). A study by Tycko and co-workers in the 
year 2005 first reported that both the morphology and molecular structure of Aβ40 
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fibrils are retained by self-propagation in-vitro when the fibrils are grown from their 
respective preformed seeds by adding them to the soluble Aβ40 substrate (Petkova 
et al. 2005). Aβ-fibrils are known to adopt multiple different fibril structures (Aβ 
polymorphism), the total number of fibril structures that Aβ can adopt has not yet 
been completely determined (Refer, Introduction, Section- 1.4). Hence, a seeding 
assay was developed by Paravastu et.al to determine the molecular structure of Aβ in 
the AD brain by seeding the soluble substrate Aβ40 with sonicated brain-extracted 
Aβ seeds (Roher & Kuo 1999) from the deceased AD patients. They subsequently 
obtained evidence that the fibrils seeded from the AD brain tissue from two AD 
patients have similar molecular structures (homogenous) but are different from the 
de-novo aggregated Aβ40 fibrils (heterogeneous) (Paravastu et al. 2009). 
 
In a later investigation by Tycko and coworkers in the year 2013 they spiked soluble 
Aβ40 substrate with sonicated brain extracts from two deceased AD patients who 
had quite different clinical presentation. The result from this study indicated that fibrils 
grown from Aβ extracted from multiple brain regions of the same patient had identical 
structures whereas fibrils from the two patients varied markedly from each other and 
also differed from Aβ40 de-novo aggregated fibrils. This study indicated the first 
concrete evidence to presence of Aβ strains in AD patients (Lu et al. 2013). The fibril 
amplification assay developed by Tycko and co-workers however do have few 
limitations. Firstly, the fibril amplification protocol only utilized Aβ40 (not Aβ42) as the 
substrate peptide to capture the brain aggregated-Aβ fibril conformation. 
Furthermore, they have also acknowledged that their brain-seeded Aβ40 fibrils are 
most likely to be seeded from the Aβ40 fibrils (not Aβ42 fibrils) in the brain tissue of 
AD patients as polymorphic Aβ42 fibrils prepared in-vitro did not seed the growth of 
Aβ40 fibrils in their hands (Lu et al. 2013). Secondly, the denaturants and detergents 
used in the lengthy multistep amyloid extraction protocol to obtain pure Aβ fibrils from 
the AD brains can potentially select out an particular Aβ strain or the reagents used in 
extraction procedure can alter the seed structure and also potentially interfere with 
the Aβ substrate oligomerization in the amplification assay. Thirdly, it is well know 
that Aβ can adopt plethora of polymorphic conformations in the brain (different chain 
length and modifications), still after seeding the final Aβ40 fibril structure was found to 
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be more homogenous than the heterogeneous initial seed added in the amplification 
assay. This selective amplification of a particular fibril type could be due to arbitrary 
sonication performed on the brain extracted Aβ fibrils to generate seeds. Arbitrary 
sonication can lead in selective fragmentation or denaturation of the seed structure 
from polymorphic Aβ sample pool. Aβ40 polymorphic fibrils having significantly 
different rates of fragmentation in the presence of shear forces have been shown to 
favour growth of a particular type of Aβ40 fibril over the other in a study by same 
group (Qiang et al. 2013). Due to these limitations in the fibril amplification assay, the 
final brain Aβ seeded Aβ40 fibril structure cannot be trusted to faithfully represent the 
fibrillar heterogeneity found in AD brains. 
 
Few seeding assays have partially addressed the limitations of fibril amplification 
assay. The kinetic aggregation assay developed by Jeffery Kelly and co-workers is 
one such assay. The kinetic aggregation assay is selective and sensitive method for 
quantifying Aβ fibrils in complex biological samples without having need to purify or 
extract the Aβ fibrils from the sample. However, this assay is also based on utilizing 
Aβ40 (not Aβ42) as the substrate peptide to capture the fibrillar seeds in the sample. 
The major limitation of this assay is that it does not claim structure amplification of in-
vivo aggregated Aβ fibril but rather focuses more on quantification of amyloid load in 
the biological sample (Du et al. 2011). 
 
Recently a new seeding assay, Aβ-PMCA (Protein Misfolding Cyclic Amplification) for 
detection and amplification of Aβ seeds was established by the Soto’s lab, which 
originally developed the PMCA assay for prion amplification. It is the first seeding 
assay to utilize Aβ42 peptide as the substrate to detect oligomeric seeds from the 
CSF. Rather than applying sonication to multiply the seeds as used in the earlier 
protocols, Aβ-PMCA uses strong shaking (agitation) to fragment and improve the 
seeding in the assay. The major drawback of this assay is that it can only capture the 
Aβ oligomeric seeds from the CSF samples. The assay is incompatible to capture Aβ 
seeds from complex biological samples like brain homogenate tissues and hence no 
in-vivo AD specific Aβ seed structural amplification is possible (Salvadores et al. 
2014). 
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We do not yet know whether there is a connection between variations in Aβ fibril 
structure and the development of AD, but this remains a promising and interesting 
hypothesis that we are pursuing. So in order to amplify and characterize the brain 
aggregated-Aβ conformation there persists a need for the development of a Aβ 
conformational seeding assay method that utilizes recombinant Aβ42 as the 
substrate combined with addition of whole brain homogenate as a seed without 
purifying the Aβ seeds. 
 
5.2  Development of Aβ-Conformational Seeding Assay 
 
Keeping in mind the needs and perspectives a seeding assay development was 
undertaken in our lab. The assay was developed using recombinant Aβ(1-42)M35L 
and Aβ(1-40)M35L as the substrate for initially detecting de-novo quiescently 
aggregated Aβ(1-42)M35L and Aβ(1-40)M35L fibrils as seeds in the assay. We 
initially concentrated on establishing an optimized method for detection of Aβ seed in 
the assay by assessing key parameters like substrate concentration, effect of Aβ 
substrate mixes, cross-seeding, seed detection limit, plate reading interval, buffer pH 
condition etc. that would influence either positive or negative effect to detect the de-
novo aggregated Aβ seed added in the assay. Fibril seed detection by concentration 
and time dependent linearity was established for Aβ(1-42)M35L fibrils in the assay. 
 
 The substrate peptides that were used in the development of the assay are 
recombinant Aβ(1-40)M35L and Aβ(1-42)M35L, single mutants of the wild type Aβ 
that contains methionine instead of leucine at the 35th position. The M35L mutants 
were preferred as Aβ substrates in the assay as the wild-type Aβ42 peptide starts to 
aggregate within few seconds (Finder et al. 2010), making it difficult to maintain in a 
soluble state for seeding studies. Owing to the wild type peptide’s higher aggregation 
propensity and difficulty in maintaining it in a monomeric state, single mutants Aβ(1-
40)M35L and Aβ(1-42)M35L were preferred as substrates and  were produced 
recombinantly in higher quantities and purity for the seeding in the assay. The Aβ 
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mutants (M35L) are known to aggregate slower compared the recombinant Aβ42 wild 
type peptide as the single mutation from methionine to leucine in 35th position greatly 
reduces the aggregation propensity of the peptide, which can be contributed to loss 
of methionine oxidation. Oxidation lowers the energy minima for peptide aggregation 
that results in increased aggregation propensity (Hou et al. 2004). Aβ M35L mutants 
are suitable for the assay as the Aβ(1-42)M35L  fibril structural morphology, and its 
H/D-exchange pattern has been shown to be similar to that of Aβ(1–42) 35Mox 
(Methionine Sulfoxide at 35th position) (Thorsten et al. 2005). The leucine amino acid 
substitution at the 35th position is known to occupy approximately the same molecular 
3D space as compared to methionine in the Aβ-fibril packaging. Cysteine mutation 
studies have also indicated that, introduction of cysteine residues in the 35th 
methionine position did not abolish the hexamers and tetramer formation, that are 
known represent the right pathway intermediates of wild type Aβ42 oligomerization 
(Ngo & Guo 2011). Hence, the choice of Aβ(-42)M35L is suitable as an ideal read-out 
substrate peptide for capturing the brain aggregated- Aβ conformation in the assay.  
 
The increase in fluorescence intensity in Aβ kinetic aggregation kinetics illustrates 
amyloid specific binding of thioflavin-t molecules to the β-sheets of Aβ(1-42)M35L 
and Aβ(1-40)M35L aggregates (Result, Fig.- 4.2 A&B). This result gives a clear 
indication, that thioflavin-t can be used a tracer-molecule in the assay to monitor the 
Aβ aggregation kinetics. There is substantial decrease in lagtimes (early lag-phase) 
of aggregation with the increase in Aβ substrate concentration and increase in 
lagtime (late lag-phase) of aggregation with the decrease in Aβ substrate 
concentration (Results, Fig.- 4.2C). The monomeric concentration dependent 
spontaneous Aβ aggregation data is very much in agreement with amyloid literature, 
where increase and decrease in amyloid monomeric concentration is known to 
influence the rate of Aβ peptide aggregation (Cohen et al. 2013). The Aβ substrate 
concentration in the assay was limited to 30µM, as higher substrate concentration 
would encourage spontaneous nucleation and lower substrate concentration would 
result in arbitrary nucleation among the replicates. As both the extremes can limit the 
seed resolutivity in the assay, the substrate concentration in the assay was 
maintained at 30µM.  
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Aβ is an amphipathic peptide with a theoretical pI of 5.31 and its aggregation kinetics 
is known to be pH dependent. Increase in pH of the aggregation buffer towards 
alkalinity results in impeded Aβ aggregation and pronounced increase in determined 
lagtimes. Decrease in pH nearing to pI, resulted in accelerated Aβ aggregation and 
decrease in lagtimes (Result, Fig. - 4.3B). This data is consistent with literature 
studies that have reported similar results of pH effect on Aβ aggregation have been 
reported (Burdick et al. 1992). Increase in thioflavin-t fluorescence intensity levels in 
the plateau phase is also observed with the increasing pH of Aβ aggregation 
(Results, Fig. – 4.3A, C&D). The fluorescence intensity changes can be attributed to 
the change in aggregate morphology, population of fibril structures and oligomeric 
aggregates formed because of changes in pH (Results, Fig.– 4.12, 4.13 and Table- 
4.1). From this experiment, it was decided to maintain the pH of the aggregation 
buffer at 8.1 as the lagphase was short and the pH condition did not influence 
change in Aβ fibril morphology. 
 
In the Aβ ratios co-aggregation, seeding and cross-seeding assay, soluble Aβ(1-
40)M35L and Aβ(1-42)M35L reciprocally delayed each other’s spontaneous 
aggregation in a concentration dependent manner. It was also observed that the 
aggregation lagphase was arbitrary for the reactions where Aβ(1-40)M35L peptide 
was equal or more in ratio to the soluble Aβ(1-42)M35L peptide. The seeding activity 
of Aβ stoichiometric mixtures was found to be Aβ(1-42)M35L fibril seed dependent 
(Results, Fig.– 4.4A&B). The results of co-aggregation assay are consistent with 
literature data where Aβ40 is known to inhibit the fibrillation of Aβ42 peptide (Yan & 
Wang 2007; Jan et al. 2008; Pauwels et al. 2012). Aβ40 fibrils are known to seed 
soluble substrate Aβ40 (Petkova et al. 2005; Paravastu et al. 2009; Lu et al. 2013) 
and also Aβ42 substrate (Pauwels et al. 2012) in literature. However, in our assay, 
Aβ40 fibril seeding was trivial compared to the Aβ42 fibril seeding. This could be 
because we did not fragment the added Aβ(1-40)M35L fibrils by sonication or by 
mechanical agitation before adding them to the substrate Aβ in the assay (Results, 
Fig. – 4.7B). Aβ(1-42)M35L fibrils did not seed the soluble substrate Aβ(1-40)M35L in 
our hands (Results, Fig.- 4.4A). There are however contradictory seeding claims in 
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literature, where Aβ42 fibrils have been suggested to seed (Du et al. 2011) and also 
have been shown to not seed (Lu et al. 2013; Pauwels et al. 2012) the monomeric 
Aβ40 substrate. Hence utilizing Aβ(1-42)M35L as the substrate read-out peptide is 
meaningful as it can capture and amplify both the Aβ40 and Aβ42 fibril conformations 
in the assay. 
 
An overall decrease in substrate spontaneous aggregation lagtime can be observed 
in this experiment (Result, Fig.- 4.4) compared to the earlier results (Result, Fig.- 
4.3), this is because of the reduction in plate reading interval to 25 minutes compared 
to the earlier experiment with read interval of 40 minutes. The increased movement 
of the plate introduced due to frequency of reads has lead to a dual effect, primarily 
increasing the entropy of aggregation and secondarily generating mechanical forces 
that can fragment the aggregates to promote seeded nucleation in the assay. This is 
consistent with the results in literature where aggregation is promoted by agitation 
has been shown to decrease the aggregation lagtimes in Aβ (Cohen et al. 2013).  
 
In conclusion, an in-vitro based aggregation and seeding assay was established for 
detecting de-novo aggregated Aβ(1-42)M35L fibrils with seed concentration 
dependent linearity. The assay was established with 30µM as the Aβ peptide 
substrate concentration and with aggregation buffer condition at pH 8.1. The assay 
could reproducibly resolute lagtime differences between spontaneous aggregation 
and logarithmically diluted de-novo Aβ(1-42)M35L seeded fibril from 5µM to 50pM 
(Results, Fig.- 4.4A). The next step was undertaken to detect and amplify the in-vivo 
aggregated-Aβ seed from the brain using the developed seeding assay.  
 
5.3 Amplifying brain aggregated-Aβ  in the assay 
 
In a decade of research on Aβ conformations, it has been largely accepted by 
researchers that, Aβ material aggregated in the brain has a different conformation 
compared to the Aβ that aggregates in-vitro (Hatami et al. 2014; Aguzzi 2014; Cohen 
et al. 2015). Several studies have attempted to amplify the in-vivo brain aggregated-
Aβ by developed seeding and conformational amplification assays (Paravastu et al. 
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2009; Du et al. 2011; Lu et al. 2013). So, far these assays have only succeeded in 
amplifying the Aβ40 conformations presented to them from the brain, as Aβ42 fibrils 
have been shown not seed the Aβ40 substrate (Lu et al. 2013), but Aβ40 fibrils have 
been shown to seed monomeric Aβ42 substrate (Pauwels et al. 2012). We have 
attempted to address these lacunas in our study by developing an Aβ- 
Conformational Seeding Assay (Aβ-CSA), that utilizes Aβ(1-42)M35L as the 
substrate peptide to amplify the brain aggregated-Aβ conformation.  
Addition of brain aggregated-Aβ seed (as brain homogenate) in the assay resulted in 
considerable impediment in the aggregation lag phase and there was no observable 
seeding difference between the Aβ-laden APP/PS1(TG) brains and Aβ negative 
APP/PS1(WT) brains despite the high presence protease-inhibitor in the assay 
(Results, Fig.- 4.5). This is consistent with the data in literature, where addition of 
brain homogenate material is known to retard the Aβ aggregation in the assay (Du et 
al. 2011). Proteinase-K (PK) digestion of brain homogenate greatly reduced the 
impediment in Aβ aggregation induced by the brain homogenate, but still it could not 
aid in resoluting the seeding difference between the Aβ laden APP/PS1(TG) seed 
and the Aβ negative APP/PS1(WT) brain homogenate added reactions in the assay 
(Results, Fig.- 4.6). PK was however successful in mitigating the retardation effect of 
brain homogenate added as seed in the assay by reducing the overall aggregation 
lagtimes in the same regime ranges to that of spontaneous Aβ substrate aggregation 
(Results, Fig.- 4.6). PK and PI has been shown to distinguish between Aβ laden 
brains and controls in the Aβ40 kinetic aggregation assay developed by Jeffery 
Kelly’s lab (Du et al. 2011). However, seeding did not occur in our developed seeding 
assay that utilized recombinant Aβ(1-42)M35L as the substrate. 
 
The reason for the seeding failure of the Aβ-laden brain [APP/PS1(TG)] was 
deliberated and it was hypothesized that, the added brain aggregated-Aβ seed (brain 
homogenate) could be too negligible for seeding in the assay. At the same time, it 
has to be comprehended that spontaneous nucleation and formation of de-novo 
seeds is also concomitantly occurring in the substrate Aβ in the assay. Therefore, in 
a seeding assay, there is always competition between the spontaneous nucleation 
self-seeding and the introduced seed replication. In our case, due to the limited 
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availability of the brain aggregated-Aβ seed (0.1 % and 0.2% brain homogenate) 
added in the assay, the spontaneous de-novo seed formation becomes dominant 
when competing with the introduced brain aggregated Aβ-seeding in the assay. 
Therefore, the spontaneous aggregation process of the substrate could be 
suppressing the added brain aggregated Aβ-seed amplification in the assay.  
A clever manipulation was introduced in the assay by modifying the in-vitro 
aggregation conditions to closely resemble the in-vivo brain milieu by introduction of 
phospholipids in the assay.  It is known that Aβ aggregation in the brain environment 
occurs amidst the highest concentration of lipids. Phospholipid DHPC (1,2-
dihexanoyl-sn-glycero-3-phosphocholine) as a lipid model system has been earlier 
used to study the amyloid aggregation processes in the case of Aβ40 and apoC-II 
(Apolipoprotein C-II) amyloid. DHPC is known to affect amyloid formation at micellar 
and sub-micellar concentrations playing a significant role in amyloid folding pathways 
in-vivo (Hatters et al. 2001; Dahse et al. 2010).  
 
We decided to investigate the effect of phospholipid DHPC in our developed seeding 
assay. The spontaneous aggregation kinetics of Aβ(1-42)M35L in the presence of 
DHPC (Result, Fig.- 4.7)  presents a similar trend in agreement to the aggregation 
behavior of Aβ(1-40) (Dahse et al. 2010). There are many papers in the literature that 
discuss the role of phospholipids in spontaneous Aβ aggregation, but none of them 
have investigated the influence of seeding activity in the presence of phospholipids. 
From our data, we can observe that, DHPC at 4mM overall delays both spontaneous 
and seeded aggregation in the assay. However, it impedes spontaneous Aβ 
aggregation relatively stronger than seeded aggregation. The overall increase in 
aggregation lagtimes accompanied by a preference to relatively impede the 
spontaneous aggregation has greatly boosted the seeding resolutivity in the assay at 
4mM DHPC condition. Our data shows that DHPC at 4mM increases the seeding 
resolutivity upto 4 times compared to the standard spontaneous and seeded 
aggregation (Result, Fig.- 4.7B & C).  
 
The rationale behind delay in amyloid aggregation can be hypothesized to be as 
follows: Phospholipid condition (in our case, DHPC at 4mM) delays spontaneous 
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primary nucleation by maintaining the Aβ in a non-β conformational state for a 
considerably long time indicated by an extended lagphase. Fibril nucleation is 
delayed due to slow formation of the seed in the mixed micellar condition (in our 
case, 4mM DHPC micelle condition) as compared to seed formation in the absence 
of lipid micelles (standard aggregation). Because of the number of peptides in the 
mixed micelles is smaller than the nucleus size or the seed size for fibril formation 
and due to the effect of micelles hindering the formation of homogenous seed within 
the mixed micelle condition the aggregation is substantially delayed. This hypothesis 
is so far the most accommodating hypothesis that we could obtain for our data from 
literature adapted from a simulation study of surfactants on amyloid aggregation 
kinetics (Friedman & Caflisch 2011). 
 
Our study is the first study, to report a finding that, that in the presence of 4mM 
DHPC, the seeding resolutivity in a seeding system can be dramatically improved to 
detect and amplify low amounts of added seeds in the assay. The developed assay 
can reliably detect spiked seed upto 25pM both in the presence and absence of brain 
homogenate in the assay (Result, Fig.- 4.8). It is important to note here, that our 
assay was able to detect non-sonicated fibrillar seeds. The seed detection limit can 
be further improved by fragmenting the fibrillar seeds by sonication as done in the 
kinetic seeding assay (Du et al. 2011). 
 
The increase in seeding resolutivity has enabled detection and amplification of brain 
aggregated-Aβ from the APP/PS1(TG) brain homogenate in the assay (Results, Fig.- 
4.9 & 4.10). The APP/PS1(TG) seeded reactions display higher fluorescence 
intensity compared to the non-Aβ containing APP/PS1(WT) and BL6 controls. The 
seed detection and amplification in the assay was further improved by introducing a 
number of measures that reduced the time delay between the digestion of the brain 
homogenate and production of the recombinant soluble Aβ(1-42)M35L substrate 
(Result, Fig.- 4.11). The brain homogenate seeding experiment was repeated more 
than 6-7 times and in all the assays, the brain- aggregated-Aβ seeded reactions 
displayed earlier lagtime kinetics along with higher fluorescence compared to the 
non-Aβ seeded brain homogenates. The reason for this increase in relative 
fluorescence has not yet been completely understood and whether this increased 
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fluorescence corresponds to peculiarity of an Aβ conformation type is not known. 
However, higher intensity fluorescence from brain seeded samples have also been 
observed earlier in Aβ fibril amplification assays developed by Tycko’s lab (Paravastu 
et al. 2009; Lu et al. 2013). The Aβ40 seed dominant APP23 transgenic mice brain 
homogenate did not seed the Aβ(1-42)M35L substrate in our assay (Fig.- 4.9D & 
4.10B), that agrees with our earlier data, where Aβ40 fibrils poorly seeded the Aβ42 
monomer in the assay (Results, Fig.- 4.4B). 
 
In conclusion, the developed Aβ conformational seeding assay (Aβ-CSA) could 
detecting and amplify the in-vivo brain aggregated-Aβ from the 10% brain 
homogenate added in the assay. The unique feature of our assay as compared to 
other amplification assay is that, this assay can seed the native brain aggregated -Aβ 
directly from the brain homogenate, without having to extract or purify the aggregated 
Aβ from the brain. This was possible because, we were able to strike an appropriate 
balance between two competing aggregation processes in the assay (i) Spontaneous 
primary nucleation- seeding (ii) sensitized detection of added seed by increasing the 
seeding resolutivity in the system. 
 
5.4 Brain homogenate seeded Aβ  morphologies and its 
fragmentability    
 
TEM micrographs of APP/PS1(TG) brain seeded sample showed distinct 
morphological differences when compared to APP/PS1(WT) and BL6 seeded 
reactions in the assay (Results, Fig.- 4.14, 4.15 and Table- 4.2). These differences 
distinctly point out the difference in morphology that arises from the conformational 
amplification of the brain aggregated-Aβ seeds from the APP/PS1(TG) brain 
homogenate added to the assay. The APP/PS1(WT) and BL6 seeded aggregates 
displayed similar fibrillar and oligomeric morphologies compared to APP/PS1(TG) 
seeded aggregates. The fibrillar heterogeneity was higher in non-Aβ brain 
homogenate seeded reactions compared to the distinct structures observed in 
APP/PS1(TG) seeded aggregates. Fibrillar Aβ was seldom found in the 
APP/PS1(TG) seeded reactions in sharp contrast to higher fibrillar content in 
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APP/PS1(WT) and BL6. In the APP/PS1 (TG) seeded samples large prefibrillar 
oligomeric structures were observed (~100-300nm) in large populations and fibrils 
found were thin and fragile appearance. These distinctive prefibrillar oligomeric 
structures were absent in the non-Aβ brain homogenate seeded reactions. Our 
seeding assay is the first one, where we have been able to show morphological 
differences between the brain aggregated-Aβ seeded material and non-Aβ brain 
seeded material utilizing Aβ42 as the substrate peptide. In the literature there are 
studies which shows difference in fibril structure and morphology but they are limited 
with respect to Aβ40 peptide as the substrate in the assays (Paravastu et al. 2009; 
Lu et al. 2013). 
 
Fragmentation of amyloid fibrils by sonication energy to generate seeds is widely 
used technique in amyloid seeding and aggregation studies (Yamaguchi et al. 2005; 
Chatani et al. 2009). Fragmentation of Aβ40 fibrils by ultrasonication to produce 
seeds have been used extensively in literature albeit, the sonication based 
fragmentation technique has been poorly characterized or quantified in detail to 
understand effect of sonication induced fragmentation on Aβ fibrils due to current 
limitations in biophysical methods. This limitation was overcome in our lab by 
constructing a special ultrasonication device Acoustic-SSA (Selective Shear 
Amplification) specially focusing on prion amplification. The method is very well 
established for prion amplification and explained in detail in PhD thesis of Dr. Felix. 
 
As a proof of the concept study, fragmentation of fibril by Acoustic-SSA was 
performed on aged de-novo Aβ(1-42)M35L fibrils that poorly seeded in the assay, but 
seeded robustly after fragmentation (Results, Fig.- 4.16 and 4.17). Using Acoustic-
SSA coupled with the developed seeding assay, the optimal shear force to fragment 
the de-novo Aβ(1-42)M35L fibril into homogenous seeds was determined at 1.5mm 
of height in the Acoustic-SSA device. Acoustic-SSA method was able to generate 
seeds from non-Aβ brain homogenate seeded fibrils but not from the APP/PS(TG)  
brain aggregated-Aβ seeded reactions (Results, Fig.– 4.18).  Increasing and the 
decreasing the processing times along with varying the intensity of shear force by 
adjusting the heights still did not result in seeding of the APP/PS1(TG) seeded 
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aggregates. Whereas the APP/PS1(WT) and BL6 seeded samples fragmented and 
seeded in the assay (Result, Fig.- 4.18). This result is the first indication that 
suggests amplification of a different Aβ conformation when seeded from brain 
aggregated-Aβ seed. This is in agreement with results shown by Tycko and co-
workers in Aβ40 polymorphic fibrils, where two fibrils grown in different conditions 
were found to have different rates of fragmentation in the presence of shear forces 
applied to them (Qiang et al. 2013).  
 
In summary, our experimentally developed conformational seeding assay can be 
used to detect and amplify brain aggregated-Aβ. Our study clearly indicates that the 
in-vivo brain aggregated-Aβ conformations in transgenic mice brains are different as 
compared to the de-novo spontaneous aggregated Aβ. Our indications are in 
agreement to a result where brain tissue from APP mice show the presence of 
different fibril structures in different plaque types when stained with luminescent 
conjugated polymers (Nilsson et al. 2007). 
 
5.5 Future Perspectives 
 
Aβ42 conformations and its structure elucidation continues to be a major bottleneck 
in the AD field. Many studies have only focused on the Aβ40 peptide aggregation and 
seeding, whereas it is clearly known that Aβ42 is the major culprit and amyloidogenic 
compared to Aβ40 (Bitan et al. 2003). Hence, there is an acute requirement to 
develop an assay that can amplify the brain aggregated-Aβ conformations of both the 
Aβ42 and Aβ40 variants. The Aβ42 fibril has been shown in several studies to not 
seed the Aβ40 monomer, whereas the Aβ40 fibril has been shown to seed the Aβ42 
monomer (Pauwels et al. 2012; Kuperstein et al. 2010).  
 
Our study, presents the first seeding and aggregation assay that detects brain 
aggregated-Aβ from AD transgenic mice using recombinant Aβ(1-42) as the 
substrate. Our method does not employ any amyloid extraction and purification 
protocols to isolate Aβ fibrils or oligomers from the brain cellular tissue. Using 
amyloid extraction protocol to isolate Aβ from the brains has lead to criticism, 
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where detergents and denaturants used in the protocol has been insinuated to affect, 
alter or select out an in-vivo aggregated Aβ conformation. Our assay shall enable 
researchers to detect and amplify brain aggregated-Aβ. There still exists a scope for 
improvement in the assay, where the brain-Aβ conformation could be serially 
propagated by many generations to dilute out the original added seed and perform 
structural studies by isotope labeling the substrate. But this step requires further 
intricate understanding of Aβ aggregation and nucleation processes and optimization 
of Aβ fibril fragmentation method to serially propagate over generations. 
 
With this developed Aβ-conformational seeding assay, a basic platform has been 
created that can allow researchers to amplify the brain aggregated-Aβ conformations. 
There is a growing body of evidence that suggests Aβ curls into distinct Aβ strains 
that can propagate through the brain by templated protein misfolding (Stöhr et al. 
2014; Watts et al. 2014). Recently, a new study has linked rapid clinical decline in AD 
to Aβ42 structural conformations that may play a role in pathogenesis of distinct AD 
phenotypes (Cohen et al. 2015). Since a decade, there has been a growing body of 
evidence indicating family of prion-like proteins involved in neurodegenerative 
diseases including AD (Jucker & Walker 2013; Morales et al. 2015). Applying our 
developed, Aβ conformational seeding assay framework from this study can 
immensely help in understanding the Aβ structure to its pathogenic progression in 
Alzheimer’s disease. 
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7 Supplementary Data 
 
 
 
 
 
 
Fig.- 7.1 – Aβ substrates in stoichiometric ratios [Aβ(1-42)M35L : Aβ(1-42)M35L], 
both spontaneous and seeded by de-novo aggregated Aβ(1-42) fibrillar seeds in the 
assay (Refer Legend).  (A) Only Aβ(1-42)M35L (B-D) Aβ(1-42)M35L : Aβ(1-40)M35L 
in ratios 70:30, 50:50 and 30:70 respectively (E) Only Aβ(1-40)M35L 
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Fig.- 7.2 - Aβ substrates in stoichiometric ratios [Aβ(1-42)M35L : Aβ(1-42)M35L], 
both spontaneous and seeded by de-novo aggregated Aβ(1-40) fibrillar seeds in the 
assay (Refer Legend).  (A) Only Aβ(1-42)M35L (B-D) Aβ(1-42)M35L : Aβ(1-40)M35L 
in ratios 70:30, 50:50 and 30:70 respectively (E) Only Aβ(1-40)M35L 
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Fig.- 7.3 - Brain homogenate seeding with 2X Protease inhibitor in the assay. 
(A) APP/PS1(TG/WT) and BL6 added to assay at 0.1% BH concentration. (B) 
Spontaneous aggregation in the absence of brain homogenate but with 0.1% PBS. 
(C) APP/PS1(TG/WT) and BL6 added to assay at 0.075% BH concentration. (D) 
Spontaneous aggregation in the absence of brain homogenate but with 0.075% PBS. 
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Fig.- 7.4 - Brain homogenate seeding with PK digestion (1:500) in the assay. (A) 
APP/PS1(TG/WT) and BL6 added to assay at 0.2% BH concentration. (B) 
Spontaneous aggregation in the absence of brain homogenate but with 0.2% PBS. 
(C) APP/PS1(TG/WT) and BL6 added to assay at 0.1% BH concentration. (D) 
Spontaneous aggregation in the absence of brain homogenate but with 0.1% PBS. 
(E) Standard spontaneous aggregation and seeded aggregation reaction. 
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Fig.- 7.5 – Spontaneous and seeded aggregation of Aβ(1-42)M35L substrate in 
varying concentration of DHPC (0 - 6mM) (A-G). (A) Standard spontaneous 
aggregation and seeding reaction. (B) Spontaneous and seeded aggregation at 1mM 
DHPC. (C) Spontaneous and seeded aggregation at 2mM DHPC.  (D) Spontaneous 
and seeded aggregation at 3mM DHPC. (E) Spontaneous and seeded aggregation at 
4mM DHPC. (F) Spontaneous and seeded aggregation at 5mM DHPC. (Refer, next 
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page) 
 
 
 
 
 
Fig.- 7.5 – (G) Spontaneous and seeded aggregation at 6mM DHPC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Data 
 
  
143 
 
 
Fig.- 7.6 – Detection of de-novo Aβ(1-42)M35L spiked fibrillar seeds in 
logarithmically diluted concentrations in the assay under 4mM DHPC condition. (A) 
Standard spontaneous and seeded aggregation with no DHPC. (B) PK digestion 
control Spontaneous aggregation with 0.1%BH, no DHPC. (C-H) aggregation in the 
presence specified seed in the presence of 0.1%BH, 4mM DHPC. (Refer, next page) 
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Fig.- 7.6 -  (I) Comparison of DHPC spontaneous aggregation controls in the 
presence and absence of 0.1%BH. 
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Fig.- 7.7 – Controls for brain aggregated-Aβ seeding assay. (A) Aβ(1-42)M35L 
spontaneous aggregation in the presence  of 0.2% PBS and PK digested 0.2% BL6 
brain homogenate. (B) Spontaneous Aβ(1-42)M35L aggregation in the presence of 
4mM DHPC in the presence of 0.2% PBS and PK digested aggregation buffer. 
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Fig.- 7.8 – Processing times of APP/PS1(TG)-1G aggregates by acoustic-ssa 
and later seeding in the assay. (A) Standard spontaneous aggregation in the 
presence and absence of 4mM DHPC. (B) APP/PS1(TG)-1G material sonicated (9 
seconds) and not sonicated. (C) APP/PS1(TG)-1G material sonicated for 15 and 30 
seconds. (D) APP/PS1(TG)-1G material sonicated for 60 and 120 seconds. 
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Fig.- 7.9 – Change in sonication shear forces applied for fragmenting 
APP/PS1(TG)-1G material by adjusting the sample holder height in the acoustic-ssa 
and seeding the fragmented material in the assay. (A) Standard spontaneous 
aggregation in the presence and absence of 4mM DHPC. (B-D) APP/PS1(TG)-1G 
material fragmentation at 0.5mm, 1.5mm, 3.5mm, 7.5mm and 18mm heights. (D) 
APP/PS1(TG)-1G material not fragmented and added in the assay. 
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